

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 10-K

- Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**
For the year ended December 31, 2025
- Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**
For the transition period from _____ to _____
Commission File Number 1-9810

Accendra Health, Inc.
(Exact name of registrant as specified in its charter)

Virginia
(State or other jurisdiction of
incorporation or organization)

10900 Nuckols Road, Suite 400
Glen Allen, Virginia
(Address of principal executive offices)

54-1701843
(I.R.S. Employer
Identification No.)

23060
(Zip Code)

Registrant's telephone number, including area code (804) 277-4304
Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$2 par value	ACH	New York Stock Exchange

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer (as defined in Rule 405 of the Securities Act). Yes No

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes No

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	<input checked="" type="checkbox"/>	Accelerated filer	<input type="checkbox"/>
Non-accelerated filer	<input type="checkbox"/>	Smaller reporting company	<input type="checkbox"/>
Emerging growth company	<input type="checkbox"/>		

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b).

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

The aggregate market value of Common Stock held by non-affiliates (based upon the closing sales price) was \$677,542,557 as of June 30, 2025.

The number of shares of the Company's common stock outstanding as of January 31, 2026 was 76,436,813 shares.

Documents Incorporated by Reference

The proxy statement for the annual meeting of shareholders to be held on May 14, 2026, is incorporated by reference for Item 5 of Part II and Part III.

[Table of Contents](#)

Form 10-K Table of Contents

Item	Page
Part I	
1. Business	3
1A. Risk Factors	12
1B. Unresolved Staff Comments	29
1C. Cybersecurity	29
2. Properties	30
3. Legal Proceedings	31
4. Mine Safety Disclosures	31
Information about our Executive Officers	31
Part II	
5. Market for Registrant’s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities	33
6. Reserved	34
7. Management’s Discussion and Analysis of Financial Condition and Results of Operations	34
7A. Quantitative and Qualitative Disclosures About Market Risk	47
8. Financial Statements and Supplementary Data	47
9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	47
9A. Controls and Procedures	47
Management’s Report on Internal Control over Financial Reporting	48
Changes in Internal Control	49
9B. Other Information	49
9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections	49
Report of Independent Registered Public Accounting Firm	50
Part III	
10. Directors, Executive Officers, and Corporate Governance	52
11. Executive Compensation	52
12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	52
13. Certain Relationships and Related Transactions, and Director Independence	52
14. Principal Accountant Fees and Services	52
Part IV	
15. Exhibits and Financial Statement Schedules	53
16. Form 10-K Summary	92
17. Signatures	93

Part I

Item 1. Business

General

Accendra Health, Inc. (f/k/a Owens & Minor, Inc.) and subsidiaries (Accendra Health, we, us, our or the Company) is a leading nationwide provider of products, technology, and services that supports health beyond the hospital for millions of people each year. We connect patients, providers, and insurers, delivering innovative solutions that help promote better health outcomes and improve quality of life for people living with chronic, complex, and acute health conditions. Together, our trusted brands, Apria and Byram Healthcare, bring nearly 90 years of combined experience in promoting health beyond the hospital in communities across the country. We are headquartered in Richmond, Virginia. The description of our business should be read in conjunction with the consolidated financial statements and supplementary data included in this Form 10-K.

Sale of Products & Healthcare Services Business

On October 7, 2025, we entered into an Equity Purchase Agreement, (the Purchase Agreement) by and among the Company, Dominion Healthcare Acquisition Corporation, a Delaware corporation (the Purchaser), and Dominion Healthcare Holdings, L.P., a Delaware limited partnership (Purchaser Parent) to sell the Products & Healthcare Services (P&HS) business, for an aggregate of \$375 million in cash, subject to certain adjustments for cash, indebtedness, net working capital and transaction expenses. On December 31, 2025, we completed the sale of the P&HS business pursuant to the Purchase Agreement. We have retained a 5% equity interest in the P&HS business.

Product Offering and Services

We provide delivery of products, including disposable medical supplies sold directly to patients and home health agencies and are a leading provider of integrated home healthcare equipment and related services in the U.S. We offer a comprehensive range of products and services for in-home care and delivery across diabetes treatment, home respiratory therapy (including home oxygen and non-invasive ventilation services), and obstructive sleep apnea treatment (including continuous positive airway pressure (CPAP) and bi-level positive airway pressure devices, and patient support services). Additionally, we supply a wide range of other home medical equipment, patient care product lines including ostomy, wound care (including negative pressure wound therapy), urology, incontinence and other products and services to help improve the quality of life for patients with home care needs. Revenues are generated through fee-for-service and capitation arrangements with large government and commercial payors (Payors) for equipment, supplies, services and other items rented and sold to patients. We provide patients with a variety of clinical and administrative support services and related products and supplies, most of which are prescribed by a physician as part of a care plan. We are one of the industry's highest-quality providers of home healthcare equipment, medical supplies and related services, while maintaining a commitment to being a low-cost operator. We aim to provide a compelling value proposition to patients, providers and Payors by allowing patients to receive necessary care and services in the comfort of their own home, while, at the same time, reducing the costs of treatment. We use technology in areas such as web portals/electronic ordering, electronic claims submission and electronic funds transfer with managed care organizations to more efficiently process business transactions. This use of technology can improve the initial patient admission process, expedite claims processing and reduce the administrative costs associated with this activity for both us and our providers and Payors.

Our Customers

We provide equipment and disposable medical supplies rented and sold directly to patients and home health agencies, for which payments are received from managed care plans, the U.S. federal government under the Medicare program, state governments under their respective Medicaid or similar programs, private insurers, home health agencies, and directly from patients. Medicare contracts may be subject to a Competitive Bidding Process (CBP) for durable medical equipment, prosthetics, orthotics and supplies (DMEPOS), as further described in the *Regulation* section.

Collections and Accounts Receivable

Accendra Health has internal expertise to manage the unique reimbursement requirements of certain Payors and continue to negotiate simplifications in the claims submission process in an effort to reduce subsequent denials and shorten related collection periods. Our general practice is to collect co-payments from the patient or applicable secondary Payor.

We actively manage our accounts receivable to minimize credit risk, days sales outstanding (DSO) and accounts receivable carrying costs. We have ongoing initiatives to improve our collections. Our ability to accurately invoice and ship product to customers enhances our collection results and affects our DSO performance. As we diversify our customer portfolio, the change in business mix also affects our DSO.

Competition

The industry in which we operate is highly competitive. We compete with many healthcare companies across a variety of channels to provide medical supplies and related services for in-home care. We compete against national providers and numerous regional and local providers that deliver products and services to patients' homes, including AdaptHealth Corp., Lincare, Inogen, Viemed Healthcare, Inc., Quipt Home Medical, Cardinal Health and Rotech. In addition, pharmacy benefit managers, such as CVS Health Corporation, compete with us in the home healthcare market.

Trademarks

We have trademarks in the U.S. that are used to designate or identify our Company. We operate under registered trademarks Accendra Health, Apria, Byram Healthcare and Lofta.

Regulation

Our business is subject to federal and state laws and regulations over our operations, including the reimbursement of our products and services under various government programs that are designed to prevent fraud and abuse. We are subject to state laws governing pharmacies, nursing services, medical equipment suppliers and certain types of home health activities. Our teammates are subject to state laws and regulations governing certain professional licensure, including for respiratory therapy, pharmacy and nursing. Compliance with laws and regulations is costly and materially affects our business. We believe we are in material compliance with all statutes and regulations applicable to our operations. Notwithstanding this, violations of these laws and regulations may still occur, which could subject us to civil and criminal enforcement actions; licensure revocation, suspension, or non-renewal; severe fines and penalties; the repayment of amounts previously paid to us; and even the termination of our ability to provide services under certain government programs.

Healthcare is an industry of rapid regulatory change. Changes in the laws and regulations and new interpretations of or guidelines relating to existing laws and regulations may affect permissible activities and compliance requirements, licenses and approvals required to be held, the relative costs associated with doing business, and reimbursement amounts paid by federal, state and other third-party Payors. We cannot predict the future of federal, state and local regulation or legislation, or possible changes in national healthcare policies. Future legislative and regulatory changes could have a material adverse effect on our financial condition, results of operations and cash flows.

General Regulation

Privacy

Numerous federal and state laws and regulations, including the Health Insurance Portability and Accountability Act (HIPAA), as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (HITECH), govern the collection, dissemination, security, use and confidentiality of Protected Health Information (PHI). HIPAA includes a number of requirements pertaining to the privacy and security of certain PHI, as well as the standard formatting of certain electronic health transactions. As part of the provision of, and billing for, healthcare equipment and

[Table of Contents](#)

services, we are required to collect and maintain PHI and as such, are subject to HIPAA as a covered entity. HIPAA also applies to business associates of covered entities, which are individuals and entities that provide services for or on behalf of those covered entities. Failure of our business associates to comply with HIPAA requirements can adversely impact our business. Numerous other federal and state laws that protect the confidentiality, privacy, availability, integrity and security of PHI and healthcare related data also apply to us. In many cases, these laws are more restrictive than, and not preempted by, the HIPAA and HITECH rules and requirements, and may be subject to varying interpretation by courts and government agencies, creating complex compliance issues for us and potentially exposing us to additional expenses, adverse publicity and liability.

Further, federal and state consumer laws are being applied increasingly by the Federal Trade Commission (FTC) and state enforcement authorities, to regulate the collection, use and disclosure of personal information or PHI, and to ensure that businesses and organizations maintaining personal information about individuals implement appropriate data safeguards. For instance, the California Consumer Privacy Act (CCPA) became effective on January 1, 2020. The CCPA gives California residents expanded rights to direct the use of their personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that may result in data breach litigation. Although there are limited exemptions for PHI and HIPAA regulated entities, and the CCPA's implementation standards and enforcement practices are continuing to develop and remain uncertain for the foreseeable future, the CCPA may increase our compliance costs and potential liability. In November 2020, Californians approved the California Privacy Rights Act (the CPRA), which modified and expanded the CCPA and established a new California Privacy Protection Agency. The CPRA established January 1, 2023 as the new compliance date for most of the other substantive provisions of the CPRA. Colorado, Connecticut, Utah, and Virginia have enacted similar laws to provide for the protection of consumer privacy, and numerous other states have similar laws under consideration. Additionally, in 2023, Washington state passed the My Health My Data Act ("MHMDA") — a comprehensive data privacy law that imposes significant obligations on entities doing business or targeting consumers in Washington and creates a private right of action that may invite an influx of litigation. Some of the MHMDA's provisions went into effect in July 2023 and in March 2024. The Florida Legislature passed an update to the Florida Electronic Health Records Exchange Act, effective since 2023, that prohibits health care providers that use certified health record technologies from storing electronic health records outside the United States, its territories, or Canada. The ban also applies to patient information stored through a third-party or subcontracted computing facility or cloud computing service.

Additionally, the FTC and many state attorneys general are interpreting existing federal and state consumer protection laws to impose evolving standards for the online collection, use, dissemination and security of PHI and other personal information. Courts may also adopt the standards for fair information practices promulgated by the FTC, which concern consumer notice, choice, security, and access. Consumer protection laws require us to publish statements that describe how we handle personal information and choices individuals may have about the way we handle their personal information. If we publish information that is considered untrue, it may be subject to government claims of unfair or deceptive trade practices, which could lead to significant liabilities and consequences. Furthermore, according to the FTC, violating consumers' privacy rights or failing to take appropriate steps to keep consumers' personal information secure may constitute unfair acts or practices in or affecting commerce in violation of Section 5 of the FTC Act.

New health information standards implemented on the federal and state level could have a significant effect on the manner in which we handle personal and healthcare-related data and communicate with Payors, and the cost of complying with these standards could be significant. Failure to comply with existing or new laws and regulations (including the interpretations thereto) related to patient health information could subject us to criminal or civil sanctions.

Licensing

Our home healthcare services operations are subject to federal, state, and local laws and regulations relating to the licensure of our facilities, healthcare specialists working for or engaged by us, and medical products, and requirements vary amongst jurisdictions.

Certain of our teammates are authorized and/or licensed under various federal, state and local requirements, which cover a variety of topics including standards regarding the provision of medical or care services, clinical records,

[Table of Contents](#)

infection control and care plans. Additionally, certain states may require certain of our teammates to complete training programs, undergo background checks, and maintain state certification. In addition, various federal and state authorities and clinical practice boards regulate the licensure of our clinical specialists, working either directly as teammates or on a per diem or contractual basis, and in our facilities. We believe we are currently licensed appropriately as required by the laws of the jurisdictions in which we operate in all material respects, but additional licensing requirements may be imposed upon us in existing or future markets.

In the U.S., the Federal Food, Drug, and Cosmetic Act (FFDCA), Food and Drug Administration (FDA) regulations and other federal and state statutes and regulations govern, among other things, medical device design and development, preclinical and clinical testing, premarket clearance or approval, registration and listing, labeling, storage, advertising and promotion, sales and distribution and post-market surveillance. Even after obtaining the requisite approvals, products may still be the subject of regulatory action if new facts concerning their safety and efficacy come to light. Healthcare regulation is subject to change and can have a considerable impact on the marketing of products and services that we offer. The FDA and DOJ actively investigate allegations of off-label promotion in order to enforce regulations prohibiting these types of activities. The FDA routinely issues informal and more formal communications such as untitled letters or warning letters interpreting its authority over these matters. While such communications may not be considered final agency decisions, many companies may decide not to contest the agency's interpretations so as to avoid disputes with the FDA, even if they believe the claims they were making to be truthful, not misleading and otherwise lawful. The DOJ has used the federal False Claims Act to address and enforce alleged misconduct involving the content of promotional messaging.

We must also comply with laws and regulations governing operations, storage, transportation, manufacturing, sales, safety and security standards for each of our manufacturing and distribution centers. This includes oversight by the FDA, the Centers for Medicare and Medicaid Services, the Drug Enforcement Administration, the Department of Transportation, the Environmental Protection Agency (EPA), the Department of Homeland Security (DHS), the Occupational Safety and Health Administration, the Department of Labor, the Equal Employment Opportunity Commission, and state boards of pharmacy, or similar state licensing boards and regulatory agencies and other federal and state regulatory authorities. For example, our locations that fill and distribute medical oxygen containers must register with the FDA as a medical gas manufacturer, and these registered locations are subject to extensive regulation. Among other requirements, the FDA's Current Good Manufacturing Practice (cGMP) regulations impose certain quality control, documentation and recordkeeping requirements on the receipt, processing and distribution of medical gas. Further, in each state in which we operate medical gas facilities, we are subject to regulation under varying state health and safety laws. The FDA and state authorities conduct periodic, unannounced inspections at our facilities to assess compliance with cGMPs and other regulations. Failure to comply with applicable requirements can lead to a variety of administrative or legal sanctions, such as warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties and criminal prosecution. We expend significant resources to achieve compliance with federal and state law requirements at each of our facilities. There can be no assurance, however, that these efforts will be successful and that our facilities will achieve and maintain compliance with applicable federal, state and local law requirements. We are also subject to certain federal and state disclosure requirements regarding financial arrangements within the healthcare industry.

Environmental Laws

We are subject to federal, state and local environmental laws and regulations in the U.S. In the event of noncompliance, we could be subject to substantial fines and other penalties. These laws and regulations frequently change and have become increasingly stringent over time. Non-compliance with these laws and regulations may result in significant fines or penalties or limitations on our operations or claims for remediation costs, as well as alleged personal injury or property damages. We believe our current operations are in substantial compliance with all applicable environmental, health and safety requirements and that we maintain all material permits required to operate our business.

Certain environmental laws and regulations impose strict, and under certain circumstances joint and several, liability for investigation and remediation of the release of regulated substances into the environment. Such liability can be imposed on current or former owners or operators of contaminated sites, or on persons who dispose or arrange for disposal of wastes at a contaminated site. Based on available information, we do not believe that any known compliance

[Table of Contents](#)

obligations, releases or investigations under environmental laws or regulations will have a material adverse effect on our business, financial condition, results of operations and cash flows. However, there can be no guarantee that these releases or newly-discovered information, more stringent enforcement of or changes in environmental requirements, or our inability to enforce available indemnification agreements will not result in significant costs.

In addition, federal and state governments in the U.S. are considering new or expanded laws to address climate change. Such laws, including California's SB-253 (Climate Corporate Data Accountability Act) and SB-261 (Climate-Related Financial Risk Act), may include limitations on greenhouse gas emissions, mandates that companies implement processes to monitor and disclose climate-related matters, additional taxes or offset charges on specified energy sources, and other requirements. Compliance with climate-related laws may be further complicated by disparate regulatory approaches in various jurisdictions. New or expanded climate-related laws could impose substantial costs on us. Until the timing and extent of climate-related laws are clarified, we cannot predict their potential effect on our financial condition, results of operations and cash flows.

Antitrust Laws

The federal government and most states have enacted antitrust or competition laws that prohibit certain types of conduct deemed to be anti-competitive. These laws prohibit price fixing, market allocation, bid-rigging, concerted refusal to deal, market monopolization, price discrimination, tying arrangements, certain acquisitions of competitors and other practices that have, or may have, an adverse effect on competition. Violations of federal or state antitrust laws can result in various sanctions, including criminal and civil penalties. Antitrust enforcement in the healthcare sector is currently a priority of the FTC and the Department of Justice (DOJ). In addition, the DOJ has been pursuing criminal antitrust enforcement actions for conduct of parties that the DOJ is alleging to be fixing wages or limiting worker mobility. We believe we are in compliance with such federal and state laws, but courts or regulatory authorities may reach a determination in the future that could adversely affect our operations.

Fraud and Abuse Laws

There are various federal and state laws that regulate the operation of healthcare providers, including those that prohibit fraudulent and abusive business practices by healthcare providers, suppliers, and parties that contract with such providers and suppliers who participate in, receive payments from or are in a position to make or influence referrals in connection with government-sponsored healthcare programs, including the Medicare and Medicaid programs. Of particular importance, each of which may be amended and updated from time to time, are:

- The federal Anti-Kickback statute and similar state equivalents prohibit providers and others from directly or indirectly soliciting, receiving, offering or paying any remuneration with the intent of generating referrals or orders for services or items covered by a federal healthcare program. Courts have interpreted this statute broadly and held that there is a violation of the Anti-Kickback Statute if just one purpose of the remuneration is to generate referrals. Violations of the federal Anti-Kickback Statute may result in civil and criminal penalties. Similarly, violations can result in exclusion from participation in government healthcare programs, including Medicare and Medicaid;
- The federal Physician Self-Referral Law, commonly known as the Stark Law, prohibits physicians from referring Medicare and Medicaid patients to healthcare entities in which they or any of their immediate family members have ownership interests or other financial arrangements, if these entities provide certain designated health services (including home healthcare services) reimbursable by Medicare or Medicaid, unless an exception applies. The Stark Law also prohibits entities that provide designated health services reimbursable by Medicare and Medicaid from billing the Medicare and Medicaid programs for any items or services that result from a prohibited referral and requires the entities to refund amounts received for items or services provided pursuant to the prohibited referral on a timely basis. Sanctions for violating the Stark Law include denial of payment, civil monetary penalties and exclusion from the federal healthcare programs. Failure to refund amounts received as a result of a prohibited referral on a timely basis may constitute a false or fraudulent claim and may result in civil penalties and additional penalties under the federal False Claims Act (FCA);

[Table of Contents](#)

- The FCA and similar state laws provide, in part, that the federal government may bring a lawsuit against any person whom it believes has knowingly presented, or caused to be presented, a false or fraudulent request for payment from the federal government, or who has made a false statement or used a false record to get a claim approved. Among the many other potential bases for liability is the knowing and improper failure to report and refund amounts owed to the government within 60 days of identifying an overpayment. Submission of claims for services or items generated in violation of the Anti-Kickback Statute constitutes a false or fraudulent claim under the FCA. The federal government has taken the position, and some courts have held, that providers who allegedly have violated other statutes, such as the Stark Law, have thereby submitted false claims under the FCA. The FCA may be enforced directly by the federal government or by a whistleblower on the government's behalf;
- The federal Eliminating Kickbacks in Recovery Act, which imposes criminal liability on individuals or entities that pay, receive, or solicit any remuneration in return for patient referrals to recovery homes, clinical treatment facilities, or laboratories;
- The federal Civil Monetary Penalties Law prohibits, among other things, the offering or transfer of remuneration to a Medicare or state healthcare program beneficiary if the person knows or should know it is likely to influence the beneficiary's selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state healthcare program, unless an exception applies;
- Similar state law provisions pertaining to Anti-Kickback, self-referral and false claims issues, some of which may apply to items or services reimbursed by any third-party Payor, including commercial insurers or services paid out-of-pocket by patients; and
- Federal and state laws that prohibit providers from billing and receiving payment from Medicare and Medicaid for services unless the services are medically necessary, adequately and accurately documented, and billed using codes that accurately reflect the type and level of services rendered.

To enforce compliance with the federal laws, the U.S. Department of Justice (DOJ) and the U.S. Department of Health and Human Services (HHS) Office of Inspector General (OIG) have continued their scrutiny of healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. The DOJ's continued prioritization of corporate and healthcare enforcement is evidenced by both the September 2022 release of the Monaco Guidelines, which reflect enhancements to long-standing DOJ guidelines on corporate accountability, and the record-breaking enforcement results in recent years. In 2025, the DOJ reported \$6.8 billion in False Claims Act (FCA) settlements and judgments, the highest in history, with more than \$5.7 billion related to healthcare matters specifically. Dealing with investigations can be time- and resource-consuming and can divert management's attention from the business. Any such investigation or settlement could increase costs or otherwise have an adverse effect on operations. In addition, because of the potential for large monetary exposure under the FCA, which provides for treble damages and mandatory minimum penalties, healthcare providers often resolve allegations without admissions of liability for significant and material amounts to avoid the uncertainty of treble damages that may be awarded in litigation proceedings. Such settlements often contain additional compliance and reporting requirements as part of a consent decree, settlement agreement or corporate integrity agreement. Given the significant size of actual and potential settlements, it is expected that the government will continue to devote substantial resources to investigating healthcare providers' compliance with the healthcare reimbursement rules and fraud and abuse laws.

On December 18, 2020, prior to the Acquisition of Apria on the Apria Acquisition Date, a federal judge approved a civil and administrative settlement between Apria and the U.S. and certain state Medicaid programs, in a complaint filed by three relators under the qui tam provisions of the FCA, 31 U.S.C. § 3729 et seq., as well as comparable state false claims laws, in connection with the rental of non-invasive ventilation products (NIVs). Apria also entered into separate settlements to resolve the relators' claims brought on behalf of the states of California and Illinois related to NIVs covered by private insurers.

To resolve any potential liability regarding alleged improper use of NIVs, Apria agreed to enter a civil settlement agreement and to pay \$40 million to the federal government and the states. Apria also agreed with the

[Table of Contents](#)

California Department of Insurance to pay \$0.5 million to resolve claims asserted by the relators under the California Insurance Frauds Prevention Act, Cal. Ins. Code § 1871 et seq. Apria separately agreed with the relators to settle all remaining claims from their complaint, including: (1) claims for retaliation in violation of federal and state laws; (2) claims for attorneys' fees and costs available under federal and state law; and (3) claims under the Illinois Insurance Claims Fraud Prevention Act, 740 Ill. Comp. Stat. 92/1 et seq. Apria did not admit that any of its conduct was illegal or otherwise improper. All amounts were paid prior to the Apria Acquisition Date.

As part of the settlement, Apria also entered into a five-year Corporate Integrity Agreement (CIA) with the HHS OIG. The CIA requires Apria to maintain its ongoing corporate compliance program and implement a set of defined corporate integrity activities for a period of five years from the effective date of the CIA. Among other things, the CIA requires Apria to impose certain oversight obligations on Apria's board of directors; provide certain management certifications; continue or implement, as applicable, certain compliance training and education; and engage an Independent Review Organization to perform certain reviews. The CIA also includes certain reporting, certification, record retention, and notification requirements. In the event of a breach of the CIA, Apria could become liable for payment of certain stipulated penalties or could be excluded from participation in federal healthcare programs. We expect final closure of the CIA to occur in 2026.

Federal and state agencies and health insurance carriers often conduct audits and request customer records and other documents to support claims submitted for payment of services rendered to customers. In response to an audit or inquiry, we are obligated to procure and submit the underlying medical records retained by various clinical providers, medical facilities and prescribers, which may be challenging. If a determination is made that our records or the patients' medical records are insufficient to meet requirements for the claims, we could be subject to denials or overpayment demands for claims submitted for Medicare reimbursement. In the rare event that such an audit results in major discrepancies of claims records which lacked medical necessity, we may be subject to broader corrective measures, including extrapolation of audit results across a wider population of claims, submission of recoupment demands for claims other than those examined in the audit, or placing us on a full pre-payment review.

Reimbursement

To participate in and qualify for reimbursement under governmental reimbursement programs such as Medicare and Medicaid, we must comply with extensive conditions of participation imposed by federal and state authorities as well as third-parties administering such governmental reimbursement programs. If we were to violate the applicable regulations or requirements governing participation, we could be excluded from participation in federal and state healthcare programs and be subject to substantial administrative, civil and criminal penalties.

Demand for many of the existing and new medical devices and supplies we provide to patients is, and will continue to be, affected by the extent to which government healthcare programs and private health insurers reimburse us and our customers for their members'/beneficiaries' medical expenses in the jurisdictions where we do business. Statutory and regulatory requirements for Medicare, Medicaid and other government healthcare programs govern provider reimbursement levels. From time to time, legislative changes are made to government healthcare programs that impact our business, and the federal and/or state governments may continue to enact measures in the future aimed at containing or reducing reimbursement levels for medical expenses paid for in whole or in part with government funds. The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, ACA), the Medicare Improvements for Patients and Providers Act of 2008 (MIPPA), the Deficit Reduction Act of 2005 (DRA) and the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA), each contains provisions that have directly impacted reimbursement for the products and services we provide. Reimbursement from private third-party Payors varies and is dependent on contract negotiations and there is no guarantee that such contracts will be profitable, and failure to comply with these contracts may result in termination or financial liabilities. Efforts by Payors to reduce healthcare costs have intensified in recent years and will likely continue, which may result in reductions or slower growth in reimbursement for certain services provided by healthcare companies. It is possible that healthcare companies will continue to experience a shift in Payor mix away from fee-for-service Payors, resulting in an increase in the percentage of revenues attributable to reimbursement based upon value-based principles and quality-driven managed care programs, and general industry trends that include pressures to control

[Table of Contents](#)

healthcare costs. Pressures to control healthcare costs and a shift away from traditional health insurance reimbursement to payments based upon quality outcomes have increased the uncertainty of payments.

The ACA affects how healthcare services are delivered and reimbursed through the expansion of health insurance coverage, constraining Medicare and Medicaid program spending, and establishing programs that tie reimbursement to quality and integration. Potential changes to the ACA may impact our business including, but not limited to, court challenges, and administration and legislative modifications. Lower numbers of insured individuals, reduced coverage for insured individuals and reduced government funding for programs could each cause our revenues to decrease to the extent such legislation reduces reimbursement rates.

The MMA established a Competitive Bidding Process (CBP) for certain DMEPOS we provide. The DMEPOS CBP impacts the Medicare reimbursement amounts for suppliers of certain DMEPOS items, and in the past, included some DMEPOS items that we provide to our patients. Cumulatively, in previous competition rounds of the DMEPOS CBP in effect between 2011 and 2018, our business (including the Apria operations acquired in March 2022) were offered contracts for a substantial majority of the product categories for which we submitted bids. Competitive bidding contracts are expected to be re-bid at least every three years. While we cannot predict the outcome of the DMEPOS CBP on our business in the future nor the Medicare payment rates that will be in effect in future years, the program may materially adversely affect our financial condition, results of operations and cash flows.

State Medicaid programs implement reimbursement policies for the products and services we provide which can vary from state to state. We cannot predict whether states may consider adopting reimbursement reductions or whether any such changes could have a material adverse effect on our business.

Marketing and Transparency Reporting Laws

Communications with consumers are also subject to laws and regulations governing communications, including the Telephone Consumer Protection Act of 1991 (TCPA), the Federal CAN-SPAM Act, additional fax regulations under the Junk Fax Act and the Telemarketing Sales Rule and Medicare regulations. Under such regulations, companies are restricted in the methods used to contact consumers by email, telephone, and text message, for example, through the use of random or sequential “auto-dialer” devices. Numerous class-action suits under federal and state laws have been filed in recent years against companies that conduct SMS texting programs, with many resulting in multi-million-dollar settlements to the plaintiffs. We believe we are in substantial compliance with the federal regulations we are subject to, as well as state equivalents where applicable. The scope and interpretation of the laws that are or may be applicable to the delivery of consumer phone calls, emails and text messages are continuously evolving and developing. If we do not comply with these laws or regulations or if we become liable under these laws or regulations, we could face direct liability, could be required to change some portions of our business model, could face negative publicity and our business, financial condition, results of operations and cash flows could be adversely affected.

Fair Debt Collection Practices Act

Some of our operations may be subject to compliance with certain provisions of the Fair Debt Collection Practices Act (FDCPA) and comparable statutes in many states. Under the FDCPA, a third-party collection company is restricted in the methods it uses to contact consumer debtors and elicit payments with respect to placed accounts. Requirements under state collection agency statutes vary, with most requiring compliance similar to that required under the FDCPA. We believe we are in substantial compliance with the FDCPA and comparable state statutes where applicable. If our collection practices are viewed as inconsistent with these standards, we may be subject to damages and penalties.

Human Capital Resources

Teammate Overview

Our teammates are at the heart of everything that we do. Through their creativity, talent and hard work, our teammates allow us to offer exceptional products and services, and they provide the force that propels our mission to

[Table of Contents](#)

empower our customers to advance healthcare. Thus, we are committed to maintaining a results-driven culture and providing benefits that will attract and retain top talent. We are also committed to creating an environment that allows our teammates to perform at a high level, emphasizes a culture of safety and is conducive to professional and personal growth. At the end of 2025, following the sale of our Products & Healthcare Services segment (the “P&HS Sale”), we employed over 6,500 full-time and part-time teammates. None of our teammates are represented by a labor union or subject to a collective bargaining agreement (CBA). Throughout our operations, we continue to have positive relationships with our teammates.

We depend on our key personnel to successfully operate our business, including our executive officers and senior corporate management. We seek to attract and retain top talent for these critical roles by offering competitive base and incentive compensation packages (and in certain instances share-based compensation and retention incentives), attractive benefits, and opportunities for advancement and rewarding careers. We periodically review and adjust, if needed, our teammates’ total compensation (including salaries, annual cash incentive compensation, other cash and equity incentives, and benefits) to ensure that our offerings are competitive within the industry and consistent with our performance. We have enterprise-wide talent development and succession planning programs designed to identify future and/or replacement candidates for key positions.

In order to take advantage of available opportunities and successfully implement our long-term strategy, we understand that we must be able to employ, train and retain skilled personnel. To that end, we support and utilize various training and educational initiatives, and we have developed Company-wide and project-specific teammate training and educational programs. Key programs focus on teammate safety, leadership development, health and wellness, work-life balance, talent management, and teammate engagement. We believe that teammate engagement is integral to our Bringing Care to Life purpose, vision, strategy and business success. We also believe that our teammates are the face of Accendra Health, and we expect every teammate to model our values and commitment to ethical business practices as set forth in our Code of Honor.

We believe that our efforts to create an environment that is conducive to our values and teammate success have been successful. Our values reflect our commitment to our customers, our teammates and the environment and the communities where we live and work. Our values embody “IDEAL” behavior — Integrity, Development, Excellence, Accountability and Listening. All teammates are expected to reflect these values in all they do each and every day. We also hold our teammates to a high standard of performance, and we regularly evaluate teammates’ productivity against current requirements, future demand expectations and historical trends. From time to time, we may add, reduce or adjust resources in certain areas to align with changing circumstances.

Our Board of Directors’ Role in Human Capital Resource Management

Our Board of Directors (Board) believes that human capital management, and particularly the ability to attract, retain and develop key talent, is essential to our continued growth and success. Our Board also believes that effective human capital management is vital to maintaining a culture that reflects our core values and our shared commitment to excellence and ethical business practices.

Management regularly reports to the Our People & Culture Committee of the Board on human capital management topics, including corporate culture, teammate development, compensation, and benefits. From time to time, we also conduct teammate engagement surveys to solicit feedback, and report findings from these surveys to the Board. The Our People & Culture Committee has oversight of talent retention and development, including succession planning, and the Board provides input on important decisions in each of these areas.

Available Information

The Company files annual reports, quarterly reports, proxy statements and other documents with the Securities and Exchange Commission (SEC) under the Securities Exchange Act of 1934, as amended (Exchange Act). We make these filings available free of charge through the SEC Filings link in the Investor Relations content section on our website located at www.accendrahealth.com as soon as reasonably practicable after they are filed with or furnished to

[Table of Contents](#)

the SEC. Information included or accessible on our website is not incorporated by reference into this Annual Report on Form 10-K.

Furthermore, the SEC also maintains a website that contains reports, proxy and information statements, and other information regarding Accendra Health, Inc. The public can obtain any documents that the Company files with the SEC at www.sec.gov.

We announce material financial information to our investors using our Investor Relations website, including SEC filings, press releases, public conference calls and webcasts. We use these channels as well as social media and blogs to communicate with our teammates and the public about our Company, our services and other developments. It is possible that the information we post on social media and blogs could be deemed to be material information. Therefore, we encourage investors, the media, and others interested in our Company to review the information we post on the social media channels and blogs listed on our Investor Relations website.

Additionally, we have adopted a written Code of Honor that applies to all of our directors, officers and teammates, including our principal executive officer and senior financial officers. This Code of Honor (including any amendments to or waivers of a provision thereof) and our Corporate Governance Guidelines are available on our website at www.accendrahealth.com.

Item 1A. Risk Factors

Index to Risk Factors

Section	Page
Operational Risks	14
Risks Related to the Sale of our Products & Healthcare Services business	18
Industry and Economic Risks	19
Litigation and Regulatory Risks	21
Risks Related to Our Debt	26
General Risk Factors	28

Forward-Looking Statements and Risk Factors Summary

This report contains certain statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, and generally can be identified by the use of words such as “may,” “could,” “aim,” “seek,” “believe,” “will,” “expect,” “project,” “estimate,” “intend,” “target,” “anticipate,” “plan,” “continue,” or similar expressions. The forward-looking statements in this Annual Report are based on certain risks and uncertainties, including the risk factors described below and the specific risk factors discussed herein and in connection with forward-looking statements throughout this Annual Report, which could cause actual results to vary materially from the expectations and projections expressed or implied by our forward-looking statements. Risks and uncertainties that may cause such differences include, among other things: increasing competitive and pricing pressures in the marketplace; our ability to retain existing and attract new customers and our dependence on certain customers, vendors, suppliers and third-parties; our ability to successfully identify, manage or integrate acquisitions; risks arising from the legal, regulatory or licensing requirements of the markets in which we operate; and general economic, regulatory and business conditions, including related to our international operations, among others. New risks and uncertainties may arise from time to time and are difficult to predict. Although we believe our expectations with respect to the forward-looking statements are based upon reasonable assumptions within the bounds of our knowledge of our business and operations, all forward-looking statements involve risks and uncertainties and, as a result, actual results could differ materially from those projected, anticipated or implied by these statements. We could also be affected by risks that we currently are not aware of or that we currently do not consider material to our business.

[Table of Contents](#)

The following is a summary of the risk factors that we currently believe could materially and adversely affect our business, financial condition, results of operations and cash flows and are not all of the risks that we face. We undertake no obligation to update or revise any forward-looking statements, except as required by law.

Operational Risks

- Our concentration in and dependence on certain Payors.
- Our failure to maintain our relationships with hospital and physician referral sources may cause revenue decline.
- Changes in customer and product mix could materially adversely affect our financial condition and results of operations.
- Our business dependence on certain significant suppliers.
- Our operations depend on proper functioning of information systems; and a cyberattack or systems breach could adversely affect business.
- The recent termination of our contracts with a large commercial payor could negatively impact our financial condition and liquidity.
- A CMS determination reducing reimbursement qualification for non-invasive ventilation products could negatively impact our financial results.
- Our ability to attract and retain talented teammates is critical to our success.
- Our inability to adequately integrate acquisitions could materially adversely affect operations.
- The storage, transportation and provision of compressed and liquid oxygen carries inherent risk of rupture or accidents.
- Our goodwill may become further impaired, requiring significant charge to earnings.

Risks Related to the Sale of our Products & Healthcare Services Business

- The sale of the P&HS business may negatively impact our financial condition, results of operations, cash flows, capital resources and liquidity.
- We are required to provide transitional services which may divert the management's attention and harm our business.
- We are dependent on the successful execution of transitional services by third party.
- Certain of our contracts were transferred or may need to be transferred or replaced and the failure to obtain replacements could increase our expenses.
- The sale of P&HS assets could negatively impact business, and the retained liabilities could adversely affect our financial results.

Industry and Economic Risks

- We face increasing competition, accelerating pricing pressure and changes in technology.
- Uncertainty about economic conditions and adverse political changes may affect demand for our products, services and our accounts receivable collectability.
- Changing conditions in the U.S. healthcare industry may impact the results of our operations and cash flows.

Litigation & Regulatory Risks

- We are subject to stringent regulatory and licensing requirements; and potential federal and state investigations and compliance reviews.
- We must obtain regulatory clearance prior to consummating certain healthcare transactions.

[Table of Contents](#)

- Our failure to comply with regulatory requirements or receive clearances or approvals for our medical gas facilities could adversely affect our business.
- Our business may be adversely affected if we are unable to establish, maintain, protect and enforce intellectual property rights.
- We may become subject to litigation, investigations, claims and legal proceedings.
- We could be subject to adverse tax law changes, challenges to tax positions and audits resulting in additional payments.
- Our ESG-related aspirations, goals and disclosures expose us to risks including reputational and stock price risks.
- Our amended bylaws designate U.S. District Court for Eastern District of Virginia as the exclusive forum for certain litigation, which could limit our stockholders' ability to obtain favorable judicial forum.

Risks Related to Our Debt

- We may not be able to refinance, extend or repay our substantial indebtedness.
- We may not be able to generate sufficient cash to service debt and other obligations.
- Our credit facilities and existing notes have restrictive covenants that could limit financial flexibility.
- Our variable rate indebtedness subjects us to interest rate risk.
- We may continue to incur additional substantial indebtedness in the future.

General Risk Factors

- Our continued success is substantially dependent on positive perceptions of our reputation.
- We are subject to risks related to public health crises and future outbreaks.
- The market price for our common stock and debt have been and may continue to be volatile.
- We may be adversely affected by global climate change or legal, regulatory or market responses to such change.

Operational Risks

We have concentration in and dependence on certain Payors.

During the year ended December 31, 2025, our two largest commercial Payors represented approximately 23% and 14% of our net revenue, derived from multiple separately managed contracts. Revenue reimbursed under arrangements with Medicare and state Medicaid programs was approximately 19% of our net revenue for the year ended December 31, 2025. A commercial Payor, with which we have multiple separately managed contracts, has terminated, or is in the process of terminating, certain of our contracts with them. The terminated agreements reflected \$322 million or 12% of our net revenue, including \$231 million of capitation revenue, which represents nearly all of our capitation revenue, for the year ended December 31, 2025. Refer to the risk factor titled, "The recent contract termination from a large commercial Payor could negatively impact our financial condition, results of operations, cash flows, capital resources and liquidity risk" below for additional information. Changes in a significant individual Payor relationship could have a material adverse effect on our financial condition, results of operations, cash flows, capital resources and liquidity.

Our failure to establish and maintain relationships with hospital and physician referral sources may cause our revenue to decline.

We do not have contracts or exclusive arrangements with most hospitals or physicians, but we attempt to work closely with hospitals and physicians to accept discharges and referrals of their patients who require our services. Therefore, our success is significantly dependent on referrals from hospital and physician sources. If we are unable to

[Table of Contents](#)

successfully establish new referral sources and maintain strong relationships with our current referral sources, if there is an actual or perceived decrease in the quality of service and care levels we provide, or if efforts to increase the skill level and effectiveness of our sales force fail, our revenues may decline. In addition, our relationships with referral sources are subject to federal and state healthcare laws such as the U.S. federal Anti-Kickback Statute (Anti-Kickback Statute) and the U.S. federal Stark Law (Stark Law), and compliance with these laws limits the scope of our relationships with our referral sources.

Possible changes in customer and product mix could have a material adverse effect on our business, financial condition, results of operations, cash flows, capital resources and liquidity.

Our revenues are determined by a number of factors, including mix of customers, the rates of payment among customers and the mix of our products and services provided. A shift towards customers with lower compensation, or from higher gross margin products to lower gross margin products, would reduce our gross profits. Changes in the mix of our customers, products and services provided and payment methodologies could have a material adverse effect on our business, financial condition, results of operations, cash flows, capital resources and liquidity.

Our business is dependent on certain significant suppliers.

We currently rely on a relatively small number of suppliers to provide us with the majority of our patient service equipment and supplies for our home healthcare business. During the year ended December 31, 2025, our three largest suppliers contributed 16%, 14% and 11% of our purchases collectively accounting for approximately 40%. From time to time, we also enter into certain exclusive arrangements with suppliers for the provision of patient service equipment and supplies. Further, some of our supply agreements contain pricing scales that depend on meeting certain order volumes. Our inability to procure certain equipment and supplies, including as a result of failure to maintain and renew certain agreements and access arrangements, could have a materially adverse effect on our results of operations and cash flows. We often use suppliers selectively for quality and cost reasons. Significant price increases, or disruptions in the ability to obtain such equipment and supplies from existing suppliers, such as the disruptions that were associated with the Philips Respiroics recall as described in Management's Discussion and Analysis of Financial Condition and Results of Operations, which primarily affected our 2024 results, may reduce our income and could force us to use alternative suppliers. Any change in the existing suppliers we use could cause delays in the delivery of products and possible losses in revenue, which could adversely affect our results of operations and cash flows. In addition, alternative suppliers may not be available, or may not provide their products and services at similar or favorable prices. If we cannot obtain the patient service equipment and supplies we currently use, or alternatives at similar or favorable prices, our ability to provide such products may be severely impacted, which could have an adverse effect on our business, financial condition, results of operations, cash flows, capital resources and liquidity.

Our operations depend on the proper functioning of information systems, and our business or results of operations could be adversely affected if we experience a cyberattack or other systems breach or failure.

Our business depends on the proper functioning and availability of computer systems and networks to meet operational needs. These systems are also relied upon for receiving and filling orders for customers, billings to and collections from customers, the purchase of and payment for inventory and related transactions from our suppliers, and the secure electronic transmission, processing, storage, and hosting of sensitive information, including protected health information and other types of personal information, confidential financial information, proprietary information, and other sensitive information relating to our customers, company, and teammates. In addition, the success of our long-term growth strategy is dependent upon the ability to continually monitor and upgrade our information systems to provide better service to customers.

As described in Item 1C, we have an integrated framework to prevent, identify and mitigate risks related to cybersecurity attacks on our systems. Despite physical, technical, and administrative security measures by us and our external service providers and consultants, our technology systems and operations have been subject to cyberattacks in the past and may be subject to cyberattacks in the future from sources beyond our control. In recent years, cyberattacks in our industry have increased and become more sophisticated. For instance, we expect threat actors may use more advanced tools and techniques, such as artificial intelligence (AI), that are designed to circumvent security controls. As a

result, the risk of a cyberattack on our systems has increased. We do not oversee or actively monitor cybersecurity risks related to our external service providers and we rely on these providers to inform us of risks, breaches or cyberattacks. Cyberattacks include actual or attempted unauthorized access, tampering, malware insertion, ransomware attacks, or other system integrity events. A future cybersecurity incident could involve a material data breach or other material impact to the operations of our technology systems, or the third party service providers on which we rely, which could result in failure of our systems to operate properly for an extended period of time, litigation or regulatory action, loss of customers or revenue, and increased expense, any of which might have a material adverse impact on our business operations, reputation, our growth and strategic initiatives, results of operations, financial condition and cash flows.

The recent termination of certain contracts commercial Payor could negatively impact our financial condition, results of operations, cash flows, capital resources and liquidity.

A commercial Payor, with which we have multiple separately managed contracts, has terminated, or is in the process of terminating, as applicable certain of our contracts with them. The termination resulted in minimal impacts to our operating income for the year ended December 31, 2025, as the transitions of agreements and services started late in the fourth quarter of 2025. While the transitions of agreements and services are expected to continue throughout the first half of 2026, the specific timing of when these contracts will wind down is highly dependent on the Payor's successor provider's ability to successfully transition customers among other factors. The terminated agreements reflected \$322 million or 12% of our net revenue, including \$231 million of capitation revenue, which represents nearly all of our capitation revenue, for the year ended December 31, 2025.

If we are unable to win new business to substitute this loss, effectively execute cost reduction actions, or maintain volume-based supplier discounts, the loss of this contractual relationship could negatively impact our financial condition, results of operations, cash flows, capital resources and liquidity.

A determination from the Centers for Medicare and Medicaid Services (CMS) would reduce reimbursement qualification for non-invasive ventilation products, which could negatively impact our financial condition, results of operations, cash flows, capital resources and liquidity.

In June 2025, CMS released a final national coverage determination for non-invasive positive pressure ventilation (NIPPV) in the home for the treatment of chronic respiratory failure due to chronic obstructive pulmonary disease (COPD). This determination may make qualifying for NIPPV more difficult for new COPD patients seeking this treatment, as patients must meet a number of criteria before qualifying for coverage of an initial six-month period for respiratory assist devices and home mechanical ventilation. This CMS determination could adversely affect our business, results of operations, and financial condition.

Our ability to attract and retain talented and qualified teammates is critical to our success and competitiveness.

The success of our business depends on our ability to attract, engage, develop and retain qualified and experienced teammates, including key executives. We may not be able to successfully compete for, attract, or retain qualified and experienced teammates, especially in North America where labor markets continue to be highly competitive. Competition among potential employers, labor shortages, and inflationary pressures might result in increased salaries, benefits or other teammate-related costs, or in our failure to recruit and retain teammates. We may experience sudden loss of key personnel due to a variety of causes, including competitive recruitment, retirement, illness, death, or disability, and must adequately plan for succession of key executive roles. Teammates might not successfully transition into new roles. If we are unable to recruit or retain a sufficient number of qualified employees, or if the costs of compensation or employee benefits increase substantially, our ability to deliver services effectively could suffer and our profitability would likely be adversely affected. In addition, employee union organizing activities have occurred in the past and may occur in the future, and the adverse impact of unionization and organizing activities on our costs and operating results could be substantial.

Our inability to adequately integrate acquisitions could have a material adverse effect on our operations.

In connection with our growth strategy, we from time to time acquire other businesses, that we believe will expand or complement our existing businesses and operations. The integration of acquisitions involves a number of significant risks, which may include but are not limited to, the following: expenses and difficulties in the transition and integration of operations and systems; complexities associated with managing the expanded operations; retention of current customers and the ability to obtain new customers; the assimilation and retention of personnel; accounting, tax, regulatory and compliance issues; difficulties in implementing uniform controls, procedures, policies and information systems; unanticipated expenses, delays or regulatory issues associated with integrating the operations; general economic conditions in the markets in which the acquired businesses operate; difficulties encountered in conducting business in markets where we have limited experience and expertise; difficulties obtaining or failure to obtain necessary regulatory licenses and Payor-specific approvals; diversion of management's attention caused by completing the integration of the operations; inadequate indemnification from the seller; and failure of the seller to perform under any transition services agreement.

Even if we are able to integrate an acquired business successfully, this integration may not result in the realization of the full benefits that we expected or may be more costly than we expected. If we are unable to successfully complete and integrate our strategic acquisitions in a timely manner, our business, growth strategies, results of operations and cash flows could be adversely affected.

Our operations involve the storage, transportation and provision of compressed and liquid oxygen, which carries an inherent risk of rupture or other accidents with the potential to cause substantial loss.

Our operations are subject to the many hazards inherent in the storage, transportation and provision of medical gas products and compressed and liquid oxygen, including ruptures, leaks and fires. These risks could result in substantial losses due to personal injury or loss of life, severe damage to and destruction of property and equipment and pollution or other environmental damage and may result in curtailment or suspension of our related operations. If a significant accident or event occurs, it could adversely affect our business, financial condition, results of operations, and cash flows. Additionally, corrective action plans, fines or other sanctions may be levied by government regulators who oversee the storage, transportation and provision of hazardous materials such as compressed or liquid oxygen.

Our goodwill may become further impaired, which would require us to record a significant charge to earnings in accordance with generally accepted accounting principles.

U.S. Generally Accepted Accounting Principles (GAAP) require us to test our goodwill for impairment on an annual basis, or more frequently if indicators for potential impairment exist. The testing required by GAAP involves estimates and judgments by management. Although we believe our assumptions and estimates are reasonable and appropriate, any significant adverse changes in one or a combination of key assumptions, including, but not limited to, a further decrease in our market capitalization, an increase in the discount rate, a failure to meet our business plans or expected earnings and cash flows, unanticipated events and circumstances such as the loss of a contract with a significant Payor, changes in assumptions about the duration and magnitude of increased supply chain expense, commodities costs or inflationary pressures and our planned efforts to mitigate such impacts, disruptions in the supply chain, a decrease in the terminal growth rate, increases in tax rates (including potential tax reform) or a significant change in industry or economic trends, may affect the accuracy or validity of such estimates and may result in goodwill impairment. As a result of an interim impairment test performed during the three months ended December 31, 2024, we recorded a goodwill impairment charge in our Apria reporting unit of \$307 million. No impairment charges to goodwill were recorded in continuing operations 2025 or 2023. We may be required to record a material charge to earnings in our consolidated financial statements during the period in which any impairment of our goodwill is determined, which charge could adversely affect our results of operations.

Risks Related to the Sale of our Products & Healthcare Services Business

We have sold our P&HS business, and there may be negative impacts on our financial condition, results of operations, cash flows, capital resources and liquidity.

On December 31, 2025, we completed the P&HS Sale after which we are a significantly smaller, less diversified company with a single segment. We may be more vulnerable to changing market conditions, which could have a material adverse effect on our business, results of operations, financial condition and cash flows. In addition, the diversification of revenue, costs, and cash flows has diminished, such that our results of operations, cash flows, working capital, effective tax rate, and financing requirements may be subject to increased volatility and our ability to fund capital expenditures and investments and service debt may be diminished. We may be unable to achieve the full strategic and financial benefits that we believe we may be able to achieve through the sale of our P&HS business, or such benefits may be delayed or may never occur at all. For example, we believe the sale could provide the following benefits, among others:

- directing capital toward the higher growth and higher margin Accendra Health business; and
- applying proceeds from the sale to repay certain of our indebtedness.

We may not achieve these or other anticipated benefits for a variety of reasons, including, among others: (i) the possibility that we may not benefit as expected from the increased focus on our Accendra Health business and simpler business model made possible by the sale and (ii) the risk of litigation, injunctions or other legal proceedings relating to the sale. If we fail to achieve some or all of the benefits we expect to achieve as a result of the sale of our P&HS business, or if such benefits are delayed, our business, results of operations, financial condition and cash flows could be materially and adversely affected.

The sale of our P&HS business has resulted and will continue to result in significant separation costs, and we are obligated to reimburse Purchaser for the first \$65 million of such costs subsequent to the completion of the sale, subject to conditions described in Note 3. See Note 3 “discontinued operations” in the Notes to Consolidated Financial Statements for additional information.

Furthermore, the sale process could cause disruptions and create uncertainty surrounding our business and affect our relationships with our customers, suppliers and teammates. Although we have taken actions to reduce any adverse effects, these uncertainties could cause customers, suppliers and others that deal with us to seek to change existing business relationships. In addition, teammate retention could be negatively impacted. If key teammates depart because of concerns relating to the uncertainty, our business could be harmed. Additionally, until the market has fully analyzed our valuation following the sale of the P&HS business, the price of our common stock may fluctuate. Furthermore, the sale has decreased the diversification of our revenues, costs and cash flows, and so our operations, cash flows, working capital, effective tax rate and financing requirements may be subject to increased volatility, and our ability to fund capital expenditures and investments, pay dividends and meet debt obligations and other liabilities may be diminished.

In connection with the sale of the P&HS business, we are required to provide certain transitional services which may divert management’s attention and harm our business.

In connection with the P&HS Sale, we are required to provide certain services to the Purchaser for a transitional period. Such transitional services arrangements may be in exchange for fees that do not fully compensate us for the cost of providing such transitional services and may also divert management’s attention and resources, away from the existing business, which could harm our business.

In connection with the sale of the P&HS business, we are receiving certain transitional services and are dependent on the successful execution of these services by a third party.

In connection with the P&HS Sale, we are receiving certain services from the Purchaser for a transitional period. We are dependent on the Purchaser to provide us with these services over a transitional period. If we are not able

[Table of Contents](#)

to successfully transition off of these transitional services timely, it could negatively impact our ability to achieve our strategic objectives and could have a material adverse effect on our results of operations or financial condition.

Certain contracts used in our business were transferred or may need to be transferred or replaced in connection with the sale of the P&HS business and any failure to obtain such replacement contracts could increase our expenses or otherwise adversely affect our results of operations.

In connection with the sale of the P&HS business, we have been required and will be further required to replace certain shared contracts. It is possible that, in connection with the replacement process, some parties may seek more favorable contractual terms from us. If we are unable to obtain such replacement contracts, the loss of these contracts could increase our expenses or otherwise materially adversely affect our business, results of operations and financial condition.

The sale of certain assets associated with the P&HS business could negatively impact our business, and retained liabilities from businesses or assets that we have sold could adversely affect our financial results.

The asset sales in connection with the P&HS business pose risks and challenges that could negatively impact our business, including retained liabilities related to divested businesses and sold assets, obligations to indemnify buyers against contingent liabilities and potential disputes with buyers. If post-completion liabilities and obligations related to divestitures and asset sales are substantial and exceed our expectations, our financial position, results of operations and cash flows could be negatively impacted. Any divestiture or asset sale may result in a dilutive impact to our future earnings if we are unable to offset the dilutive impact from the loss of revenue and profits associated with the divestiture or sold asset, as well as significant write-offs, including those related to goodwill and other intangible assets, which could have a material adverse effect on our results of operations or financial condition.

Industry and Economic Risks

We face increasing competition, accelerating pricing pressure and changes in technology.

The home healthcare industry in which we operate is intensely competitive and highly fragmented. There are a large number of providers, including hospital systems, physician specialists and sleep labs, industrial gas manufacturers, home healthcare agencies, health maintenance organizations, and alternative treatment providers. There are also relatively few barriers to entry in local home healthcare markets. Hospitals, health systems, and Payors are routinely looking to provide coverage and better control of post-acute healthcare services, including home healthcare services of the types we provide. From time to time our contracts are amended (sometimes through unilateral action regarding payment policy), renegotiated, subjected to a bidding process with our competitors, or terminated altogether. Payors may enlarge their provider networks, reducing the amount of referrals or revenue we may receive from them, reduce their provider networks in exchange for lower payment rates or change the order of preference among the providers to which they refer business. In addition, pharmacy benefit managers, such as CVS Health Corporation, are competing with us in the home healthcare market. Large technology companies, such as Amazon.com, Inc. and Alphabet Inc., have disrupted other supply businesses and, in the case of Amazon.com, Inc. and its emerging pharmacy offerings, entered the healthcare market. In the event such providers enter the home healthcare market, we may experience a loss of referrals or revenue.

Traditional distribution relationships are also being challenged by online commerce solutions. Such competition will require us to cost-effectively adapt to changing technology, to continue to provide enhanced service offerings and to continue to differentiate our business (including with additional value-added services) to address demands of consumers and customers on a timely basis. The emergence of such competition and our inability to anticipate and effectively respond to changes on a timely basis could have a material adverse effect on our business.

Some of our competitors may now or in the future have greater financial or marketing resources than we do, or have more effective sales and marketing activities, which may increase pricing pressure and limit our ability to maintain or increase our market share. In addition, in certain markets, competitors may have other products and services that are or perceived to be superior to our own.

It is also possible that major changes in available technology, Payor benefit or coverage policies related to those changes, or the preferences of customers, patients and referral sources, may cause our current product offerings to become less competitive or obsolete, and it will be necessary for us to adapt to those changes. Such unanticipated changes could cause us to incur increased capital expenditures and change strategies and could have a material adverse effect on our business, results of operations, financial condition and cash flows.

Uncertainty about current and future economic conditions and other adverse changes in general political conditions may adversely affect demand for our products and services and collectability of our accounts receivable.

Poor or deteriorating economic and political conditions in the U.S could adversely affect the demand for healthcare services and consequently, the demand for our products and services. Such change in demand may result in further inventory valuation adjustments. Poor economic conditions also could lead our suppliers to offer less favorable terms, which would negatively affect our profitability. Further, the potential decline in federal and state revenues that may result from a deterioration in economic and political conditions may create additional pressures to contain or reduce reimbursements for our services from Medicare, Medicaid and other government sponsored programs. There can be no assurance that our products or services will be considered cost-effective or that adequate third-party reimbursement will be available to enable a company to maintain price levels sufficient to realize profitability. Increases in job losses in the U.S. as a result of adverse economic conditions could result in a smaller percentage of our patients being covered by an employer group health plan and a larger percentage being covered by lower paying Medicare and Medicaid programs. Employers may also select more restrictive commercial plans with lower reimbursement rates. To the extent that Payors are negatively impacted by a decline in the economy, we may experience further pressure on commercial rates, a slowdown in collections and a reduction in the amounts we expect to collect. Furthermore, the collection of accounts receivable requires constant focus and involvement by management and ongoing enhancements to information systems and billing center operating procedures. There can be no assurance that we will be able to improve upon or maintain current levels of collectability and DSO in future periods. Worsening economic conditions have had and may continue to have an adverse impact on the businesses and financial health of many of our customers and hurt their creditworthiness. The bankruptcy, insolvency or other credit failure of one or more customers with substantial balances due to us could have a material adverse effect on our results of operations, financial condition and cash flows. These and other possible consequences of financial and economic decline could have a material adverse effect on our business, results of operations, financial condition and cash flows.

The U.S. and global economies experienced elevated inflation rates significantly above Central Bank targets from 2021 through 2023, with inflation moderating but remaining above target levels through 2025. The Federal Reserve and other Central Banks raised interest rates during 2023 and 2024 and could do so again in the future. The present conditions and state of U.S. and global economies make it difficult to predict whether and/or when and to what extent a recession has occurred or will occur in the near future. Uncertainty about the effects of current and future economic and political conditions on us, our customers, suppliers and partners makes it difficult for us to forecast operating results and to make decisions about future investments. Inflation has and may continue to materially impact the costs to source materials or produce and distribute products to customers. Continued inflationary pressures could result in market pressures on our customers to reduce costs, which could impact our profitability and cash flows. Additionally, there is uncertainty that we will be able to pass elevated costs onto customers in an effort to offset inflationary pressures, or that such increases may outpace the compensating inflation-based increase in Medicare payment rates, or any other rate increases we may receive.

Any significant downturn in the health of the general economy, or any recession, depression or other sustained adverse market event, including inflationary pressures, could have an adverse effect on our revenues and financial performance, resulting in impairment of assets.

Changing conditions in the U.S. healthcare industry may impact our results of operations and cash flows.

We, along with our customers and suppliers, are subject to extensive federal and state regulations relating to healthcare as well as the policies and practices of the private healthcare insurance industry. In recent years, there have been a number of government and private initiatives to reduce healthcare costs and government spending. These changes

have included an increased reliance on managed care; consolidation of competitors, suppliers and customers; a shift in healthcare provider venues from acute care settings to clinics, physician offices and home care; and the development of larger, more sophisticated purchasing groups. National and regional insurers and managed care organizations are regularly attempting to seek reductions in the prices we charge for our products and services to them and their members, including through direct contracts with healthcare providers, increased oversight and greater enrollment of patients in managed care programs and preferred provider organizations. We have faced, and expect to continue to face, pricing pressures due to reductions in provider reimbursement for our products and services. In addition, in recent years, the healthcare industry in the U.S. has experienced and continues to experience significant consolidation in response to cost containment legislation and general market pressures to reduce costs. This consolidation of our customers, health insurers and suppliers generally gives them greater bargaining power to reduce the pricing available to them. All of these changes place additional financial pressure on healthcare provider customers, who in turn seek to reduce the costs and pricing of products and services provided by us. We expect the healthcare industry to continue to change significantly and these potential changes, which may include a reduction in government support of healthcare services, adverse changes in legislation or regulations, and further reductions in healthcare reimbursement practices, could have a material adverse effect on our business, results of operations, financial condition and cash flows.

Litigation & Regulatory Risks

We are subject to stringent regulatory and licensing requirements, and we have been, are and in the future could become the subject of federal and state investigations and compliance reviews.

We are required to comply with extensive and complex laws and regulations at the federal, state and local government levels in the U.S. We, and certain of our employees, also are required to hold permits and licenses and to comply with the operational and security standards of various governmental bodies and agencies. Any failure to comply with these laws and regulations or any failure to maintain the necessary permits, licenses or approvals, or to comply with the required standards, could disrupt our operations and/or adversely affect our results of operations, financial condition and cash flows.

Among the U.S. healthcare related laws that we are subject to include the federal Anti-Kickback Statute, the federal Ethics in Patient Referrals Act, the Stark Law, the FCA the federal Civil Monetary Penalties Law, the criminal healthcare fraud provisions of the federal Health Insurance Portability and Accountability Act of 1996, federal laws and regulations that prohibit providers from billing and receiving payment from Medicare and Medicaid for services unless the services are medically necessary, adequately and accurately documents, and billed using codes that accurately reflect the type and level of services rendered, and similar state laws relating to fraud, waste and abuse. The requirements of these laws are complex and subject to varying interpretations, and it is possible that regulatory authorities could challenge our policies and practices. If we fail to comply with these laws, we could be subject to federal or state government investigations or qui tam actions (false claims cases initiated by private parties purporting to act on behalf of federal or state governments), which could result in civil or criminal sanctions, including the loss of licenses or the ability to participate in Medicare, Medicaid and other federal and state healthcare programs. Such sanctions and damages could adversely affect our results of operations, financial condition and cash flows.

We are a Medicare-certified supplier and participates in state Medicaid programs. Failure to comply with applicable standards and regulations could result in civil or criminal sanctions, including the loss of our ability to participate in Medicare, Medicaid and other federal and state healthcare programs.

We collect, handle and maintain patient-identifiable health information and other sensitive personal and financial information, which are subject to federal, state and foreign laws that regulate the use and disclosure of such information. Regulations currently in place continue to evolve, and new laws in this area could further restrict our ability to collect, handle and maintain personal or patient information, or could require us to incur additional compliance costs, either of which could have an adverse impact on our results of operations and cash flows. Violations of federal (such as HIPAA) and state laws concerning privacy and data protection could subject us to civil or criminal penalties, breach of contract claims, costs for remediation and harm to our reputation. AI, particularly generative AI, is an emerging technology subject to a complex and evolving regulatory landscape at both the federal and state level. Regulatory considerations surrounding AI in healthcare are still developing and many regulatory agencies including the FDA are

[Table of Contents](#)

developing and implementing requirements related to the functionality, safety, efficacy, and privacy of AI and machine learning technologies. The increased cost and difficulty with complying with such legal requirements, or a failure to do so, may have an adverse effect on our business.

Our operations, including our billing practices and our arrangements with healthcare providers, are also subject to extensive federal and state laws and audits, inquiries and investigations from government agencies. For example, in connection with the settlement agreements resolving the investigation conducted by the U.S. Attorney's Office for the Southern District of New York regarding civil investigative demands, Apria was required to enter into a five-year CIA with the HHS OIG. The CIA provides that Apria will, among other things, impose certain oversight obligations on Apria's board of directors, provide certain management certifications, and continue or implement, as applicable, certain compliance training and education. The CIA also requires Apria to engage independent third parties to review compliance with the CIA, as well as certain reporting, certification, record retention and notification requirements. Failure to comply with the obligations under the CIA could have material consequences for us including monetary penalties or exclusion from participation in federal healthcare programs.

Applicable laws may be directed at payments for the products and services we provide, conduct of our operations, preventing fraud and abuse, and billing and reimbursement from government programs such as Medicare, Medicaid and from commercial Payors. These laws may have related rules and regulations that are subject to interpretation and may not provide definitive guidance as to their application to our operations, including our arrangements with hospitals, physicians, and other healthcare providers.

Federal and state governments have contracted with private entities to audit and recover revenue resulting from payments made in excess of those permitted by federal and state benefit program rules. These entities include, but are not limited to, Recovery Audit Contractors that are responsible for auditing Medicare claims, Unified Program Integrity Contractors that are responsible for the identification of suspected fraud through medical record review and Medicaid Integrity Contractors, that are responsible for auditing Medicaid claims. We believe audits, inquiries, and investigations from these contractors and others will occur from time to time in the ordinary course of our business. We also may be subject to increased audits from commercial Payors and pursuant to federal, civil, and criminal statutes that relate to our billings to commercial Payors. Our efforts to be responsive to these audits, inquiries, and investigations may result in substantial costs and divert management's time and attention away from the operation of our business. Moreover, an adverse outcome with respect to any audit, inquiry or investigation may result in damage to our reputation, or in fines, penalties or other sanctions imposed on us. Such pending or future audits, inquiries, or investigations, or the public disclosure of such matters, could have a material adverse effect on our business, financial condition, results of operations, cash flows, capital resources and liquidity.

Federal and state laws are broadly worded and may be interpreted or applied by prosecutorial, regulatory, or judicial authorities in ways that we cannot predict. Additionally, in many instances, there are only limited publicly available guidelines and methodologies for determining errors with certain audits. As a result, there can be a significant lack of clarity regarding required documentation and audit methodology. The clarity and completeness of each patient medical file, some of which is the work product of physicians not employed by us, is essential to successfully challenging any payment denials.

Certain of our former operations under the P&HS business engaged in Ethylene Oxide (EtO) sterilization of medical products either directly or indirectly through third-parties. In the U.S., several regulators, including the EPA, the FDA, and agencies at the state and local level, play a role in regulating the use of EtO sterilization. Recent announcements of the temporary or permanent closure of sterilization facilities operated by others have been associated with state and/or local regulatory or other legal action related to EtO emissions at those facilities. We have been named as a defendant in a lawsuit alleging personal injury as a result of EtO emissions. Additionally, we have incurred, and may incur additional costs associated with defending EtO emissions litigation. We have taken measures to comply with all applicable emissions regulations and to reduce emissions. However, no assurance can be given that current or future legislative or regulatory action, or current or future litigation to which we may become a party, will not significantly increase the costs of conducting sterilization operations or curtail or eliminate the use of EtO in our operations. Further, we could be liable for damages and fines as a result of legislative or regulatory action or litigation, which could have a material adverse effect on our financial condition, results of operations, cash flows, capital resources and liquidity.

[Table of Contents](#)

Accordingly, our arrangements and business practices may be the subject of government scrutiny or be found to violate applicable laws. If federal or state government officials challenge our operations or arrangements with third parties that we have structured based upon our interpretation of these laws, rules, and regulations, such a challenge could potentially disrupt our business operations and we may incur substantial defense costs, even if we successfully defend our interpretation of these laws, rules, and regulations. If the government or third parties successfully challenge our interpretation, such a challenge may have a material adverse effect on our business, financial condition, results of operations, cash flows, capital resources and liquidity.

We must obtain clearance or approval from appropriate regulatory authorities prior to consummating transactions of certain healthcare related businesses.

In the U.S., there has been a trend towards increasing government oversight of investments in the healthcare industry. This trend is occurring at both the federal and state levels, with at least 15 states adopting laws requiring state regulators to be notified of investments in various healthcare entities. Some of these laws increase the authority of the relevant governmental authority to review and approve, deny, or require modifications to such transactions. The governmental authorities can, in some cases, delay or stop the proposed transaction from proceeding. These laws may make certain jurisdictions less suitable for investments into healthcare businesses and may result in increased compliance costs, introduce delays to investment and divestment transactions, alter transaction terms and structures and ultimately impact the returns of such investments.

Our failure to comply with regulatory requirements or receive regulatory clearances or approvals for our medical gas facilities, products or operations could adversely affect our business.

We have a number of medical gas facilities in several states. These facilities are subject to federal and state regulatory requirements. Our medical gas facilities and operations are subject to extensive regulation by the FDA and other federal and state authorities. The FDA regulates medical gases, including medical oxygen, pursuant to its authority under the FFDCA. Among other requirements, the FDA's cGMP regulations impose certain quality control, documentation, and recordkeeping requirements on the receipt, processing, and distribution of medical gas. Further, in each state where we operate medical gas facilities, we are subject to regulation under state health and safety laws, which vary from state to state. The FDA and state authorities conduct periodic, unannounced inspections at medical gas facilities to assess compliance with the cGMP and other regulations. We expend significant time, money, and resources in an effort to achieve substantial compliance with the cGMP regulations and other federal and state law requirements at each of our medical gas facilities. There can be no assurance, however, that these efforts will be successful and that our medical gas facilities will achieve and maintain compliance with federal and state laws and regulations. Our failure to achieve and maintain regulatory compliance at our medical gas facilities could result in enforcement action, including warning letters, fines, product recalls or seizures, temporary or permanent injunctions, or suspensions in operations at one or more locations, as well as civil or criminal penalties, all of which could materially harm our business, financial condition, results of operations, cash flows, capital resources, and liquidity.

The medical gas products we distribute and certain other products we distribute are subject to extensive regulation by the FDA and other federal and state governing authorities. Compliance with FDA, state, and other requirements regarding production, safety, quality, manufacturing, distribution and marketing is costly and time-consuming, and while we seek to be in full compliance, instances of non-compliance could arise from time to time. We cannot be assured that any of our medical gases will be certified by the FDA. We have applied for, and received, designated gas certifications for our medical gas products. We may not be successful in receiving certification in the future.

Failure to comply with applicable regulatory requirements could result in administrative enforcement action by the FDA or state agencies, which may include any of the following: adverse publicity; warning or untitled letters; fines; injunctions; consent decrees; civil money penalties; recalls; termination of distribution or seizure of our products; operating restrictions or partial suspension or total shutdown of production; delays in the introduction of products into the market; withdrawals or suspensions of current medical gas certifications or drug approvals, resulting in prohibitions on sales of our products; and criminal prosecution. There is also a risk that we may not adequately implement sustainable processes and procedures to maintain regulatory compliance and to address future regulatory agency

findings, should they occur. The FDA may change its policies, adopt additional regulations or revise existing regulations, each of which could prevent or delay certification of our medical gases, or could impact our ability to market a device that was previously certified or cleared by the FDA. Any of these sanctions could result in higher than anticipated costs or lower than anticipated sales and have a material adverse effect on our business, financial condition, results of operations, cash flows, capital resources and liquidity.

Our business may be adversely affected if we are unable to adequately establish, maintain, protect and enforce our intellectual property and proprietary rights or prevent third parties from making unauthorized use of such rights.

Our intellectual property is an important part of our business. Failure to adequately protect our intellectual property rights could result in our competitors offering similar products and services, potentially resulting in the loss of our competitive advantage and a decrease in our revenue, which would adversely affect our business prospects, financial condition, results of operations, and cash flows. Our success depends in part on our ability to protect our proprietary rights and intellectual property. We rely on a combination of intellectual property rights, such as patents, trademarks, copyrights, trade secrets (including know-how) and domain names, in addition to teammate and third-party confidentiality agreements, intellectual property licenses and other contractual rights, to establish, maintain, protect and enforce our rights in our technology, proprietary information and processes. For example, we rely on trademark protection to protect our rights to various marks as well as distinctive logos and other marks associated with our products and services. Furthermore, intellectual property laws and our procedures and restrictions provide only limited protection and any of our intellectual property rights may be challenged, invalidated, circumvented, infringed or misappropriated. If we fail to protect our intellectual property rights adequately, we may lose an important advantage in the markets in which we compete.

Other parties may also independently develop technologies, products and services that are substantially similar or superior to ours. We also may be forced to bring claims against third parties. However, the measures we take to protect our intellectual property from unauthorized use by others may not be effective, and there can be no assurance that our intellectual property rights will be sufficient to protect against others offering technologies, products or services that are substantially similar or superior to ours and that compete with our business. Our management's attention may be diverted by these attempts, and we may need to use funds in litigation to protect our proprietary rights against any infringement, misappropriation or other violation.

We may become subject to litigation, investigations, claims and other legal proceedings brought by regulatory agencies, third parties, or individuals.

Our commercial success depends in part on avoiding infringement, misappropriation or other violations of the intellectual property and proprietary rights of third parties. However, we may become party to disputes from time to time over rights and obligations concerning intellectual property held by third parties. For example, third parties may allege that we have infringed upon or not obtained sufficient rights in the technologies used in our products and services. We cannot assure that we are not infringing or violating, and have not infringed or violated, any third-party intellectual property rights, or that we will not be held to have done so or be accused of doing so in the future. Any claim that we have violated intellectual property or other proprietary rights of third parties, with or without merit, and whether or not it results in litigation, is settled out of court or is determined in our favor, could be time consuming and costly to address and resolve, and could divert the time and attention of management and technical personnel from our business. Our liability insurance may not cover potential claims of this type adequately or at all. Any of these events could have a material adverse effect on our business, results of operations, financial condition and cash flows.

We are subject to risks relating to asserted claims, litigation and other proceedings relating to employment and pay practices. We are facing, or may face, claims or become a party to a variety of legal actions that affect our business, including breach of contract actions, employment and employment discrimination-related suits or employee benefit claims under California and Federal law. We may also be subject to examination of our payroll practices from various federal and state taxation authorities from time to time. While we believe that our employment and pay practices materially comply with relevant laws and regulations, interpretations of these laws may change. There is a risk that we could be subject to payment of additional wages, insurance and employment, and payroll-related taxes and sizeable statutory penalties negatively impacting our financial position, results of operations and cash flows. In addition, our

involvement in these matters and any related adverse rulings may result in increased costs and expenses, significant costs in defending such claims, even if groundless, reputational damage, cause us from time to time to significantly increase our legal expenses and/or modify our pay practices, all of which would likely have an adverse impact on our financial performance and profitability.

We could be subject to adverse changes in the tax laws or challenges to our tax positions.

We operate throughout the U.S., and we are subject to the tax laws and regulations of the U.S. federal, state and local governments. From time to time, legislative and regulatory initiatives are proposed, including but not limited to proposals for changes in tax accounting methods for inventory, import tariffs and taxes, including the pass through impact from certain indirect suppliers, or other tax items. Changes in tax laws and regulations could adversely affect our tax positions, tax rate or cash payments for taxes. There can be no assurance that our effective tax rate will not be materially adversely affected by legislative developments.

Audits by tax authorities could result in additional tax payments for prior periods, and tax legislation could materially adversely affect our financial results and tax liabilities.

The amount of income taxes we pay is subject to ongoing audits by U.S. federal, state and local tax authorities and by non-U.S. tax authorities. In addition, tax laws and regulations are extremely complex and subject to varying interpretations. Although we believe that our historical tax positions are sound and consistent with applicable laws, regulations and existing precedent, there can be no assurance that our tax positions will not be challenged by relevant tax authorities or that we would be successful in any such challenge. If these audits result in assessments different from our reserves, our future results may include unfavorable adjustments to our tax liabilities.

Our aspirations, goals and disclosures related to ESG matters expose us to numerous risks, including risks to our reputation and stock price.

Companies are facing increasing scrutiny from regulators, investors, consumers and other stakeholders related to ESG matters. We engage with key stakeholders to develop ESG focus areas and to set ESG-related goals, many of which are aspirational. We have set and disclosed these focus areas, goals and related objectives as part of our continued commitment to ESG matters, but our goals and objectives, including our climate commitments, reflect our current plans and aspirations and are not guarantees that we will be able to achieve them. Our efforts to accomplish and accurately report on these goals and objectives present numerous operational, reputational, financial, legal and other risks, certain of which are outside of our control, and could have, under certain circumstances, a material adverse impact on us, including on our reputation and stock price.

Moreover, while we create and publish voluntary disclosures regarding ESG matters from time to time, some of the statements in those voluntary disclosures may be based on hypothetical expectations and assumptions that may or may not be representative of current or actual risks or events or forecasts of expected risks or events, including the costs associated therewith. Such expectations and assumptions are necessarily uncertain and may be prone to error or subject to misinterpretation given the long timelines involved and the lack of an established single approach to identifying, measuring and reporting on many ESG matters. In addition, our interpretation of reporting frameworks or standards may differ from those of others and such frameworks or standards may change over time, any of which could result in significant revisions to our goals or reported progress in achieving such goals.

There are efforts by some stakeholders and regulators to reduce companies' efforts on certain ESG-related matters. Both advocates and opponents to certain ESG initiatives are increasingly resorting to a range of activism forms, including media campaigns and litigation, to advance their perspectives. To the extent we are subject to such activism, it may require us to incur costs or otherwise adversely impact our business.

Our failure or perceived failure to adequately pursue or fulfill our goals and objectives, including our climate commitments, or to satisfy various reporting standards within the timelines we announce, or at all, could also have similar negative impacts and expose us to other risks, which under certain circumstances could be material. In addition, some stakeholders may disagree with our goals and initiatives. Further, organizations that provide information to

investors on corporate governance and related matters have developed ratings processes for evaluating companies on ESG matters. Such ratings are used by some investors to inform their investment and voting decisions, and thus unfavorable ESG ratings may have a negative impact on our reputation, stock and debt prices and access to and costs of capital.

Our amended and restated bylaws designate the U.S. District Court for the Eastern District of Virginia as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders' ability to obtain a favorable judicial forum for disputes with us.

Pursuant to our amended and restated bylaws, unless we consent in writing to the selection of an alternative forum, the U.S. District Court for the Eastern District of Virginia, (or, if such court lacks subject matter jurisdiction, another state or federal court located within the Commonwealth of Virginia) will be the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of the Company, (ii) any action asserting a claim of breach of a duty owed to the Company by any director or officer or other employee of the Company or the Company's shareholders, (iii) any action asserting a claim against the Company or any director or officer or other employee of the Company arising pursuant to any provision of the Virginia Stock Corporation Act, our articles of incorporation or our amended and restated bylaws (as applicable) or (iv) any action asserting a claim against the Company or any director or officer or other employee of the Company governed by the internal affairs doctrine. In addition, our amended and restated bylaws provide that, unless we consent in writing to the selection of an alternative forum, the U.S federal district courts shall, to the fullest extent permitted by law, be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended. The forum selection clause in our amended and restated bylaws may have the effect of discouraging lawsuits against us or our directors and officers and may limit our stockholders' ability to obtain a favorable judicial forum for disputes with us.

Risks Related to Our Debt

We may not be able to refinance, extend or repay our substantial indebtedness which would have a material adverse effect on our financial condition.

The Term Loan A will mature in March 2027 and the Term Loan B will mature in March 2029. The Term Loan A and Term Loan B have \$326 million and \$511 million of principal outstanding excluding unamortized deferred financing costs as of December 31, 2025. The Revolving Credit Agreement matures in March 2027 and as of December 31, 2025, we had an outstanding balance of \$204 million. The 2029 Notes and 2030 Notes become due and payable in March 2029 and April 2030. We may need to raise capital in order to repay our indebtedness. As of December 31, 2025, we owed \$479 million and \$552 million in principal under our 2029 Notes and 2030 Notes, respectively. If we are unable to raise sufficient capital to repay these obligations at maturity and we are otherwise unable to extend the maturity dates or refinance these obligations, we would be in default. We cannot provide any assurances that we will be able to raise the necessary amount of capital to repay these obligations or that we will be able to extend the maturity dates or otherwise refinance these obligations. Upon a default, our lenders would have the right to exercise its rights and remedies to collect, which would include foreclosing on our assets. Accordingly, a default would have a material adverse effect on our business and financial condition.

We may not be able to generate sufficient cash to service our debt and other obligations.

As of December 31, 2025, on a consolidated basis we had \$2.1 billion of aggregate principal amount of indebtedness, excluding deferred financing costs and third party fees, \$217 million of undrawn availability under our revolving credit facility, as well as other contractual obligations due beyond the next twelve months. See Part II, Item 7 "Management's Discussion and Analysis of Financial Condition and Results of Operations – Contractual Obligations" of this Annual Report on Form 10-K for additional details.

Our ability to make payments on our indebtedness and our other obligations will depend on our financial and operating performance, which is subject to prevailing economic and competitive conditions and to certain financial, business and other factors beyond our control. We may be unable to maintain a level of cash flows from operating activities sufficient to permit us to pay the principal, premium, if any, and interest on our indebtedness.

[Table of Contents](#)

If our cash flows and capital resources are insufficient to fund our debt service obligations, we may be forced to reduce or delay investments and capital expenditures, or to sell assets, seek additional capital or restructure or refinance our indebtedness. These alternative measures may not be successful and may not permit us to meet our scheduled debt service obligations. We cannot assure you that we would be able to implement any of these alternatives on satisfactory terms or at all. In the absence of such operating results and resources, we could face substantial liquidity problems and may be required to dispose of material assets or operations to meet our debt service and other obligations. We may not be able to consummate those dispositions or to obtain the proceeds that we could realize from them, and these proceeds may not be adequate to meet any debt service obligations then due.

If we are unable to service our debt obligations from cash flows, we may need to refinance all or a portion of our debt obligations prior to maturity. Our ability to refinance or restructure our debt will depend upon our financial condition or the condition of the capital markets at such time. Any refinancing of our debt could be at higher interest rates and may require us to comply with more onerous covenants, which could further restrict our business operations. We may not be able to refinance any of our indebtedness on commercially reasonable terms or at all.

Our credit facilities and our existing notes have restrictive covenants that could limit our financial flexibility.

Our Credit Agreement and Revolver, as well as the indentures that govern our existing senior notes, contain financial and other restrictive covenants that limit our ability to engage in activities that may not be in our long-term best interests. Our credit facilities and the indentures governing our existing notes include restrictions that, among other things, limit our ability to: incur indebtedness; grant liens; engage in acquisitions, mergers, consolidations and liquidations; use proceeds from asset dispositions for general corporate purposes, restricted payments, or investments; enter into transactions with affiliates; and amend, modify or prepay certain indebtedness. Under our credit facilities, we are subject to financial covenants that require us to maintain ratios for leverage and interest coverage, including on a pro forma basis in the event of an acquisition or disposition.

These restrictions limit our ability to manage our business in our sole discretion, which could adversely affect our business by, among other things, limiting our ability to take advantage of financings, mergers, acquisitions and other corporate opportunities that we believe would be beneficial to us. The terms of any future indebtedness we may incur could include more restrictive covenants. We cannot assure you that we will be able to maintain compliance with these covenants in the future and, if we fail to do so, that we will be able to obtain waivers from the lenders and/or amend the covenants. Our ability to comply with these various covenants may be affected by events beyond our control, including prevailing economic, financial and industry conditions. Our failure to comply with these restrictions or covenants could result in a default under the agreements governing the relevant indebtedness. If a default under the credit facilities and the indentures governing our existing notes is not cured or waived, such default could result in the acceleration of debt or other payment obligations under our debt or other agreements that contain cross-acceleration, cross-default or similar provisions, which could require us to repurchase or pay debt or other obligations prior to the date it is otherwise due.

Our variable rate indebtedness subjects us to interest rate risk, which could cause our indebtedness service obligations to increase significantly.

Certain borrowings under our Credit Agreement bear interest at variable rates and expose us to interest rate risk. If interest rates were to increase, our debt service obligations on our variable rate indebtedness would increase even though the amount borrowed remained the same, and our earnings and cash flows will correspondingly decrease.

Despite current indebtedness levels, we may continue to incur indebtedness in the future, and the amount of that additional indebtedness may be substantial, which could further exacerbate the risks described herein.

We may incur substantial additional indebtedness in the future. If new debt is added to our current debt levels, the related risks that we and our subsidiaries now face to service debt levels and the risks associated with failure to adequately service our debt could intensify.

General Risk Factors

Our continued success is substantially dependent on positive perceptions of our reputation.

One of the reasons customers choose to do business with us and teammates choose us as a place of employment is the reputation that we have built over many years. To be successful in the future, we must continue to preserve, grow and leverage the value of our brand. Reputational value is based in large part on perceptions of subjective qualities. Even an isolated incident, or the aggregate effect of individually insignificant incidents, can erode trust and confidence, particularly if they result in adverse publicity, governmental investigations or litigation, and as a result, could tarnish our brand and lead to adverse effects on our business, results of operations, financial condition and cash flows.

We are subject to risks related to public health crises, future outbreaks of health crises or other adverse public health developments.

As a healthcare solutions company, we could be impacted by public health crises, pandemic or contagious diseases. For example, the COVID-19 pandemic disrupted capital markets, supply chains for equipment and medical supplies, and our services.

Further, actions by the U.S. federal, state or local governments in response to any such public health developments could adversely affect our business and operations, such as closure of one or more facilities for an unknown period of time.

We may incur additional costs to ensure we meet the needs of our customers and protect our workforce or to implement operational changes in response to any future pandemics. We may experience additional impacts which are not currently known.

The market price for our common stock and debt have been, and may continue to be, highly volatile.

A variety of factors may have a significant impact on the market price of our common stock and debt, including, but not limited to: the publication of earnings estimates or other research reports and speculation in the press or investment community; changes in our financial projections or our failure to meet these projections; changes in our industry and competitors; changes in government or legislation; government debt and/or budget crises; changes in our Board or management; our financial condition, results of operations and cash flows and prospects; activism by any single large shareholder or combination of shareholders; lawsuits threatened or filed against us; any future issuances of our common stock, which may include primary offerings for cash, stock splits, issuances in connection with business acquisitions, issuances of restricted stock/units and the grant or exercise of stock options from time to time; the trading volume of our common stock and debt; general market and economic conditions; any future outbreaks, and any future pandemics; the threat or outbreak of war, terrorism or public unrest (including, without limitation, geopolitical conflicts, including the war in Ukraine, conflicts in the Middle East, or tensions involving other regions); and the other factors discussed in this Item 1A. "Risk Factors," any of which could have a material effect on us.

The stock and bond markets have recently experienced extreme price and volume fluctuations. The market prices of securities of companies have experienced fluctuations that often have been unrelated or disproportionate to their operating results. In the past, following periods of volatility in the market price of a company's securities, securities class action litigation has often been instituted against companies. This type of litigation, if instituted, could result in substantial costs and a diversion of management's attention and resources, which could have a material adverse effect on our business.

Additionally, our common stock is subject to continued listing requirements on NYSE, including maintaining a minimum \$1.00 share closing price for a period of 30 consecutive trading days. If the closing bid price of our common stock falls below \$1.00 per share for 30 consecutive trading days, NYSE could issue a deficiency notice and ultimately delist our common stock if we fail to regain compliance. Given our recent stock price and recent financial challenges, including the loss of significant Payor contracts, goodwill impairment charges and the divestiture of our P&HS business, there is a risk that our stock price could fall below the minimum share price requirement. If our stock were delisted and

traded on the over-the-counter market, it would significantly reduce liquidity, make it more difficult for shareholders to sell their shares, impair our ability to raise capital and could have a material effect on our business operations and our financial condition, results of operations and cash flows.

We may be adversely affected by global climate change or by legal, regulatory or market responses to such change.

The long-term effects of global climate change are difficult to predict and may be widespread. The impacts may include physical risks (such as rising sea levels or frequency and severity of extreme weather conditions), social and human effects (such as population dislocations or harm to health and well-being), compliance costs and transition risks (such as regulatory or technology changes) and other adverse effects. The effects could impair, for example, the availability and cost of certain products, commodities and energy (including utilities), which in turn may impact our ability to procure goods or services required for the operation of our business at the quantities and levels we require. In addition, certain of our operations and facilities are in locations that may be impacted by the physical risks of climate change, and we face the risk of losses incurred as a result of, for example, physical damage to or destruction of our facilities (such as distribution centers), loss or spoilage of inventory, and business interruption. Insurance may not be available or cost effective for the coverage limits needed to address such losses.

In addition, federal, state, and local governments are increasingly focused on climate change and sustainability and new legal or regulatory requirements have and may in the future be enacted to prevent, mitigate, or adapt to the implications of a changing climate and its effects on the environment. For example, in 2024 the state of California enacted a series of laws that will require reporting of greenhouse gas emissions and climate risks. These and similar regulatory requirements, which may differ across jurisdictions, are likely to result in increased costs and complexities of compliance in order to collect, measure and report on the relevant climate-related information. Our supply chain will likely be subject to these same transitional risks and may pass along any related cost increases to us. These events and impacts could materially adversely affect our business operations and our financial position, results of operations and cash flows.

Item 1B. Unresolved Staff Comments

None.

Item 1C. Cybersecurity

Risk Management and Strategy

Our cybersecurity risk management processes are integrated within our enterprise risk management framework. We conduct periodic cybersecurity risk assessments to identify, evaluate and prioritize threats and vulnerabilities across our information technology environment and business operations. These assessments consider the evolving threat landscape, vulnerabilities in our systems and those of our third-party service providers and potential impacts to our business. Identified risks are evaluated based on likelihood and potential business impact, and we implement controls and mitigation measures aligned with business priorities.

We model our cybersecurity program to align with the practices and standards referenced within the National Institute of Standards and Technology cybersecurity framework. Our information security program is integrated within our larger enterprise risk management program and includes, but is not limited to:

- Following the methodology of Identify, Protect, Detect, Respond, and Recover;
- Mandatory annual cybersecurity awareness training for all teammates accessing our network;
- Monthly Company-wide phishing prevention and awareness exercises;
- Identification and remediation of information security risks and vulnerabilities in our information technology systems, including regular scanning of both internal and externally facing systems and annual third-party penetration testing;
- Implementation of security technologies intended to identify and assist in containing and remediating malware risks;

[Table of Contents](#)

- Active monitoring of logs and events for our network perimeter and internal systems;
- Due diligence of information security maintained by third-party vendors that handle our data;
- Partnering with the Cybersecurity and Infrastructure Security Agency (CISA), DHS, and the Federal Bureau of Investigation, to leverage their provided sensitive or confidential threat intel and with CISA for weekly vulnerability scans of our key public-facing servers;
- Maintaining a cyber insurance policy that provides coverage for security breach recovery and response; and
- Engagement of third party consultants to assess the health of our cybersecurity program.

We maintain a Cybersecurity Incident Response Plan (CIRP) to assist in promptly responding to, resolving and recovering from cybersecurity incidents. The CIRP includes guidelines for assessing, identifying, managing, reporting and remediating cyber incidents, including protocols for disclosure of material breaches with the SEC. Following a cybersecurity incident, we consult external subject matter experts, including legal counsel, to reduce the risk of further compromise to our information and to ensure proper reporting and documentation. Material cybersecurity incidents are escalated to our disclosure committee and senior management for materiality assessment, and the Audit Committee is informed promptly of material cybersecurity incidents in the event that they arise. For more information see Item 1A. “Risk Factors” for the Risk Factor entitled “Our operations depend on the proper functioning of information systems, and our business or results of operations could be adversely affected if we experience a cyberattack or other systems breach or failure.”

Governance

Our Cybersecurity program is managed by our Chief Information Security Officer (CISO). Our CISO works collaboratively with senior management, including the Chief Financial Officer, General Counsel, and other business leaders. The CISO has eighteen years of experience in cybersecurity. The CISO is responsible for developing and managing the overall strategy, leading the response to cybersecurity incidents and reporting to the Board.

Our policies require teammates, contractors, service providers and suppliers who become aware of a cybersecurity incident to immediately report it to their supervisor or the CISO through the appropriate reporting channels. In the event of a cybersecurity incident, in addition to the standing members, teammates would be selected to serve on the Cybersecurity Incident Response Team (CIRT) based on the facts and circumstances of the particular cybersecurity incident. Additionally, our outside legal counsel is held on retainer to assist with our response to cybersecurity incidents.

The Audit Committee of the Board has primary responsibility for oversight of our cybersecurity risk management program. The Audit Committee receives updates from management at least quarterly, or more frequently as appropriate, on our cybersecurity program including the threat environment, program initiatives and investments, cyber insurance coverage, significant incidents or risks, and key metrics.

To date, we have not experienced any cybersecurity incidents that have materially affected, or are reasonably likely to materially affect, our business strategy, results of operations, or financial condition.

Item 2. Properties

As of December 31, 2025, following the P&HS Sale, we had over 250 locations to serve patients across the U.S., centers of excellence aligned with specific mail order product categories, as well as regional distribution and repair centers, customer service and billing centers, a national pharmacy and a biomedical center for the repair, maintenance and distribution of patient service equipment.

We regularly assess our business needs and make changes to the capacity and the location of our facilities. We believe that our facilities are adequate to carry on our business as currently conducted. A number of leases are scheduled to expire within the next several years. We believe that, if necessary, we could find facilities to replace these leased premises without suffering a material adverse effect on our business. For information on material lease commitments see Note 6, “Leases”, in the Notes to Consolidated Financial Statements.

Item 3. Legal Proceedings

Certain legal proceedings in which we are involved are discussed in Note 15, “Commitments, Contingent Liabilities, and Legal Proceedings”, in the Notes to Consolidated Financial Statements in this Annual Report.

We are party to various legal claims that are ordinary and incidental to our business, including ones related to commercial disputes, employment, workers’ compensation, product liability, regulatory and other matters. We maintain insurance coverage for cybersecurity, employment, product liability, workers’ compensation and other personal injury litigation matters, subject to policy limits, applicable deductibles and insurer solvency. From time to time, we establish estimated liabilities based upon periodic assessment of the potential outcomes of pending matters.

Based on current knowledge and the advice of counsel, we believe that the liability recorded on the consolidated balance sheet as of December 31, 2025 for currently pending matters considered probable of loss, is sufficient. In addition, we believe that other currently pending matters are not reasonably possible to result in a material loss, as payment of the amounts claimed is remote, the claims are immaterial, individually and in the aggregate, or the claims are expected to be adequately covered by insurance, subject to policy limits, applicable deductibles, exclusions, and insurer solvency.

Item 4. Mine Safety Disclosures

Not applicable.

Information about our Executive Officers

Edward A. Pesicka (58)

President, Chief Executive Officer & Director

Mr. Pesicka has served as President and Chief Executive Officer since joining Accendra Health in March 2019. Mr. Pesicka was also appointed to the Board of Directors at the time he joined the Company. Previously Mr. Pesicka served as an independent consultant and advisor in the healthcare, life sciences and distribution industries since January 2016. From January 2000 through April 2015, Mr. Pesicka served in various roles of increasing responsibility at Thermo Fisher Scientific Inc., including Chief Commercial Officer and Senior Vice President from January 2014 to April 2015. Prior to that, he was President, Customer Channels at Thermo Fisher from July 2008 to January 2014 and President, Research Market from November 2006 to July 2008. Earlier in his career, Mr. Pesicka held various Vice President-level roles in Thermo Fisher Scientific’s finance department, serving as Chief Financial Officer of numerous divisions. Prior to Thermo Fisher Scientific, Mr. Pesicka spent eight years with TRW, Inc. in its finance department and three years with PricewaterhouseCoopers as an auditor.

Jonathan A. Leon (59)

Executive Vice President, Chief Financial Officer

Mr. Leon has served as Executive Vice President and Chief Financial Officer of Accendra Health since September 2024 and has served as interim Chief Financial Officer since June 2024. Previously Mr. Leon served as Senior Vice President, Corporate Treasurer of the Company since May 2018. Prior to that, Mr. Leon served as Vice President, Treasurer, after joining Accendra Health in January 2017. Before joining Accendra Health, Mr. Leon worked for Universal Corporation and The Brinks Company for 18 years where he served as Vice President and Treasurer.

Perry Bernocchi (67)

Executive Vice President & Chief Operating Officer

Mr. Bernocchi has served as Executive Vice President and Chief Operating Officer since January 2025 and was previously Executive Vice President and Chief Executive Officer, Patient Direct since March 2023. Prior to that, Mr. Bernocchi served as President & Chief Executive Officer of the Company’s Byram Healthcare division, a position he

[Table of Contents](#)

held since 2009. Mr. Bernocchi joined Byram Healthcare in 2006 as its Chief Operating Officer. Prior to that, Mr. Bernocchi served as Chief Operating Officer of Hemophilia Resources of America from 2000 to 2005 prior to its sale to Accredo Health. Prior to that, Mr. Bernocchi worked for Caremark/Coram from 1982 to 2000 in various roles of increasing responsibility in operations and general management within Coram Resource Network and as Senior Vice President of Operations.

Heath Galloway (49)

Executive Vice President, General Counsel & Corporate Secretary

Mr. Galloway joined Accendra Health in February 2013, serving as Assistant General Counsel until April 2016 and Associate General Counsel until May 2023, when he was appointed as Executive Vice President, General Counsel & Corporate Secretary. In this role, Mr. Galloway oversees the Accendra legal and government relations teams and has responsibility for corporate governance, M&A, dispute resolution, and legal compliance. In January 2026, Mr. Galloway also assumed oversight responsibility for the Company's human resources function. Before joining Accendra, Mr. Galloway spent nine years in private practice and was a partner at Williams Mullen, a full-service law firm based in Richmond, Virginia. Mr. Galloway received his Bachelor of Arts and Juris Doctorate degrees from Washington & Lee University.


Part II

Item 5. Market for Registrant's Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities

Accendra Health, Inc.'s common stock trades on the New York Stock Exchange under the symbol ACH (formerly OMI). As of January 31, 2026, there were 1,772 common shareholders of record. Because many of our shares of common stock are held by brokers and other institutions on behalf of stockholders, the common shareholders of record do not reflect the total number of stockholders.

5-Year Total Shareholder Return

The following performance graph compares the performance of our common stock to the Russell 2000 Index and the Russell 3000 Medical Equipment and Services Sector Index, an index that includes more than 100 companies in the medical equipment and services industry. This graph assumes that the value of the investment in the common stock and each index was \$100 on December 31, 2020, and that all dividends were reinvested.



[Table of Contents](#)

Company Name / Index	Base Period	Years Ended				
	12/2020	12/2021	12/2022	12/2023	12/2024	12/2025
Accendra Health, Inc.	\$ 100.00	\$ 160.85	\$ 72.22	\$ 71.26	\$ 48.33	\$ 10.35
Russell 2000 Index	100.00	114.78	91.30	106.71	119.00	134.23
Russell 3000 Medical Equipment and Services Sector	100.00	120.76	93.91	98.59	104.83	110.56

On February 26, 2025, our Board of Directors authorized a share repurchase program of up to \$100 million and expires in February 2027. Under the program, we may repurchase shares of common stock on a discretionary basis from time to time through open market repurchases, privately negotiated transactions and 10b5-1 trading plans.

The following table summarizes share repurchase activity for the year ended December 31, 2025:

(in thousands, except per share data)

Period	Total Number of Shares Purchased	Average Price Paid Per Share	Total Number of Shares Purchased as Part of Publicly Announced Program ⁽¹⁾	Approximate Dollar Value of Shares That May Yet be Purchased Under the Program ⁽²⁾
February 26-February 28, 2025	—	\$ —	—	\$ 100,000
March 1-March 31, 2025	173	\$ 8.66	173	\$ 98,500
April 1-April 30, 2025	653	\$ 7.87	653	\$ 93,360
May 1-May 31, 2025	—	\$ —	—	\$ 93,360
June 1-June 30, 2025	—	\$ —	—	\$ 93,360
July 1-July 31, 2025	—	\$ —	—	\$ 93,360
August 1-August 31, 2025	—	\$ —	—	\$ 93,360
September 1-September 30, 2025	—	\$ —	—	\$ 93,360
October 1-October 31, 2025	—	\$ —	—	\$ 93,360
November 1-November 30, 2025	1,129	\$ 3.10	1,129	\$ 89,860
December 1-December 31, 2025	—	\$ —	—	\$ 89,860
Total ⁽³⁾	1,955		1,955	

- (1) On February 26, 2025, our Board of Directors authorized a share repurchase program of up to \$100 million. The program expires in February 2027. Under the program, we may repurchase shares of common stock on a discretionary basis from time to time through open market repurchases, privately negotiated transactions and 10b5-1 trading plans.
- (2) During the period from February 26, 2025 (the date the share repurchase program was authorized) through December 31, 2025, we repurchased shares in open-market transactions and retired approximately 2.0 million shares of our common stock for an aggregate of \$10 million, or a weighted average price per share of \$5.19.
- (3) Represents the period from February 26, 2025 (the date the share repurchase program was authorized) through December 31, 2025.

Item 6. [Reserved]

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations

Sale of Products & Healthcare Services Business

On February 28, 2025, we announced that we were actively engaged in discussions regarding the potential sale of our Products & Healthcare Services business. On October 7, 2025, we entered into an Equity Purchase Agreement (the Purchase Agreement) by and among the Company, Dominion Healthcare Acquisition Corporation, a Delaware

[Table of Contents](#)

corporation (the Purchaser), and Dominion Healthcare Holdings, L.P., a Delaware limited partnership (Purchaser Parent) to sell the P&HS business, for an aggregate of \$375 million in cash, subject to certain adjustments for cash, indebtedness, net working capital and transaction expenses. On December 31, 2025, we completed the sale of the P&HS business pursuant to the Purchase Agreement. We retained a 5% equity interest in the P&HS business.

In accordance with GAAP, the financial position and results of operations of the P&HS business are presented as discontinued operations and, as such, have been excluded from continuing operations for all periods presented. With the exception of Note 3, the Notes to Consolidated Financial Statements reflect the continuing operations of Accendra Health, Inc. unless otherwise noted. See Note 3 in the Notes to Consolidated Financial Statements for additional information regarding discontinued operations.

Overview

Accendra Health, Inc. (f/k/a Owens & Minor, Inc.) and subsidiaries (Accendra Health, we, us, our or the Company) is a leading nationwide provider of products, technology, and services that supports health beyond the hospital for millions of people each year. As discussed later within Note 1 to Consolidated Financial Statements, our business activities comprise a single operating and reporting segment.

Net (loss) per share from continuing operations was \$(1.34) for the year ended December 31, 2025 as compared to net (loss) per share from continuing operations of \$(4.57) for the year ended December 31, 2024. Our financial results for the year ended December 31, 2025 as compared to the prior year were favorably impacted by the following: (1) no goodwill impairment charges for the year ended December 31, 2025 as compared to charges incurred for the year ended December 31, 2024 of \$307 million, or a \$3.97 negative impact per share (see Notes 1 and 5 in the Notes to Consolidated Financial Statements); (2) revenue growth of \$82 million; (3) a reduction in exit and realignment charges of \$28 million; (4) the remeasurement of an uncertain tax position for the year ended December 31, 2024, including interest which resulted in a \$19 million, or a \$0.24 negative income tax charge per share (see Note 12 in the Notes to Consolidated Financial Statements); that did not reoccur and (5) a \$15 million reduction in selling, general and administrative expense. These impacts were partially offset by (1) an \$80 million transaction breakage fee incurred in connection with the termination of the Rotech acquisition; (2) an increase in cost of net revenue of \$73 million; (3) an increase in intangible amortization of \$33 million; and (4) \$18 million in transaction fees during the year ended December 31, 2025.

Net (loss) per share from continuing operations was \$(4.57) for the year ended December 31, 2024 as compared to net income per share from continuing operations of \$0.12 for the year ended December 31, 2023. Our financial results for the year ended December 31, 2024 as compared to the prior year were unfavorably impacted by the following: (1) a goodwill impairment charge incurred for the year ended December 31, 2024 of \$307 million, or a \$3.97 negative impact per share; (2) an \$81 million increase in selling, general, and administrative expenses including legal settlements of \$17 million related primarily to compensation and wage and hour disputes; (3) a \$64 million increase in cost of net revenue; and (4) a \$39 million increase in exit and realignment costs. These unfavorable impacts were partially offset by (1) a \$128 million increase in net revenue; (2) a decrease in intangible amortization of \$18 million; and (3) a \$9.2 million decrease in interest expense, net.

Refer to “Results of Operations” for further detail of quantitative and qualitative drivers of our results.

Termination of Acquisition of Rotech

As previously disclosed, on July 22, 2024, we entered into an Agreement and Plan of Merger (the Merger Agreement) pursuant to which we agreed to acquire Rotech Healthcare Holdings Inc. (Rotech) subject to the terms and conditions within the Merger Agreement. On June 3, 2025, the Company, Rotech and Merger Sub mutually agreed to terminate the Merger Agreement and entered into a mutual termination agreement (the Termination Agreement). In accordance with the terms of the Termination Agreement, on June 5, 2025, we made a cash payment to Rotech of \$80 million.

Contract Termination with a Commercial Payor

A commercial Payor, with which we have multiple separately managed contracts, has terminated, or is in the process of terminating, certain of our contracts with them. This termination resulted in minimal impacts to our operating income for the year ended December 31, 2025, as the transitions of agreements and services started late in the fourth quarter of 2025. While such transitions of agreements and services are expected to continue throughout the first half of 2026, the specific timing of when these contracts will wind down is highly dependent on the Payor's successor provider's ability to successfully transition customers among other factors. The terminated contracts reflected \$322 million or 12% of our net revenue, including \$231 million of capitation revenue, which represents nearly all of our capitation revenue, for the year ended December 31, 2025.

Results of Operations

Our Management's Discussion and Analysis of Financial Condition and Results of Operations within this Annual Report on Form 10-K discusses 2025, 2024 and 2023 items and year-to-year comparisons between 2025, 2024 and 2023.

2025 compared to 2024 and 2024 compared to 2023

Net revenue.

	For the Years Ended December 31,		Change	
	2025	2024	\$	%
<i>(Dollars in thousands)</i>				
Diabetes	\$ 783,370	\$ 777,483	\$ 5,887	0.8 %
Sleep therapy	740,052	702,950	37,102	5.3 %
Home respiratory therapy	433,050	435,954	(2,904)	(0.7)%
Ostomy	212,838	195,923	16,915	8.6 %
Wound care	188,508	192,407	(3,899)	(2.0)%
Urology	116,022	107,121	8,901	8.3 %
Other	288,192	268,274	19,918	7.4 %
Net revenue	\$ 2,762,032	\$ 2,680,112	\$ 81,920	3.1 %

The increase in our net revenue for the year ended December 31, 2025 was driven primarily by sales growth in several product categories, including sleep therapy, ostomy, and urology. The growth in these categories includes the benefits from certain successful sales activities including our *Sleep Journey Initiative*. This increase was partially offset by \$11 million of benefits in the last half of 2024 associated with two settlement benefits related to two multi-year claims reprocessing matters.

	For the Years Ended December 31,		Change	
	2024	2023	\$	%
<i>(Dollars in thousands)</i>				
Diabetes	\$ 777,483	\$ 723,318	\$ 54,165	7.5 %
Sleep therapy	702,950	669,784	33,166	5.0 %
Home respiratory therapy	435,954	457,675	(21,721)	(4.7)%
Ostomy	195,923	177,890	18,033	10.1 %
Wound care	192,407	170,949	21,458	12.6 %
Urology	107,121	97,985	9,136	9.3 %
Other	268,274	254,971	13,303	5.2 %
Net revenue	\$ 2,680,112	\$ 2,552,572	\$ 127,540	5.0 %

[Table of Contents](#)

The increase in our net revenue for the year ended December 31, 2024 was driven primarily by sales growth in several product categories, including sleep therapy, diabetes, and wound care. The growth in these categories includes the benefits from certain successful sales activities including our *Sleep Journey Initiative*.

Cost of net revenue.

(Dollars in thousands)	For the Years Ended		Change	
	December 31,		\$	%
	2025	2024		
Cost of products sold	\$ 1,323,336	\$ 1,245,684	77,652	6.2 %
Patient service equipment depreciation	126,830	126,796	34	0.0 %
Other costs	22,567	27,252	(4,685)	(17.2)%
Cost of net revenue	\$ 1,472,733	\$ 1,399,732	\$ 73,001	5.2 %
As a % of net revenue	53.3%	52.2%		

The increase in cost of net revenue reflects the increased cost associated with sales growth of 3.1% and manufacturer price increases, as compared to prior year.

(Dollars in thousands)	For the Years Ended		Change	
	December 31,		\$	%
	2024	2023		
Cost of products sold	\$ 1,245,684	\$ 1,172,760	72,924	6.2 %
Patient service equipment depreciation	126,796	138,444	(11,648)	(8.4)%
Other costs	27,252	24,348	2,904	11.9 %
Cost of net revenue	\$ 1,399,732	\$ 1,335,552	64,180	4.8 %
As a % of net revenue	52.2%	52.3%		

The increase in our cost of net revenue reflects the increased cost associated with sales growth of 5.0% and manufacturer price increases, as compared to prior year.

Operating expenses.

(Dollars in thousands)	For the Years Ended		Change	
	December 31,		\$	%
	2025	2024		
Selling, general and administrative expenses	\$ 1,067,560	\$ 1,082,344	\$ (14,784)	(1.4)%
As a % of net revenue	38.7%	40.4%		
Goodwill impairment charge	\$ —	\$ 307,112	\$ (307,112)	(100.0)%
Transaction breakage fee	\$ 80,000	\$ —	\$ 80,000	NM %
Acquisition-related charges and intangible amortization	\$ 95,832	\$ 61,848	\$ 33,984	54.9 %
Exit and realignment charges, net	\$ 18,447	\$ 46,806	\$ (28,359)	(60.6)%

NM - Not meaningful

The decrease in SG&A expenses for the year ended December 31, 2025 as compared to the prior year was driven primarily from a reduction in teammate benefit costs of \$23 million and operating efficiencies in our revenue cycle and information technology, partially offset by inflationary increases and the cost to service the revenue growth of \$82 million.

Goodwill impairment charge for the year ended December 31, 2024 reflected impairment recognized in our former Apria reporting unit during the quarter ended December 31, 2024 relating to a combination of factors occurring in the fourth quarter of 2024. The majority of these factors are related to financial market changes inclusive of a decline in our stock price and rising interest rates. Additionally, anticipated changes in pricing of a capitated contract also contributed to this charge.

[Table of Contents](#)

Transaction breakage fee represents a cash payment to Rotech of \$80 million made on June 5, 2025 for the termination of the Rotech acquisition.

Acquisition-related charges were \$22 million for the years ended December 31, 2025 and 2024 related to the terminated acquisition of Rotech, which consisted primarily of legal and professional fees. Intangible amortization was \$74 million and \$40 million for the years ended December 31, 2025 and 2024 and related primarily to intangible assets acquired in the Apria and Byram acquisitions. The increase was due to the remaining useful life for an intangible asset being modified as of June 30, 2025 as a result of a notice of a contract termination with a commercial Payor. See Note 5 in the Notes to Consolidated Financial Statements.

Exit and realignment charges, net were \$18 million for the year ended December 31, 2025. These charges included professional fees associated with strategic initiatives of \$8.4 million, \$6.8 million related to wind-down costs of Fusion5, severance associated with strategic realignments of \$5.4 million, a \$4.8 million gain on sale of patient service equipment in response to the contract termination with a commercial Payor and IT strategic initiatives and other of \$1.5 million. Exit and realignment charges, net were \$47 million for the year ended December 31, 2024 which included professional fees associated with strategic initiatives of \$36 million and IT strategic initiatives and other of \$11 million.

	For the Years Ended December 31,		Change	
	2024	2023	\$	%
<i>(Dollars in thousands)</i>				
Selling, general and administrative expenses	\$ 1,082,344	\$ 1,001,656	\$ 80,688	8.1 %
<i>As a % of net revenue</i>	<i>40.4%</i>	<i>39.2%</i>		
Goodwill impairment charge	\$ 307,112	\$ —	\$ 307,112	NM %
Acquisition-related charges and intangible amortization	\$ 61,848	\$ 74,797	\$ (12,949)	(17.3)%
Exit and realignment charges, net	\$ 46,806	\$ 7,336	\$ 39,470	538.0 %
<i>NM - Not meaningful</i>				

The increase in SG&A expenses was driven primarily by incremental costs to support the \$128 million net revenue growth, along with future revenue growth, an increase in teammate incentive expense, excluding restricted stock, of \$13 million.

Goodwill impairment charges relates to impairment recognized in the Apria reporting unit during the quarter ended December 31, 2024 relating to a combination of factors occurring in the fourth quarter of 2024. The majority of these factors are related to financial market changes inclusive of a decline in Accendra Health's stock price and rising interest rates. Additionally, anticipated changes in pricing of a capitated contract also contributed to this charge.

Acquisition-related charges were \$22 million for the year ended December 31, 2024 related to the terminated acquisition of Rotech, which consisted primarily of legal and professional fees. Acquisition-related charges for the year ended December 31, 2023 were \$17 million, consisting of costs related to the acquisition of Apria. Intangible amortization was \$40 million and \$58 million for the years ended December 31, 2024 and 2023 and related primarily to intangible assets acquired in the Apria and Byram acquisitions. The decline is related to certain intangible assets being fully amortized. See Note 5 in the Notes to Consolidated Financial Statements.

Exit and realignment charges, net were \$47 million for the year ended December 31, 2024 which included professional fees associated with strategic initiatives of \$36 million and IT strategic initiatives and other of \$11 million. Exit and realignment charges, net were \$7.3 million for the year ended December 31, 2023, which included professional fees associated with strategic initiatives of \$2.1 million and IT strategic initiatives and other of \$5.3 million.

[Table of Contents](#)

Non-operating expenses

(Dollars in thousands)	For the Years Ended December 31,		Change	
	2025	2024	\$	%
Interest expense, net	\$ 107,183	\$ 107,566	\$ (383)	(0.4)%
<i>Effective interest rate</i>	6.94 %	7.09 %		
Transaction financing fees, net	\$ 18,288	\$ —	\$ 18,288	NM %
Other expense, net	\$ 3,942	\$ 4,589	\$ (647)	(14.1)%
<i>NM - Not meaningful</i>				

The decrease in interest expense was primarily due to lower average outstanding borrowings of \$45 million and a decrease in the effective interest rate of 15 basis points, partially offset by a reduction in interest income of \$6.4 million.

Transaction financing fees, net for the year ended December 31, 2025 consisted of debt financing fees associated with the terminated acquisition of Rotech, including \$12 million of costs, net of income on the related cash held in escrow, on the financing issued in connection with the previously expected Rotech acquisition and \$6.7 million in recognition of related previously deferred debt issuance costs.

Other expense, net for the years ended December 31, 2025 and 2024 includes interest cost and net actuarial losses related to our U.S. retirement plan. Other expense, net for the year ended December 31, 2024 also includes a \$1.1 million loss on extinguishment of debt.

(Dollars in thousands)	For the Years Ended December 31,		Change	
	2024	2023	\$	%
Interest expense, net	\$ 107,566	\$ 116,769	\$ (9,203)	(7.9)%
<i>Effective interest rate</i>	7.09 %	6.96 %		
Other expense, net	\$ 4,589	\$ 1,197	\$ 3,392	283.4 %

The decrease in interest expense was primarily due to lower average outstanding borrowings of \$227 million, partially offset by an increase in the effective interest rate of 13 basis points.

Other expense, net for the years ended December 31, 2024 and 2023 includes a \$1.1 million loss on extinguishment of debt and a \$3.5 million gain on extinguishment of debt, as well as interest cost and net actuarial losses related to our U.S. retirement plan.

Income taxes.

(Dollars in thousands)	For the Years Ended December 31,		Change	
	2025	2024	\$	%
Income tax provision	\$ 729	\$ 20,850	\$ (20,121)	(96.5)%
<i>Effective tax rate</i>	(0.7)%	(6.3)%		

The change in the effective tax rate for the year ended December 31, 2025 compared to 2024 resulted primarily from the pre-tax goodwill impairment charge of \$307 million (\$305 million net of tax) related to Apria and a one-time income tax charge of \$19 million, or a \$0.24 negative impact per share, related to a recent decision associated with Notices of Proposed Adjustments (NOPA) that we received in 2020 and 2021. Both of these charges were incurred during the year ended December 31, 2024. The change also includes the tax treatment associated with the \$80 million transaction breakage fee incurred during the year ended December 31, 2025. See Notes 5 and 12 in the Notes to Consolidated Financial Statements.

[Table of Contents](#)

<i>(Dollars in thousands)</i>	For the Years Ended December 31,		Change	
	2024	2023	\$	%
Income tax provision	\$ 20,850	\$ 6,360	\$ 14,490	227.8 %
Effective tax rate	(6.3)%	41.7 %		

The change in the effective tax rate for the year ended December 31, 2024 compared to 2023 resulted primarily from the pre-tax goodwill impairment charge and the one-time income tax charge mentioned above for the year ended December 31, 2024.

Non-GAAP Financial Measures

The following financial measures, Adjusted EBITDA and Free Cash Flow (FCF), are not calculated in accordance with U.S. generally accepted accounting principles (GAAP). In general, non-GAAP measures exclude items and charges that (i) management does not believe reflect the Company's core business and relate more to strategic, multi-year corporate activities; or (ii) relate to activities or actions that may have occurred in multiple or prior periods without predictable trends.

Management provides these non-GAAP financial measures to investors as supplemental metrics to assist readers in assessing the effects of items and events on its financial and operating results and in comparing the Company's performance to that of its competitors. However, the non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies.

The non-GAAP financial measures disclosed by the Company should not be considered substitutes for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations to those financial statements set forth below should be carefully evaluated.

We use Adjusted EBITDA, a financial measure that is not in accordance with GAAP, to analyze our financial results and as one of our incentive metrics and to provide an understanding of underlying operating results and trends by excluding items that are not closely related with ongoing operations. We use FCF, a financial measure that is not in accordance with GAAP, to evaluate the capacity of our operations to generate free cash flow. We utilize FCF as a performance metric.

The costs of the P&HS business that are classified as discontinued operations include only direct operating expenses. Indirect costs, such as those related to corporate and shared services previously allocated to the P&HS business, do not meet the criteria for discontinued operations and are reported within continuing operations. These costs (stranded costs) are reported within continuing operations and are included within Adjusted EBITDA.

[Table of Contents](#)

The following tables present the reconciliations of loss from continuing operations, net of tax to Adjusted EBITDA and FCF for the years ended December 31, 2025 and 2024:

	Years Ended December 31,	
	2025	2024
Loss from continuing operations, net of tax, as reported (GAAP)	\$ (102,682)	\$ (350,735)
Income tax provision	729	20,850
Interest expense, net	107,183	107,566
Acquisition-related charges and intangible amortization ⁽¹⁾	95,832	61,848
Transaction breakage fee ⁽²⁾	80,000	—
Exit and realignment charges, net ⁽³⁾	18,447	46,806
Transaction financing fees, net ⁽⁴⁾	18,288	—
Litigation and related charges ⁽⁵⁾	2,418	17,119
Goodwill impairment charge ⁽⁶⁾	—	307,112
Other depreciation and amortization ⁽⁷⁾	140,935	141,545
Stock compensation ⁽⁸⁾	12,001	15,581
Other ⁽⁹⁾	1,696	2,823
Adjusted EBITDA (non-GAAP)	374,847	370,515
Non-cash convert to sale write off expense ⁽¹⁰⁾	46,951	34,105
Patient service equipment capital expenditures	(188,823)	(166,659)
Interest paid	(134,710)	(141,547)
Free cash flow (non-GAAP)	<u>\$ 98,265</u>	<u>\$ 96,414</u>

⁽¹⁾ Acquisition-related charges and intangible amortization for the years ended December 31, 2025 and 2024 include \$22 million of acquisition-related costs related to the terminated acquisition of Rotech, which consisted primarily of legal and professional fees. Acquisition-related charges and intangible amortization also include amortization of intangible assets established during acquisition method of accounting for business combinations. Acquisition-related charges consist primarily of one-time costs related to acquisitions, including transaction costs necessary to consummate acquisitions, which consist of investment banking advisory fees and legal fees, director and officer tail insurance expense, as well as transition costs, such as severance and retention bonuses, IT integration costs and professional fees. These amounts are highly dependent on the size and frequency of acquisitions and are being excluded to allow for a more consistent comparison with forecasted, current and historical results.

⁽²⁾ Transaction breakage fee represents a cash payment to Rotech of \$80 million made on June 5, 2025, for the termination of the Rotech Acquisition.

⁽³⁾ During the year ended December 31, 2025 exit and realignment charges, net were \$18 million. These charges included professional fees associated with strategic initiatives of \$8.4 million, \$6.8 million related to wind-down costs of Fusion5, severance associated with strategic realignments of \$5.4 million, a \$4.8 million gain on sale of patient service equipment in response to the contract termination with a commercial Payor and IT strategic initiatives and other of \$1.5 million. Exit and realignment charges, net were \$47 million for the year ended December 31, 2024 which included professional fees associated with strategic initiatives of \$36 million and IT strategic initiatives and other of \$11 million. These costs are not normal recurring, cash operating expenses necessary for the Company to operate its business on an ongoing basis.

⁽⁴⁾ Transaction financing fees, net includes \$12 million, net of income on the related cash held in escrow, on the financing issued in connection with the previously expected Rotech acquisition and \$6.7 million in recognition of related previously deferred debt issuance costs.

⁽⁵⁾ Litigation and related charges includes settlement costs and related charges of certain legal matters. These costs do not occur in the ordinary course of our business and are inherently unpredictable in timing and amount.

⁽⁶⁾ Goodwill impairment charge relates to a non-cash goodwill impairment charge recognized in the Apria reporting unit during the quarter ended December 31, 2024 resulting from a combination of factors, including fourth quarter 2024

[Table of Contents](#)

market changes inclusive of a decline in the Company’s stock price and rising interest rates. Additionally, anticipated changes in pricing of a capitated contract within the Apria division also contributed to this charge. This is a non-cash charge and does not occur in the ordinary course of our business and is inherently unpredictable in timing and amount.

(7) Other depreciation and amortization relates to patient service equipment and other fixed assets, excluding such amounts captured within exit and realignment charges, net or acquisition-related charges and intangible amortization.

(8) Stock compensation includes share-based compensation expense related to our share-based compensation plans, excluding such amounts captured within exit and realignment charges, net or acquisition-related charges and intangible amortization. For the year ended December 31, 2025 stock compensation includes a \$4.0 million benefit associated with updated expected achievement for our performance share awards.

(9) For the years ended December 31, 2025 and 2024, other includes interest costs and net actuarial losses related to our frozen noncontributory, unfunded retirement plan for certain retirees in the United States (U.S.).

(10) Non-cash convert to sale write off expense includes non-cash charges primarily for equipment converted from rental to sales. This reflects the non-cash write-off of the remaining book value of patient service equipment at the time of sale. The purchase of patient service equipment is captured within capital expenditures and is subsequently charged to our statements of operations through normal depreciation and this non-cash convert to sale write off expense.

Financial Condition, Liquidity and Capital Resources

Financial condition. We monitor operating working capital through DSO and merchandise inventory days. We estimate a hypothetical increase (decrease) in DSO of one day would result in a decrease (increase) in our cash balances, an increase (decrease) in borrowings against our Revolving Credit Agreement, or a combination thereof of approximately \$7.7 million.

The majority of our cash and cash equivalents are held in cash depository accounts with major banks in the U.S. Our working capital can vary in the normal course of business based upon the timing of inventory purchases, collections of accounts receivable, and payments to suppliers.

	December 31,		Change	
	2025	2024	\$	%
<i>(Dollars in thousands)</i>				
Cash and cash equivalents	\$ 281,989	\$ 27,572	\$ 254,417	922.7 %
Accounts receivable	\$ 95,907	218,270	\$ (122,363)	(56.1)%
<i>DSO</i> ⁽¹⁾	12.4	28.9		
Inventories	\$ 74,435	67,581	\$ 6,854	10.1 %
<i>Inventory days</i> ⁽²⁾	17.8	17.2		
Accounts payable	\$ 363,565	\$ 359,927	\$ 3,638	1.0 %

⁽¹⁾Based on year end accounts receivable and net revenue for the fourth quarter ended December 31, 2025 and 2024. DSO in 2025 reflected the impact of the reduction in accounts receivable, net due to sales of accounts receivable under the Amended Receivables Sale Program. Excluding the impact of the Amended Receivables Sale Program, DSO would have been 29.8 as of December 31, 2025. DSO in 2024 reflected the impact of the reduction in accounts receivable, net due to sales of accounts receivable under the Receivables Sale Program. Excluding the impact of the Receivables Sale Program, DSO would have been 30.7 as of December 31, 2024.

⁽²⁾ Based on year end inventories and cost of net revenue for the fourth quarter ended December 31, 2025 and 2024.

[Table of Contents](#)

Liquidity and capital expenditures. The following table summarizes our consolidated statements of cash flows for the year ended December 31, 2025, 2024 and 2023:

<i>(Dollars in thousands)</i>	For the Years Ended		
	December 31,		
	2025	2024	2023
Net cash provided by (used for):			
Operating activities from continuing operations	\$ 154,496	\$ 143,686	\$ 336,458
Operating activities from discontinued operations	(256,286)	17,809	404,252
Operating activities	(101,790)	161,495	740,710
Investing activities from continuing operations	198,993	(98,036)	(107,893)
Investing activities from discontinued operations	(54,570)	(18,497)	(29,361)
Investing activities	144,423	(116,533)	(137,254)
Financing activities from continuing operations	190,205	(250,023)	(411,056)
Financing activities from discontinued operations	(2,127)	(17,580)	(6,274)
Financing activities	188,078	(267,603)	(417,330)
Effect of exchange rate changes	1,896	(901)	613
Net increase (decrease) in cash, cash equivalents and restricted cash	<u>\$ 232,607</u>	<u>\$ (223,542)</u>	<u>\$ 186,739</u>

Cash used for operating activities for the year ended December 31, 2025 reflected a net loss including the impact of the \$80 million termination fee of the Rotech acquisition, \$18 million in transaction financing fees, net for the Rotech acquisition financing, \$22 million in legal settlement payments for two litigation matters, and favorable changes in working capital, including a \$122 million reduction in continuing operations accounts receivable driven by a \$120 million increase in accounts receivable that had been sold and removed from our consolidated balance sheets. Cash used for operating activities for the year ended December 31, 2025 was also impacted by \$256 million of unfavorable changes in discontinued operations operating cash flow, driven by net losses and unfavorable changes in discontinued operations working capital.

Cash provided by operating activities for the year ended December 31, 2024 reflected earnings from continuing operations, excluding non-cash charges such as the goodwill impairment charge and depreciation and amortization, as well as favorable changes in working capital. Cash provided by operating activities for the year ended December 31, 2024 was also impacted by \$18 million of favorable changes in discontinued operations operating cash flow, driven by operating earnings, partially offset by unfavorable changes in working capital.

Cash provided by operating activities for the year ended December 31, 2023 reflected earnings from continuing operations, excluding non-cash charges such as depreciation and amortization, as well as favorable changes in working capital. Cash provided by operating activities for the year ended December 31, 2023 was also impacted by \$404 million of favorable changes in discontinued operations operating cash flow, driven by operating earnings and positive changes in working capital.

Cash provided by investing activities in 2025 included \$342 million in proceeds from the sale of the P&HS business, \$18 million of cash sold, and \$78 million in proceeds from the sale of patient service equipment, partially offset by continuing operations capital expenditures of \$201 million for patient service equipment and our strategic and operational efficiency initiatives associated with other fixed assets and capitalized software. Cash used for investing activities in 2025 also included \$55 million of discontinued operations capital expenditures.

Cash used for investing activities in 2024 included continuing operations capital expenditures of \$183 million primarily for patient service equipment, other fixed assets and capitalized software, partially offset by \$70 million in proceeds from the sale of patient service equipment and \$18 million included in the 'other, net' line item for settlement with Philips for returned equipment as described in the 'Philips Respironics Recall' section above. Cash used for investing activities in 2024 also included \$45 million of discontinued operations capital expenditures and \$34 million in proceeds from the sale of our former corporate headquarters.

[Table of Contents](#)

Cash used for investing activities in 2023 included continuing operations capital expenditures of \$179 million primarily for patient service equipment, and our strategic and operational efficiency initiatives associated with other fixed assets and capitalized software, partially offset by \$72 million in proceeds from the sale of patient service equipment. Cash used for investing activities in 2023 also included \$29 million of discontinued operations capital expenditures.

Cash provided by financing activities in 2025 included net borrowings of \$204 million under our Revolving Credit Facility and \$10 million used for share repurchases. Cash used for financing activities in 2024 included repayments of debt of \$244 million, including \$171 million paid to redeem the 4.375% senior notes that were due in December 2024, and \$45 million of unscheduled and \$28 million of scheduled repayments on term loans. Cash used for financing activities in 2023 included repayments of debt of \$321 million, and \$170 million of unscheduled and \$15 million of scheduled repayments on term loans, \$135 million of cash to repurchase \$144 million aggregate principal of the 2024 Notes, the 4.500% senior unsecured notes due in 2029 (2029 Unsecured Notes) and the 6.625% senior notes due in 2030 (the 2030 Unsecured Notes). We had no borrowings under our Revolving Credit Facility for 2024 and the activity under our amended Receivables Financing Agreement netted to no impact on our outstanding borrowings. We had no borrowings under our revolving credit facility on a net basis for 2023 and made net repayments of \$96 million under our amended Receivables Financing Agreement.

Capital resources. Our primary sources of liquidity include cash and cash equivalents, our Amended Receivables Sale Program and our Revolving Credit Agreement.

On October 18, 2024, we entered into a Receivables Purchase Agreement (the Receivables Sale Program) with persons from time to time, as Purchasers, PNC Bank, National Association, as Administrative Agent, and PNC Capital Markets LLC, as Structuring Agent, pursuant to which accounts receivable with an aggregate outstanding amount not to exceed \$450 million are sold, on a limited-recourse basis, to the Purchasers in exchange for cash. The Receivables Sale Program amends and restates in its entirety, the Receivables Financing Agreement. Transactions under this agreement are accounted for as sales in accordance with ASC 860, *Transfers and Servicing*, with the sold receivables removed from our consolidated balance sheets. Total accounts receivable sold under the Receivables Sale Program and net cash proceeds were \$325 million related to continuing operations during the year ended December 31, 2025. We collected \$330 million of the sold accounts receivable related to continuing operations for the year ended December 31, 2025. The losses on sales of accounts receivable of continuing operations, inclusive of professional fees incurred to establish the agreement, recorded in selling, general, and administrative expenses in the consolidated statements of operations were \$2.2 million for the year ended December 31, 2025. In connection with the amendment to the Receivables Sale Program, as described below, any uncollected accounts receivable sold from were settled on December 31, 2025.

On December 31, 2025, we entered into an Amended & Restated Receivables Purchase Agreement (the Amended Receivables Sale Program) with persons from time to time party thereto, as Purchasers, PNC Bank, as Administrative Agent, and PNC Capital Markets LLC, as Structuring Agent, pursuant to which accounts receivable with an aggregate outstanding amount not to exceed \$150 million are sold, on a limited-recourse basis, to the Purchasers in exchange for cash. The Amended Receivables Sale Program amends and restates in its entirety, the Receivables Sale Program, dated as of October 18, 2024.

Total accounts receivable sold under the Amended Receivables Sale Program were \$134 million. As of December 31, 2025 there was a total of \$134 million of uncollected accounts receivable sold and removed from our consolidated balance sheet under the Amended Receivables Sale Program.

The Revolving Credit Agreement provides a revolving borrowing capacity of \$450 million. We have \$837 million in outstanding term loans under a term loan credit agreement (the Credit Agreement). The interest rate on our Revolving Credit Agreement is based on a spread over a benchmark rate (as described in the Revolving Credit Agreement). The Revolving Credit Agreement matures in March 2027. The interest rate on the Term Loan A is based on either the Term SOFR or the Base Rate plus an Applicable Rate which varies depending on the current Debt Ratings or Total Leverage Ratio, determined as to whichever shall result in more favorable pricing to the Borrowers (each as defined in the Credit Agreement). The interest rate on the Term Loan B is based on either the Term SOFR or the Base Rate plus an Applicable Rate. The Term Loan A matures in March 2027 and the Term Loan B matures in March 2029.

[Table of Contents](#)

At December 31, 2025 we had \$204 million in outstanding borrowings on our Revolving Credit Agreement. December 31, 2024, our Revolving Credit Agreement was undrawn. At December 31, 2025 and December 31, 2024, we had letters of credit, which reduce revolver availability, of \$30 million and \$31 million, leaving \$217 million and \$419 million available for borrowing.

The Revolving Credit Agreement, the Credit Agreement, the Amended Receivables Sale Program, the 2029 Unsecured Notes, and the 2030 Unsecured Notes contain cross-default provisions which could result in the acceleration of payments due in the event of default of any of the related agreements. The terms of the applicable credit agreements also require us to maintain ratios for leverage and interest coverage, including on a pro forma basis in the event of an acquisition or divestiture. We were in compliance with our debt covenants at December 31, 2025.

On April 4, 2025, we completed the sale of \$1.0 billion aggregate principal amount of 10.000% Senior Secured Notes due 2030 (the New Notes) in a private offering (the Offering) to persons reasonably believed to be “qualified institutional buyers” in the United States, as defined in Rule 144A under the Securities Act of 1933, as amended (the Securities Act), and to certain non-U.S. persons outside the United States in offshore transactions pursuant to Regulation S under the Securities Act. The Offering was conducted in connection with the financing of the Company’s proposed acquisition of Rotech. At the closing of the Offering, the gross proceeds were placed into a segregated escrow account where they were held for the benefit of the holders of the New Notes pending the consummation of the proposed acquisition of Rotech.

On June 3, 2025, the Company, Rotech and Merger Sub mutually agreed to terminate the Merger Agreement and entered into a mutual termination agreement (the Termination Agreement). On June 10, 2025 (the Redemption Date), the New Notes were redeemed in full at a price equal to 100% of the aggregate principal amount of the New Notes, plus accrued and unpaid interest to, but excluding the Redemption Date.

We regularly evaluate market conditions, our liquidity profile and various financing alternatives to enhance our capital structure. We have from time to time, entered into, and in the future, we may enter into transactions to repay, repurchase or redeem our outstanding indebtedness (including by means of open market purchases, privately negotiated repurchases, tender or exchange offers and/or repayments or redemptions pursuant to the debt’s terms). Our ability to consummate any such transaction will depend on prevailing market conditions, our liquidity requirements, contractual restrictions and other factors. We cannot provide any assurance as to if or when we will consummate any such transactions or the terms of any such transaction.

On February 26, 2025, our Board of Directors authorized a share repurchase program of up to \$100 million over the next two years. Under the program, we may repurchase shares of common stock on a discretionary basis from time to time through open market repurchases, privately negotiated transactions and 10b5-1 trading plans. During the year ended December 31, 2025 we repurchased in open-market transactions and retired 2.0 million shares of our common stock for an aggregate of \$10 million, or a weighted average price per share of \$5.19.

We believe cash generated by operating activities, including available cash proceeds from the Amended Receivables Sale Program, available financing sources, and borrowings under the Revolving Credit Agreement, as well as cash on hand, will be sufficient to fund our working capital needs, capital expenditures, long-term strategic growth, payments under long-term debt and lease arrangements, debt repurchases, share repurchases and other cash requirements. While we believe that we will have the ability to meet our financing needs in the foreseeable future, changes in economic conditions may impact (i) the ability of financial institutions to meet their contractual commitments to us, (ii) the ability of our customers and suppliers to meet their obligations to us or (iii) our cost of borrowing.

Pillar 2 Global Minimum Tax

In December 2021, the Organization for Economic Cooperation and Development (OECD) released Pillar Two Model Rules defining the global minimum tax, which calls for the taxation of large corporations at a minimum rate of 15%. The OECD continues to release additional guidance on how the Pillar Two rules should be interpreted and applied. We do not expect Pillar Two to have a material impact on our financial position, results of operations and cash flows.

Seasonality

Our business is affected by seasonality, which historically has resulted in higher sales volume during our third and fourth quarters, ending September 30 and December 31.

Contractual Obligations

As of December 31, 2025, other material cash requirements, including known contractual and other obligations and excluding anticipated voluntary prepayments of debt, in the next twelve months were primarily comprised of \$49 million in operating leases, \$58 million in fixed interest payments on our outstanding senior notes, and \$35 million associated with the NOPA matter, which includes \$11 million of interest accrued on the matter through December 31, 2025. Additionally, as of December 31, 2025, material cash requirements, including known contractual and other obligations, due beyond the next twelve months were primarily comprised of \$2.1 billion in principal debt payments, \$167 million in fixed interest payments on our outstanding senior notes, \$83 million in operating leases and \$28 million in U.S. retirement plan benefits, based on the same assumptions used to measure our year-end benefit obligation. Due to the uncertainty of forecasting variable interest rate payments, interest payment amounts on our variable rate debt are excluded from the contractual obligations disclosed in this section. See Note 6, "Leases", Note 8, "Debt", Note 10, "Retirement Plan", Note 12, "Income Taxes", and Note 15, "Commitments, Contingent Liabilities, and Legal Proceedings" in the Notes to Consolidated Financial Statements.

Off-Balance Sheet Arrangements

We do not have off-balance sheet financing arrangements or guarantees, including variable interest entities, which we believe could have a material impact on financial condition or liquidity.

Critical Accounting Estimates

Our consolidated financial statements and accompanying notes have been prepared in accordance with U.S. GAAP. The preparation of the financial statements requires us to make estimates and assumptions that affect the reported amounts and related disclosures. We continually evaluate the accounting policies and estimates used to prepare the consolidated financial statements.

Critical accounting estimates are defined as those estimates that require us to make assumptions about matters that are highly uncertain at the time the estimate is made and could have a material impact on our results due to changes in the estimate or the use of different assumptions that could reasonably have been used. Our estimates are generally based on historical experience and various other assumptions that are judged to be reasonable in light of the relevant facts and circumstances. Because of the uncertainty inherent in such estimates, actual results may differ. We believe our critical accounting estimates include accounting for revenue recognition.

Revenue Recognition. Due to the nature of our industry and the reimbursement environment in which we operate, revenue recognition requires significant estimates and judgments. We determine the transaction price based on contractually agreed-upon amounts or rates, adjusted for estimates of variable consideration including but not limited to rebates, discounts, performance guarantees, and implicit price concessions. The Company utilizes the expected value method to estimate the amount of variable consideration that should be included to arrive at the transaction price, using contractual agreements, historical experience, and other operating trends. The Company applies constraint to the transaction price, such that net revenue is recorded only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in the future. The complexity of many third-party billing arrangements, contractual terms and the uncertainty of reimbursement amounts may result in adjustments to amounts originally recorded. Such adjustments are typically identified and recorded at the point of cash application, claim denial or account review. If actual amounts of consideration ultimately received differ from the Company's estimates, the Company adjusts these estimates, which would affect net revenue in the period such adjustments become known.

Recent Accounting Pronouncements

For a discussion of recent accounting pronouncements, see Note 1 in the Notes to Consolidated Financial Statements.

Item 7A. Quantitative and Qualitative Disclosures About Market Risk

We are exposed to market risk from changes in interest rates related to our borrowing under our Revolving Credit Agreement, and related to our participation in the Amended Receivables Sale Program. Excluding deferred financing costs and third party fees, we had \$326 million in borrowings under our Term Loan A, \$511 million in borrowings under our Term Loan B, \$204 million in outstanding borrowings under our Revolving Credit Agreement and \$134 million of uncollected accounts receivable under our Amended Receivables Sale Program at December 31, 2025. After considering the effects of our interest rate swap agreement (See Note 11 in the Notes to Consolidated Financial Statements), we estimate an increase in interest rates of 100 basis points would result in a potential reduction in future pre-tax earnings of approximately \$9.2 million per year based on our borrowings and uncollected accounts receivable sold under our Amended Receivables Sale Program at December 31, 2025.

Item 8. Financial Statements and Supplementary Data

See Item 15. Exhibits and Financial Statement Schedules.

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

None.

Item 9A. Controls and Procedures

Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures

We carried out an evaluation, with the participation of management, including our principal executive officer and principal financial officer, of the effectiveness of our disclosure controls and procedures (pursuant to Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this report. Based upon that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective as of December 31, 2025.

Management's Report on Internal Control over Financial Reporting

Management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934, as amended. Our internal control system is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, controls deemed effective now may become inadequate in the future because of changes in conditions, or because compliance with policies or procedures has deteriorated or been circumvented.

Management assessed the effectiveness of our internal control over financial reporting as of December 31, 2025. In making this assessment, management used the criteria established in the Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (the COSO criteria). Based on management's assessment and the COSO criteria, management believes that our internal control over financial reporting was effective as of December 31, 2025 to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with GAAP.

The effectiveness of our internal control over financial reporting as of December 31, 2025, has been audited by KPMG LLP, an independent registered public accounting firm, as stated in their unqualified report which is included in this annual report.

/s/ Edward A. Pesicka

Edward A. Pesicka, President, Chief Executive Officer & Director

/s/ Jonathan A. Leon

Jonathan A. Leon, Executive Vice President & Chief Financial Officer

Changes in Internal Control over Financial Reporting

On December 31, 2025, we completed the sale of the P&HS business pursuant to the Purchase Agreement. We designed and implemented internal controls over financial reporting, including those related to discontinued operations accounting, which were assessed as of December 31, 2025. There were no other changes in our internal control over financial reporting that occurred during the fourth quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Item 9B. Other Information

During the three months ended December 31, 2025, none of our directors or officers informed us of the adoption or termination of a trading plan intended to satisfy Rule 10b5-1(c).

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

None.

Report of Independent Registered Public Accounting Firm

To the Shareholders and Board of Directors
Accendra Health, Inc.:

Opinion on Internal Control Over Financial Reporting

We have audited Accendra Health, Inc. and subsidiaries' (the Company) internal control over financial reporting as of December 31, 2025, based on criteria established in *Internal Control – Integrated Framework (2013)* issued by the Committee of Sponsoring Organizations of the Treadway Commission. In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2025, based on criteria established in *Internal Control – Integrated Framework (2013)* issued by the Committee of Sponsoring Organizations of the Treadway Commission.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2025 and 2024, the related consolidated statements of operations, comprehensive (loss) income, changes in shareholders' equity, and cash flows for each of the years in the three-year period ended December 31, 2025, and the related notes (collectively, the consolidated financial statements), and our report dated February 20, 2026 expressed an unqualified opinion on those consolidated financial statements.

Basis for Opinion

The Company's management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management's Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company's internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

Definition and Limitations of Internal Control Over Financial Reporting

A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become

[Table of Contents](#)

inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ KPMG LLP

Richmond, Virginia
February 20, 2026

Part III

Items 10-14.

Information required by Items 10-14 can be found under Information about our Executive Officers under Part I of this Form 10-K and the registrant's 2026 Proxy Statement pursuant to instructions G(3) of the General Instructions to Form 10-K.

We have adopted an insider trading policy which governs transactions in our securities by the Company and its directors, officers, and teammates that is designed to promote compliance with insider trading laws, rules and regulations applicable to the Company. A copy of our insider trading policy is filed as an exhibit to this Annual Report on Form 10-K.

Because our common stock is listed on the New York Stock Exchange (NYSE), our Chief Executive Officer is required to make, and he has made, an annual certification to the NYSE stating that he was not aware of any violation of the corporate governance listing standards of the NYSE. Our Chief Executive Officer made his annual certification to that effect to the NYSE as of June 10, 2025. In addition, we have filed, as exhibits to this Annual Report on Form 10-K, the certifications of our principal executive officer and principal financial officer required under Sections 906 and 302 of the Sarbanes-Oxley Act of 2002 to be filed with the Securities and Exchange Commission regarding the quality of our public disclosure.

Part IV

Item 15. Exhibits and Financial Statement Schedules

The following documents are filed as part of this report:

	Page
Consolidated Statements of Operations for the Years Ended December 31, 2025, 2024 and 2023	54
Consolidated Statements of Comprehensive (Loss) Income for the Years Ended December 31, 2025, 2024 and 2023	55
Consolidated Balance Sheets as of December 31, 2025 and 2024	56
Consolidated Statements of Cash Flows for the Years Ended December 31, 2025, 2024 and 2023	57
Consolidated Statements of Changes in Shareholders' Equity for the Years Ended December 31, 2025, 2024 and 2023	58
Notes to Consolidated Financial Statements	59
Report of Independent Registered Public Accounting Firm (KPMG, LLP, Richmond, VA, Auditor Firm ID: 185)	86

a) Exhibits:

See Index to Exhibits on page 88.

ACCENDRA HEALTH, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share data)

Years Ended December 31,	2025	2024	2023
Net revenue	\$ 2,762,032	\$ 2,680,112	\$ 2,552,572
Operating costs and expenses:			
Cost of net revenue	1,472,733	1,399,732	1,335,552
Selling, general and administrative expenses	1,067,560	1,082,344	1,001,656
Goodwill impairment charge	—	307,112	—
Transaction breakage fee	80,000	—	—
Acquisition-related charges and intangible amortization	95,832	61,848	74,797
Exit and realignment charges, net	18,447	46,806	7,336
Total operating costs and expenses	<u>2,734,572</u>	<u>2,897,842</u>	<u>2,419,341</u>
Operating income (loss)	27,460	(217,730)	133,231
Interest expense, net	107,183	107,566	116,769
Transaction financing fees, net	18,288	—	—
Other expense, net	3,942	4,589	1,197
(Loss) income from continuing operations before income taxes	(101,953)	(329,885)	15,265
Income tax provision	729	20,850	6,360
(Loss) income from continuing operations, net of tax	(102,682)	(350,735)	8,905
Loss from discontinued operations, net of tax	(997,960)	(11,951)	(50,206)
Net loss	<u>\$ (1,100,642)</u>	<u>\$ (362,686)</u>	<u>\$ (41,301)</u>
Basic loss per common share:			
(Loss) income from continuing operations, net of tax	\$ (1.34)	\$ (4.57)	\$ 0.12
Loss from discontinued operations, net of tax	(12.97)	(0.16)	(0.66)
Net loss	<u>\$ (14.31)</u>	<u>\$ (4.73)</u>	<u>\$ (0.54)</u>
Diluted loss per common share:			
(Loss) income from continuing operations, net of tax	\$ (1.34)	\$ (4.57)	\$ 0.12
Loss from discontinued operations, net of tax	(12.97)	(0.16)	(0.65)
Net loss	<u>\$ (14.31)</u>	<u>\$ (4.73)</u>	<u>\$ (0.53)</u>

See accompanying notes to consolidated financial statements.

ACCENDRA HEALTH, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME

<i>(in thousands)</i>	<u>2025</u>	<u>2024</u>	<u>2023</u>
Years Ended December 31,			
Net loss	\$ (1,100,642)	\$ (362,686)	\$ (41,301)
Other comprehensive income (loss), net of tax:			
Currency translation adjustments	26,211	(15,145)	7,141
Change in unrecognized net periodic pension costs	1,053	(655)	2,086
Change in gains and losses on derivative instruments	(3,534)	(1,726)	(5,190)
P&HS Sale reclassification adjustment	24,729	—	—
Total other comprehensive income (loss), net of tax	48,459	(17,526)	4,037
Comprehensive loss	\$ (1,052,183)	\$ (380,212)	\$ (37,264)

See accompanying notes to consolidated financial statements.

ACCENDRA HEALTH, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(in thousands, except per share data)

December 31,	2025	2024
Assets		
Current assets		
Cash and cash equivalents	\$ 281,989	\$ 27,572
Accounts receivable, net	95,907	218,270
Inventories, net	74,435	67,581
Other current assets	95,540	82,240
Current assets held for sale - discontinued operations	—	1,625,354
Total current assets	547,871	2,021,017
Patient service equipment and other fixed assets, net	256,161	249,283
Operating lease assets	109,099	126,928
Goodwill	1,228,140	1,228,140
Intangible assets, net	136,465	210,056
Other assets, net	174,025	89,539
Noncurrent assets held for sale - discontinued operations	—	731,193
Total assets	\$ 2,451,761	\$ 4,656,156
Liabilities and (deficit) equity		
Current liabilities		
Accounts payable	\$ 363,565	\$ 359,927
Accrued payroll and related liabilities	69,426	73,678
Current portion of long-term debt	250,000	42,866
Other current liabilities	264,084	294,685
Current liabilities held for sale - discontinued operations	—	1,080,896
Total current liabilities	947,075	1,852,052
Long-term debt, excluding current portion	1,799,876	1,798,393
Operating lease liabilities, excluding current portion	70,317	89,466
Deferred income taxes, net	—	19,436
Other liabilities	95,471	72,551
Noncurrent liabilities held for sale - discontinued operations	—	237,894
Total liabilities	2,912,739	4,069,792
Commitments and contingencies		
(Deficit) equity		
Common stock, par value \$2 per share; authorized - 200,000 shares; issued and outstanding - 76,388 shares and 77,199 shares	152,777	154,398
Paid-in capital	466,882	454,151
(Accumulated deficit) retained earnings	(1,079,752)	27,159
Accumulated other comprehensive loss	(885)	(49,344)
Total (deficit) equity	(460,978)	586,364
Total liabilities and (deficit) equity	\$ 2,451,761	\$ 4,656,156

See accompanying notes to consolidated financial statements.

ACCENDRA HEALTH, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

Years Ended December 31,	2025	2024	2023
Operating activities:			
Net loss	\$ (1,100,642)	\$ (362,686)	\$ (41,301)
Loss from discontinued operations, net of tax	997,960	11,951	50,206
Adjustments to reconcile net loss to cash (used for) provided by operating activities:			
Depreciation and amortization	214,524	181,281	210,371
Goodwill impairment charge	—	307,112	—
Share-based compensation expense	12,873	16,638	14,395
Loss (gain) on extinguishment of debt	—	1,101	(3,518)
Deferred income tax benefit	(17,887)	(8,042)	(6,004)
Changes in operating lease right-of-use assets and lease liabilities	735	1,472	(57)
Gain from sale and dispositions of patient service equipment	(27,274)	(35,355)	(34,882)
Changes in operating assets and liabilities:			
Accounts receivable, net	122,363	(3,677)	(8,991)
Inventories	(6,854)	(4,591)	(5,352)
Accounts payable	6,478	66,894	5,245
Net change in other assets and liabilities	(56,779)	(36,026)	146,532
Other, net	8,999	7,614	9,814
Cash (used for) provided by operating activities from discontinued operations	(256,286)	17,809	404,252
Cash (used for) provided by operating activities	(101,790)	161,495	740,710
Investing activities:			
Proceeds from P&HS sale	342,351	—	—
Cash sold with P&HS sale	(18,091)	—	—
Additions to patient service equipment (\$189 million, \$167 million and \$167 million) and other fixed assets	(190,956)	(170,286)	(172,375)
Proceeds from sale of patient service equipment	77,968	69,926	71,574
Additions to computer software	(10,369)	(12,379)	(6,156)
Other, net	(1,910)	14,703	(936)
Cash used for investing activities from discontinued operations	(54,570)	(18,497)	(29,361)
Cash provided by (used for) investing activities	144,423	(116,533)	(137,254)
Financing activities:			
Borrowings under amended Receivables Financing Agreement	—	1,465,800	476,000
Repayments under amended Receivables Financing Agreement	—	(1,465,800)	(572,000)
Borrowings under Revolving Credit Facility	2,914,784	635,800	—
Repayments under Revolving Credit Facility	(2,711,284)	(635,800)	—
Repayments of debt	—	(244,197)	(320,693)
Repurchase of common stock	(10,179)	—	—
Other, net	(3,116)	(5,826)	5,637
Cash used for financing activities from discontinued operations	(2,127)	(17,580)	(6,274)
Cash provided by (used for) financing activities	188,078	(267,603)	(417,330)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	1,896	(901)	613
Net increase (decrease) in cash, cash equivalents and restricted cash	232,607	(223,542)	186,739
Cash, cash equivalents and restricted cash at beginning of period	49,382	272,924	86,185
Cash, cash equivalents and restricted cash at end of period	\$ 281,989	\$ 49,382	\$ 272,924
Supplemental disclosure of cash flow information:			
Income taxes paid, net	\$ 12,471	\$ 5,553	\$ (6,283)
Interest paid	\$ 134,710	\$ 141,547	\$ 153,247
Noncash investing activity:			
Unpaid purchases of patient service equipment and other fixed assets at end of period	\$ 74,119	\$ 84,562	\$ 77,279

See accompanying notes to consolidated financial statements.

ACCENDRA HEALTH, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY

(in thousands, except per share data)

	Common Shares Outstanding	Common Stock (\$2 par value)	Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Total Equity (Deficit)
Balance, December 31, 2022	76,279	\$ 152,557	\$ 418,894	\$ 431,146	\$ (35,855)	\$ 966,742
Net loss	—	—	—	(41,301)	—	(41,301)
Other comprehensive income	—	—	—	—	4,037	4,037
Share-based compensation expense, exercises and other	267	535	15,291	—	—	15,826
Balance, December 31, 2023	76,546	153,092	434,185	389,845	(31,818)	945,304
Net loss	—	—	—	(362,686)	—	(362,686)
Other comprehensive loss	—	—	—	—	(17,526)	(17,526)
Share-based compensation expense, exercises and other	653	1,306	19,966	—	—	21,272
Balance, December 31, 2024	77,199	154,398	454,151	27,159	(49,344)	586,364
Net loss	—	—	—	(1,100,642)	—	(1,100,642)
Other comprehensive income	—	—	—	—	48,459	48,459
Share-based compensation expense, exercises and other	1,144	2,289	12,731	—	—	15,020
Shares repurchased and retired	(1,955)	(3,910)	—	(6,269)	—	(10,179)
Balance, December 31, 2025	76,388	\$ 152,777	\$ 466,882	\$ (1,079,752)	\$ (885)	\$ (460,978)

See accompanying notes to consolidated financial statements.

ACCENDRA HEALTH, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(in thousands, except per share data, unless otherwise indicated)

Note 1—Summary of Significant Accounting Policies

Accendra Health, Inc. (f/k/a Owens & Minor, Inc.) and subsidiaries (we, us, our or the Company) is a leading nationwide provider of products, technology, and services that supports health beyond the hospital for millions of people each year. We connect patients, providers, and insurers, delivering innovative solutions that help promote better health outcomes and improve quality of life for people living with chronic, complex, and acute health conditions. Together, our trusted brands, Apria and Byram Healthcare, bring nearly 90 years of combined experience in promoting health beyond the hospital in communities across the country. We are headquartered in Richmond, Virginia.

Basis of Presentation and Consolidation. The consolidated financial statements include the accounts of Accendra Health, Inc. and the subsidiaries it controls and contain all adjustments necessary to conform with U.S. generally accepted accounting principles (GAAP). All significant intercompany accounts and transactions have been eliminated. In connection with the sale of our Products & Healthcare Services (P&HS) business as detailed in the discontinued operations section below, we determined that our continuing operations' business activities comprise a single operating and reporting segment. This determination is in accordance with ASC No. 280, *Segment Reporting*.

Revision of Prior Period Consolidated Financial Statements. We revised our prior period financial statements to correct for a prior period accounting error that impacted our beginning retained earnings balance and total equity. The error, which was discovered during the first quarter of 2025, related to the over accrual of accounts payable that had accumulated over multiple years.

We assessed the materiality of the error, both quantitatively and qualitatively, in accordance with the SEC's Staff Accounting Bulletin No. 99, and concluded that the error was not material to any of our previously reported financial statements based upon the nature of the error, including the immaterial annual quantitative impacts to prior period consolidated statements of operations. Accordingly, the error was corrected through beginning retained earnings as of the earliest balance sheet date presented.

The cumulative impact of the error correction on our retained earnings and total equity as of the earliest balance sheet date presented, was an increase of \$21 million. The error also resulted in a cumulative \$23 million reduction to accounts payable, a \$1.6 million increase to other current liabilities, and a \$0.5 million increase to other liabilities as of December 31, 2023.

Reclassifications. Certain prior year amounts have been reclassified to conform to the current year presentation.

Discontinued Operations and Assets Held-for-Sale. On February 28, 2025, we announced that we were actively engaged in discussions regarding the anticipated sale of our P&HS business. On October 7, 2025, we entered into an Equity Purchase Agreement, (the Purchase Agreement) by and among the Company, Dominion Healthcare Acquisition Corporation, a Delaware corporation (the Purchaser), and Dominion Healthcare Holdings, L.P., a Delaware limited partnership (Purchaser Parent) to sell the P&HS business, for an aggregate of \$375 million in cash, subject to certain adjustments for cash, indebtedness, net working capital and transaction expenses. On December 31, 2025, we completed the sale of the P&HS business pursuant to the Purchase Agreement. We have retained a 5% equity interest in the P&HS business, which is reflected in other assets, net on our consolidated balance sheets. Following the sale, we retained a 5% equity interest in the P&HS business, which is reflected in other assets, net on our consolidated balance sheets.

The P&HS business was initially classified as discontinued operations and assets held for sale as of June 30, 2025. In accordance with GAAP, the financial position and results of operations of the P&HS business are presented as discontinued operations and, as such, have been excluded from continuing operations for all periods presented. With the exception of Note 3, the Notes to the Consolidated Financial Statements reflect the continuing operations of Accendra

[Table of Contents](#)

Health, Inc. unless otherwise noted. In connection with the sale, we entered into certain transitional services arrangements with the Purchaser that governs the parties' relationship following the closing. See Note 3 for additional information regarding discontinued operations and assets held for sale.

Use of Estimates. The preparation of consolidated financial statements in conformity with GAAP requires us to make assumptions and estimates that affect reported amounts and related disclosures. Significant estimates are used for, but are not limited to, variable consideration, depreciation and amortization, goodwill valuation, valuation of intangible assets and other long-lived assets, estimated fair values of the net assets acquired in business combinations, self-insurance liabilities, tax liabilities, defined benefit obligations, share-based compensation and other contingencies. Actual results may differ from these estimates.

Cash and Cash Equivalents. Cash and cash equivalents includes cash and marketable securities with an original maturity or maturity at acquisition of three months or less. Cash and cash equivalents are stated at cost. Nearly all of our cash and cash equivalents are held in cash depository accounts in major banks in the U.S. Cash that has restrictions on its availability to us would be classified as restricted cash. There was no restricted cash as of December 31, 2025 and 2024.

The following table provides a reconciliation of cash and cash equivalents reported within the accompanying consolidated balance sheets that sum to the total of those same amounts presented in the accompanying consolidated statements of cash flows. As there were no discontinued operations or restricted cash as of December 31, 2025, only 2024 is presented below.

	December 31, 2024
Cash and cash equivalents	\$ 27,572
Cash and cash equivalents of held for sale - discontinued operations	21,810
Total cash and cash equivalents	\$ 49,382

Book overdrafts represent the amount of outstanding checks issued in excess of related bank balances and are included in accounts payable in our consolidated balance sheets, as they are similar to trade payables and are not subject to finance charges or interest. Changes in book overdrafts are classified as operating activities in our consolidated statements of cash flows.

Accounts Receivable, Net. Due to the nature of our industry and the reimbursement environment in which we operate, certain estimates are required to record net revenues and accounts receivable at their net realizable values, including estimating variable consideration. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements, contractual terms, and the uncertainty of reimbursement amounts for certain services may result in adjustments to amounts originally recorded. Such adjustments are typically identified and recorded at the point of cash application, claim amount or account review.

Included in accounts receivable were earned but unbilled receivables of \$30 million as of December 31, 2025 and 2024. Delays, ranging from a single day to several weeks, between the date of service and billing can occur due to delays in obtaining certain required Payor-specific documentation from internal and external sources. Earned but unbilled receivables are aged from the date of service and are considered in our analysis of historical performance and collectability.

Receivables Sale Program. On October 18, 2024, we entered into a Receivables Purchase Agreement (the Receivables Sale Program) with persons from time to time, as Purchasers, PNC Bank, National Association, as Administrative Agent, and PNC Capital Markets LLC, as Structuring Agent, pursuant to which accounts receivable with an aggregate outstanding amount not to exceed \$450 million are sold, on a limited-recourse basis, to the Purchasers in exchange for cash. Transactions under this agreement are accounted for as sales in accordance with ASC 860, *Transfers and Servicing*, with the sold receivables removed from our consolidated balance sheets. Under the Receivables Sale Program, we provide certain servicing and collection actions on behalf of the Purchasers; however, we do not maintain any beneficial interest in the accounts receivable sold.

[Table of Contents](#)

Proceeds from the sales of accounts receivable are recorded as an increase to cash and cash equivalents and a reduction to accounts receivable, net of allowances in the consolidated balance sheets. Cash received from the sales of accounts receivable is reflected in the change in accounts receivable within cash provided by operating activities in the consolidated statements of cash flows. Total accounts receivable sold and net cash proceeds under the Receivables Sale Program were \$1.6 billion during the year ended December 31, 2025, approximately \$325 million of which related to continuing operations. We collected \$1.6 billion of the sold accounts receivable for the year ended December 31, 2025, approximately \$330 million of which related to continuing operations. The losses on sales of accounts receivable of continuing operations, inclusive of professional fees incurred to establish the agreement, recorded in selling, general, and administrative expenses in the consolidated statements of operations were \$2.2 million for the year ended December 31, 2025. In connection with the amendment to the Receivables Sale Program, as described below, any uncollected accounts receivable sold were settled on December 31, 2025.

Total accounts receivable sold and net cash proceeds under the Receivables Sale Program were \$168 million during the year ended December 31, 2024, approximately \$34 million of which related to continuing operations. We collected \$98 million of the sold accounts receivable for the year ended December 31, 2024, approximately \$20 million of which related to continuing operations. The losses on sales of accounts receivable of continuing operations, inclusive of professional fees incurred to establish the agreement, recorded in selling, general and administrative expense in the consolidated statements of operations were \$0.4 million for the year ended December 31, 2024.

As of December 31, 2024, there was a total of \$70 million of uncollected accounts receivable sold and removed from our consolidated balance sheet under the Receivables Sale Program, \$14 million of which related to continuing operations.

Amended Receivables Sale Program. On December 31, 2025, we entered into an Amended & Restated Receivables Purchase Agreement (the Amended Receivables Sale Program) with persons from time to time party thereto, as Purchasers, PNC Bank, as Administrative Agent, and PNC Capital Markets LLC, as Structuring Agent, pursuant to which accounts receivable with an aggregate outstanding amount not to exceed \$150 million are sold, on a limited-recourse basis, to the Purchasers in exchange for cash. The Receivables Sale Program amends and restates, in its entirety, the Receivables Sale Program, dated as of October 18, 2024.

Transactions under this agreement are accounted for as sales in accordance with ASC 860, *Transfers and Servicing*, with the sold receivables removed from our consolidated balance sheets. Under the Receivables Sale Program, we provide certain servicing and collection actions on behalf of the Purchasers; however, we do not maintain any beneficial interest in the accounts receivable sold. The Receivables Sale Program has a Scheduled Termination Date of October 18, 2027.

Total accounts receivable sold under the Amended Receivables Sale Program were \$134 million. As of December 31, 2025 there was a total of \$134 million of uncollected accounts receivable sold and removed from our consolidated balance sheet under the Amended Receivables Sale Program.

Inventories, net. Inventories, net, which primarily include medical supplies to be sold to customers, are determined using the first-in, first-out or weighted-average cost method at the lower of cost or net realizable value. We periodically evaluate whether inventory valuation allowance adjustments are required. In our evaluation, we review for obsolete inventory and slow-moving inventory which includes consideration of recent sales trends. We write down inventories which are considered excess and obsolete as a result of these assessments within cost of net revenue. Shifts in market trends and conditions, as well as changes in customer or Payor preferences and behavior could affect the value of our inventories.

Patient Service Equipment and Other Fixed Assets, Net. Patient service equipment consists of medical equipment rented to customers, primarily on a month-to-month basis, as well as equipment that may be sold. Patient service equipment depreciation expense is classified in our consolidated statements of operations within cost of net revenue for equipment rented to customers. Other fixed assets are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense for financial reporting purposes is generally computed on a

straight-line method over the estimated useful lives of the assets. In general, the estimated useful lives for computing depreciation are one to 10 years for patient service equipment, and up to 15 years for other fixed assets. Straight-line and accelerated methods of depreciation are used for income tax purposes. Normal maintenance and repairs are expensed as incurred, and renovations and betterments are capitalized. We suspend depreciation and amortization on assets that are held for sale.

Leases. We account for all of our lease arrangements, including for real estate, trucks, and patient service equipment, as operating leases. We enter into non-cancelable agreements to lease most of our office, branch and warehouse facilities with remaining terms generally ranging from one to six years. Certain building leases include renewal options which the exercise of is at our sole discretion. We generally do not include options to renew (or terminate) in our lease term, as part of our right-of-use assets and lease liabilities, as we generally do not have leases for which we believe we are reasonably certain to exercise those options. Leases with a term of 12 months or less are not recorded on the consolidated balance sheets; we recognize lease expense for these leases on a straight-line basis over the lease term. The depreciable lives of right-of-use assets are limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants.

Right-of-use assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. We elected the practical expedient to not separate lease and non-lease components for our leases. Operating lease assets and liabilities are recognized at the commencement date based on the present value of unpaid lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. Our incremental borrowing rate is estimated to approximate the interest rate on a collateralized basis with similar terms and payments. We use the implicit rate when readily determinable. The right-of-use assets also include adjustments for any lease payments made and lease incentives received.

Goodwill. We account for acquired businesses using the acquisition method of accounting, which requires that the assets acquired and liabilities assumed be recorded at the date of acquisition at their respective fair values. Any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.

We evaluate goodwill for impairment annually, as of October 1, and if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. Qualitative factors are first assessed to determine if it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If it is determined that it is more likely than not the fair value does not exceed the carrying amount, then a quantitative test is performed. We may be required to record a material charge to earnings in our consolidated financial statements during the period in which any impairment of our goodwill is determined.

Intangible Assets, net. Intangible assets acquired through purchases or business combinations are stated at fair value at the acquisition date and net of accumulated amortization in the consolidated balance sheets. Intangible assets, consisting primarily of customer relationships, customer contracts and tradenames are amortized over their estimated useful lives. In determining the useful life of an intangible asset, we consider our historical experience in renewing or extending similar arrangements. Intangible assets are generally amortized over one to 15 years based on their pattern of economic benefit or on a straight-line basis. We suspend amortization on assets that are held for sale.

Computer Software. We develop and purchase software for internal use. Software development costs incurred during the application development stage are capitalized. Once the software has been installed and tested, and is ready for use, additional costs incurred in connection with the software are expensed as incurred. Capitalized computer software costs are amortized over the estimated useful life of the software, usually between three and 10 years. Capitalized computer software costs are included in other assets, net, in the consolidated balance sheets. Unamortized software at December 31, 2025 and 2024 was \$15 million and \$26 million.

Long-Lived Assets. Long-lived assets, which include patient service equipment, finite-lived intangible assets, right-of-use assets, unamortized software costs, and other fixed assets are evaluated for impairment whenever events or changes in circumstances indicate that the carrying amount of long-lived assets may not be recoverable. We assess long-

[Table of Contents](#)

lived assets for the potential impairments by comparing the carrying value of an asset, or group of related assets, to their estimated undiscounted future cash flows.

Self-Insurance Liabilities. We are self-insured for certain teammate healthcare, workers' compensation and automobile liability costs; however, we maintain insurance for individual losses exceeding certain limits. Liabilities are estimated for healthcare costs using current and historical claims data. Liabilities for workers' compensation and automobile liability claims are estimated using historical claims data and loss development factors. If the underlying facts and circumstances of existing claims change or the historical trends are not indicative of future trends, then we may be required to adjust the liability and related expense accordingly. Self-insurance liabilities are included in other current liabilities and other liabilities in the consolidated balance sheets and were \$28 million and \$27 million in total at December 31, 2025 and 2024.

Revenue Recognition. Revenues are primarily recognized under fee-for-service arrangements for sales of supplies, equipment and other items we sell to customers and equipment we rent to customers. Revenue for sales of products, including equipment and supplies, is recognized when control of the promised goods is transferred to customers and is presented net of applicable sales taxes. Revenue generated from equipment that we rent to customers is primarily recognized as earned on a straight-line basis over the non-cancellable rental period, typically one month, and commences on delivery of the equipment to the customers.

Fee-for-service arrangement revenues are recorded only to the extent it is probable that a significant reversal will not occur in the future as amounts may include implicit price concessions under reimbursement arrangements with third-party payors, including private insurers under both commercial and Medicare Advantage plans, prepaid health plans, Medicare, Medicaid and customers. Revenue is recognized under a portfolio approach, as we expect that this approach would not differ materially from considering each contract or performance obligation separately. We use the expected value method in determining the variable consideration as part of determining the sales transaction price using historical reimbursement experience, historical sales returns, and other operating trends. Payment terms and conditions vary by contract. Sales of equipment and supplies inclusive of amounts recognized under capitation arrangements for the years ended December 31, 2025, 2024 and 2023 were \$2.1 billion, \$2.0 billion and \$1.8 billion. Rental revenues inclusive of amounts recognized under capitation arrangements for the years ended December 31, 2025, 2024 and 2023 were \$679 million, \$678 million and \$708 million.

Certain revenues are recognized under arrangements with third-party payors for which we stand ready to provide all necessary healthcare services to members for the period of the stand ready obligation which generally extends beyond one year. These agreements are generally referred to as capitation arrangements. Revenue is recognized over the month that the members are entitled to healthcare services using the monthly contractual rate for each covered member. The actual number of covered members may vary each month. Capitation payments are typically received in the month members are entitled to healthcare services. Revenue for these agreements amounted to \$244 million, \$238 million and \$237 million for the years ended December 31, 2025, 2024, and 2023.

The following table summarizes net revenue by product category:

<u>Years Ended December 31,</u>	<u>2025</u>	<u>2024</u>	<u>2023</u>
Diabetes	\$ 783,370	\$ 777,483	\$ 723,318
Sleep therapy	740,052	702,950	669,784
Home respiratory therapy	433,050	435,954	457,675
Ostomy	212,838	195,923	177,890
Wound care	188,508	192,407	170,949
Urology	116,022	107,121	97,985
Other	288,192	268,274	254,971
Net revenue	\$ 2,762,032	\$ 2,680,112	\$ 2,552,572

[Table of Contents](#)

The following table summarizes net revenue by payor type:

Years Ended December 31,	2025	2024	2023
Commercial payors ⁽¹⁾	\$ 2,225,775	\$ 2,177,955	\$ 2,050,707
Medicare	497,797	461,973	463,471
Medicaid	38,460	40,184	38,394
Net revenue	\$ 2,762,032	\$ 2,680,112	\$ 2,552,572

(1) Commercial payors includes revenue from Medicare Advantage plans.

Cost of Net Revenue. Cost of net revenue includes the cost of product sold, patient service equipment depreciation expense, and other costs which are primarily personnel costs related to the set-up and utilization of equipment. Cost of product sold includes non-cash expenses primarily for equipment converted from rental to sales in the amount of \$47 million, \$34 million and \$36 million for the years ended December 31, 2025, 2024 and 2023.

Years Ended December 31,	2025	2024	2023
Cost of product sold	\$ 1,323,336	\$ 1,245,684	\$ 1,172,760
Patient service equipment depreciation	126,830	126,796	138,444
Other costs	22,567	27,252	24,348
Cost of net revenue	\$ 1,472,733	\$ 1,399,732	\$ 1,335,552

Selling, General and Administrative (SG&A) Expenses. SG&A expenses include compensation costs, expenses for selling and administrative functions, shipping and handling costs and certain depreciation and amortization expense.

Shipping and Handling. Shipping and handling costs are primarily included in SG&A expenses in the consolidated statements of operations and include costs to store, move, and prepare products for shipment, as well as costs to deliver products to customers. Shipping and handling costs totaled \$288 million, \$274 million, and \$265 million for the years ended December 31, 2025, 2024, and 2023.

Share-Based Compensation. We account for share-based payments to teammates at fair value and recognize the related expense primarily in SG&A expenses over the service period for awards expected to vest. The fair value of nonvested performance shares is dependent upon our assessment of the probability of achievement of financial targets for the performance period.

Income Taxes. We account for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are provided if it is more likely than not that a deferred tax asset will not be realized. When we have claimed tax benefits that may be challenged by a tax authority, an estimate of the effect of these uncertain tax positions is recorded. It is our policy to provide for uncertain tax positions and related interest and penalties based upon an assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. To the extent that the tax outcome of these uncertain tax positions changes, based on our assessment, such changes in estimate may impact the income tax provision in the period in which such determination is made.

Fair Value Measurements. Fair value is determined based on assumptions that a market participant would use in pricing an asset or liability. The assumptions used are in accordance with a three-tier hierarchy, defined by GAAP, that draws a distinction between market participant assumptions based on (i) observable inputs such as quoted prices in active markets (Level 1), (ii) inputs other than quoted prices in active markets that are observable either directly or

indirectly (Level 2) and (iii) unobservable inputs that require the use of present value and other valuation techniques in the determination of fair value (Level 3).

The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, and accrued payroll and related liabilities reported in the consolidated balance sheets approximate fair value due to the short-term nature of these instruments. The estimated fair value of our reporting unit determined during a quantitative review of goodwill utilizes unobservable inputs (Level 3). The fair value of debt is estimated based on quoted market prices or dealer quotes for the identical liability when traded as an asset in an active market (Level 1) or, if quoted market prices or dealer quotes are not available, on the borrowing rates currently available for loans with similar terms, credit ratings, and average remaining maturities (Level 2). See Note 8 for the fair value of debt. The fair value of our derivative contracts is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. See Note 11 for the fair value of derivatives.

Our acquisitions may include contingent consideration as part of the purchase price. The fair value of contingent consideration is estimated as of the acquisition date and at the end of each subsequent reporting period based on the present value of the contingent payments to be made using a weighted probability of possible payments (Level 3). Subsequent changes in fair value are recorded as adjustments to acquisition-related charges and intangible amortization within the consolidated statements of operations.

Acquisition-Related Charges and Intangible Amortization. Acquisition-related charges consist primarily of one-time costs related to acquisitions, including transaction costs necessary to consummate acquisitions, which consist of investment banking advisory fees and legal fees, director and officer tail insurance expense, as well as transition costs, such as severance and retention bonuses, information technology (IT) integration costs and professional fees. For the years ended December 31, 2025 and 2024, we incurred \$22 million of acquisition-related costs related to the terminated acquisition of Rotech Healthcare Holdings Inc. (Rotech), which consisted primarily of legal and professional fees. Acquisition-related charges for the year ended December 31, 2023 were \$17 million, consisting of costs related to the acquisition of Apria. Acquisition-related charges and intangible amortization also include amortization of intangible assets established during acquisition method of accounting for business combinations. These amounts are highly dependent on the size and frequency of acquisitions.

Transaction Breakage Fee. As previously disclosed, on July 22, 2024, we entered into an Agreement and Plan of Merger (the Merger Agreement) pursuant to which we agreed to acquire Rotech subject to the terms and conditions within the Merger Agreement. On June 3, 2025, the Company, Rotech and Hitchcock Merger Sub Inc. mutually agreed to terminate the Merger Agreement and entered into a mutual termination agreement (the Termination Agreement). In accordance with the terms of the Termination Agreement, we incurred and made a cash payment to Rotech of \$80 million during the year ended December 31, 2025.

Exit and Realignment Charges, net. Exit and realignment charges, net consist of costs associated with optimizing our operations including significant changes to certain processes to increase net revenue and lower costs along with costs related to IT strategic initiatives and other strategic actions. These costs include, but are not limited to, professional fees, severance and other costs to streamline functions and processes. Costs associated with exit and realignment activities are recorded at their fair value when incurred. Liabilities are established at the cease-use date for remaining contractual obligations discounted using a credit-adjusted risk-free rate of interest. We evaluate these assumptions quarterly and adjust the liabilities accordingly. Severance benefits are generally recorded when payment is considered probable and reasonably estimable. These costs are not normal, cash operating expenses necessary for the Company to operate its business on an ongoing basis.

Net (Loss) Income Per Share. Basic earnings per share is calculated by dividing net (loss) income by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflects the potential dilution that could occur if restricted awards were exercised or converted into common stock.

Business Combinations. We account for acquired businesses using the acquisition method of accounting, which requires that the assets acquired and liabilities assumed be recorded at the date of acquisition at their respective

fair values. Any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. The results of operations of the businesses acquired by the Company are included as of the respective acquisition date.

Recently Adopted Accounting Pronouncements. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires additional annual income tax disclosures, including disclosure of reconciling items by jurisdiction and nature to the extent those items exceed a specified threshold. In addition, this ASU requires disclosure of income taxes paid, net of refunds received disaggregated by federal, state, and foreign and by jurisdiction if the amount is more than 5% of total income tax payments, net of refunds received. The amendments in this ASU are effective for us in annual periods beginning after December 15, 2024. The amendments in this ASU are required to be applied on a prospective basis and retrospective adoption is permitted. We have adopted this ASU, which impacted our disclosures with no impacts to our results of operations, financial condition and cash flows.

Recently Issued Accounting Pronouncements Not Yet Adopted. In November 2024, the FASB issued ASU No. 2024-03, Income Statement – Reporting Comprehensive Income – Expense disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which will require additional disclosures about a public business entity’s expenses and address requests from investors for more detailed information about the types of expenses in commonly presented expense captions. The amendments in this ASU are effective for us in annual periods beginning after December 15, 2026. The amendments in this ASU are required to be applied on a prospective basis and retrospective adoption is permitted. We expect this ASU to only impact our disclosures with no impacts to our results of operations, financial condition and cash flows.

In July 2025, the FASB issued ASU 2025-05, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets, which provides a practical expedient permitting the assumption that conditions at the balance sheet date remain unchanged over the life of the asset when estimating expected credit losses for current accounts receivable and current contract assets. The amendments in this ASU are effective for us in annual and interim periods beginning after December 15, 2025. We do not expect this ASU to have a material impact on our consolidated financial statements.

In September 2025, the FASB issued ASU No. 2025-06—Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software, which will require us to start capitalizing software costs when management has authorized and committed to funding the software project and it is probable that the project will be completed and the software will be used to perform the function intended (referred to as the “probable-to-complete recognition threshold”). The amendments in this ASU are effective for us in annual periods beginning after December 15, 2027 and early adoption is permitted for all entities. The amendments in this Update allow us to apply the new guidance using either a prospective transition approach, a modified transition approach, or a retrospective transition approach. We expect this ASU to impact our disclosures and our results of operations, financial condition and cash flows and we will assess the impact upon adoption.

In December 2025, the FASB issued ASU No. 2025-11—Interim Reporting (Topic 270): Narrow-Scope Improvements, which will require entities to disclose events since the end of the last annual reporting period that have a material impact on the entity. The amendments in this Update apply to all entities that provide interim financial statements and notes in accordance with GAAP. The amendments in this ASU are effective for us in annual periods beginning after December 15, 2027, and interim periods within those annual reporting periods. Early adoption is permitted for all entities. The amendments in this Update can be applied either prospectively or retrospectively. We expect this ASU to only impact our disclosures with no impacts to our results of operations, financial condition and cash flows.

Note 2—Significant Concentration Risk

During the year ended December 31, 2025, our two largest commercial payors represented approximately 23% and 14% of our net revenue, derived from multiple separately managed contracts. Revenue reimbursed under arrangements with Medicare and state Medicaid programs was approximately 19% of our net revenue for the year ended December 31, 2025. The largest commercial payor has terminated, or is in the process of terminating, certain of our contracts with them. The terminated agreements reflected \$322 million or 12% of our net revenue, including \$231 million of capitation revenue, which represents nearly all of our capitation revenue, for the year ended December 31, 2025.

During the year ended December 31, 2025, our three largest suppliers contributed 16%, 14% and 11% of our patient service equipment and supplies purchases collectively accounting for approximately 40% of our total purchases.

Note 3—Discontinued Operations and Assets Held-for-Sale

On February 28, 2025, we announced that we were actively engaged in discussions regarding the anticipated sale of our P&HS business. On October 7, 2025, we entered into the Purchase Agreement by and among the Company, the Purchaser, and Purchaser Parent to sell the P&HS business, for an aggregate of \$375 million in cash, subject to certain adjustments for cash, indebtedness, net working capital and transaction expenses. On December 31, 2025 we completed the sale of the P&HS business pursuant to the Purchase Agreement. We have retained a 5% equity interest in the P&HS business.

In accordance with GAAP, the financial position and results of operations of the P&HS business are presented as discontinued operations and assets held for sale and, as such, have been excluded from continuing operations for all periods presented. The P&HS business was initially classified as discontinued operations and assets held for sale as of June 30, 2025. Accordingly, the results of operations from our P&HS business are reported in the accompanying consolidated statements of operations as “Loss from discontinued operations, net of tax” for the years ended December 31, 2025, 2024 and 2023 and the related assets and liabilities are classified as held-for-sale as of December 31, 2024 in the accompanying consolidated balance sheets. We have allocated interest expense, net to discontinued operations as a ratio of net assets and total debt in accordance with ASC 205, *Presentation of Financial Statements*.

The P&HS goodwill balance of \$106 million was fully impaired during the second quarter of 2025. Our sale process provided a basis for the fair value of the P&HS business, which includes the Global Products reporting unit. We recognized a loss of \$799 million during the year ended December 31, 2025 in connection with the classification of the related assets and liabilities as held-for-sale, based on the estimated fair value, less costs to sell. The fair value of the P&HS business was determined from information received during our sale process, including the completion of the sale on December 31, 2025. On December 31, 2025, we received cash proceeds of \$342 million and recorded a \$20 million equity investment for the 5% retained equity interest, which is in other assets, net on our consolidated balance sheet as of December 31, 2025. Net proceeds of \$324 million from the P&HS Sale, net of cash sold, as reported on our consolidated statement of cash flows, reflects \$342 million of cash proceeds received and \$18 million of P&HS cash conveyed. The final purchase price will be determined subsequent to the completion of the sale to reflect adjustments in accordance with the Purchase Agreement, including final net working capital adjustments. As of December 31, 2025, we estimated a purchase price adjustment receivable of approximately \$12 million to \$15 million, which is recorded within other current assets on our consolidated balance sheet. Subsequent changes in fair value will be recorded within discontinued operations.

We have agreed to reimburse the Purchaser and its affiliates for 80% of certain costs incurred in connection with the separation of P&HS from the Company’s retained business, subject to an aggregate cap of \$65 million. We will be obligated to reimburse Purchaser for any such costs incurred after December 31, 2025, except that such reimbursements will not need to be paid: (1) in advance of April 1, 2026; (2) for amounts in excess of \$15 million prior to October 1, 2026, or (3) for amounts in excess of \$55 million prior to January 1, 2027. We and the Purchaser will provide certain transition services to the other party pursuant to a certain customary transition services agreement. Pursuant to the terms of the transition services agreement, we have agreed that, in certain circumstances, we may be obligated to provide up to \$115 million in credit support to the P&HS business.

[Table of Contents](#)

The following table summarizes the financial results of our discontinued operations for the years ended December 31, 2025, 2024 and 2023:

Years Ended December 31,	2025	2024	2023
Net revenue	\$ 7,909,655	\$ 8,020,771	\$ 7,781,395
Cost of goods sold	7,125,144	7,081,996	6,873,254
Gross profit	784,511	938,775	908,141
Distribution, selling, and administrative expenses	782,789	835,046	812,672
Acquisition-related charges and intangible amortization	12,549	24,695	26,240
Exit and realignment charges, net	72,379	63,356	91,791
Goodwill impairment charge	106,389	—	—
Loss on classification to held for sale	798,934	—	—
Other operating expense, net	10,932	5,717	6,161
Operating (loss) income	(999,461)	9,961	(28,723)
Interest expense, net	36,001	36,238	41,146
Other expense	1,405	1,195	122
Loss from discontinued operations before income taxes	(1,036,867)	(27,472)	(69,991)
Income tax benefit for discontinued operations	(38,907)	(15,521)	(19,785)
Loss from discontinued operations, net of tax	<u>\$ (997,960)</u>	<u>\$ (11,951)</u>	<u>\$ (50,206)</u>

[Table of Contents](#)

As discussed above, the sale of the P&HS business was completed and therefore the assets and liabilities are not reflected on the consolidated balance sheets at December 31, 2025. The assets and liabilities of the P&HS business reflected on the consolidated balance sheets at December 31, 2024 are as follows:

	December 31, 2024
Assets held for sale - discontinued operations	
Cash and cash equivalents	\$ 21,810
Accounts receivable, net	471,971
Merchandise inventories	1,064,298
Other current assets, net	67,275
Current assets held for sale - discontinued operations	1,625,354
Property and equipment, net	260,064
Operating lease assets	228,699
Goodwill	103,140
Intangible assets, net	88,670
Deferred tax assets	6,726
Other noncurrent assets, net	43,894
Total assets held for sale - discontinued operations	\$ 2,356,547
Liabilities held for sale - discontinued operations	
Accounts payable	\$ 868,764
Accrued payroll and related liabilities	77,046
Current portion of long-term debt	2,683
Other current liabilities	82,400
Operating lease liabilities, current portion	50,003
Current liabilities held for sale - discontinued operations	1,080,896
Long-term debt, excluding current portion	9,654
Operating lease liabilities, excluding current portion	196,746
Other liabilities	28,474
Deferred tax liabilities	3,020
Total liabilities held for sale - discontinued operations	\$ 1,318,790

As of December 31, 2024, the assets and liabilities held for sale are classified separately as current or noncurrent because the noncurrent assets and liabilities did not meet the criteria for current classification as of December 31, 2024.

Receivables Purchase Agreement (RPA). On March 14, 2023, we entered into the RPA, pursuant to which accounts receivable with an aggregate outstanding amount not to exceed \$200 million are sold, on a limited-recourse basis, to the Purchaser (as defined therein) in exchange for cash. We account for these transactions as sales with the sold receivables removed from our consolidated balance sheets. Under the RPA, we provide certain servicing and collection actions on behalf of the Purchaser; however, we do not maintain any beneficial interest in the accounts receivable sold. The RPA is separate and distinct from the Receivables Financing Agreement and the amendment as described below. As a result of the amendment described below, we did not utilize the RPA in the year ended December 31, 2025.

Proceeds from the sale of accounts receivable are recorded as an increase to cash and cash equivalents and a reduction to current assets of discontinued operations, in the consolidated balance sheets. Cash received from the sale of accounts receivable, net of payments made to the Purchaser, is reflected as cash provided by operating activities in the consolidated statements of cash flows. The accounts receivable sold under the RPA were entirely accounts receivable of the P&HS business. Total accounts receivable sold under the RPA and net cash proceeds were \$1.7 billion and \$1.4 billion during the years ended December 31, 2024 and 2023. We collected \$1.9 billion and \$1.3 billion of the sold accounts receivable for the years ended December 31, 2024 and 2023. The losses on sales of accounts receivable are recorded in other operating expense (income), net in the consolidated statements of operations and were \$11 million for the years ended December 31, 2024 and 2023.

[Table of Contents](#)

Receivables Sale Program. On October 18, 2024, we entered into a Receivables Purchase Agreement (the Receivables Sale Program) with persons from time to time, as Purchasers, PNC Bank, National Association, as Administrative Agent, and PNC Capital Markets LLC, as Structuring Agent, pursuant to which accounts receivable with an aggregate outstanding amount not to exceed \$450 million are sold, on a limited-recourse basis, to the Purchasers in exchange for cash. Transactions under this agreement are accounted for as sales in accordance with ASC 860, *Transfers and Servicing*, with the sold receivables removed from our consolidated balance sheets. Under the Receivables Sale Program, we provide certain servicing and collection actions on behalf of the Purchasers; however, we do not maintain any beneficial interest in the accounts receivable sold.

Proceeds from the sales of accounts receivable are recorded as an increase to cash and cash equivalents and a reduction to accounts receivable, net of allowances in the consolidated balance sheets. Cash received from the sales of accounts receivable, is reflected in the change in accounts receivable within cash provided by operating activities in the consolidated statements of cash flows. Total accounts receivable sold and net cash proceeds under the Receivables Sale program were \$1.6 billion during the year ended December 31, 2025, approximately \$1.3 billion of which related to discontinued operations. We collected \$1.6 billion of the sold accounts receivable for the year ended December 31, 2025, approximately \$1.3 billion of which related to discontinued operations. The losses on sales of accounts receivable of continuing operations, inclusive of professional fees incurred to establish the agreement, recorded in loss on discontinued operations, net of tax in the consolidated statements of operations were \$8.7 million for the year ended December 31, 2025. In connection with the amendment to the Receivables Sale Program, as described below, any uncollected accounts receivable sold were settled on December 31, 2025.

Total accounts receivable sold and net cash proceeds under the Receivables Sale program were \$168 million during the year ended December 31, 2024, approximately \$134 million of which related to discontinued operations. We collected \$98 million of the sold accounts receivable for the year ended December 31, 2024, approximately \$78 million of which related to discontinued operations. The losses on sales of accounts receivable of continuing operations, inclusive of professional fees incurred to establish the agreement, recorded in loss on discontinued operations, net of tax in the consolidated statements of operations were \$1.5 million for the year ended December 31, 2024.

As of December 31, 2025, there was no uncollected accounts receivable sold and removed from our consolidated balance sheet related to discontinued operations. As of December 31, 2024, there was a total of \$70 million of uncollected accounts receivable sold and removed from our consolidated balance sheet under the Receivables Sale Program, \$56 million of which related to discontinued operations.

Note 4—Patient Service Equipment and Other Fixed Assets, Net

Patient service equipment and other fixed assets, net, consists of the following:

December 31,	2025		2024	
Patient service equipment	\$	420,527	\$	388,445
Building and leasehold improvements		13,522		23,955
Other fixed assets		29,707		20,628
Patient service equipment and other fixed assets, gross		463,756		433,028
Accumulated depreciation and amortization		(207,595)		(183,745)
Patient service equipment and other fixed assets, net	\$	256,161	\$	249,283

Note 5—Goodwill and Intangible Assets, Net

At December 31, 2025 and 2024 we had goodwill of \$1.2 billion, net of accumulated goodwill impairment of \$307 million.

As of October 1, 2025, we performed our annual impairment test and there were no impairments of goodwill. No impairment of goodwill was recorded for the year ended December 31, 2025 within continuing operations.

Intangible assets subject to amortization, at December 31, 2025 and 2024 were as follows:

	2025			2024		
	Customer Relationships	Tradenames	Other Intangibles	Customer Relationships	Tradenames	Other Intangibles
Intangible assets, gross	\$ 132,300	\$ 143,000	\$ 38,000	\$ 132,300	\$ 143,000	\$ 38,000
Accumulated amortization	(76,472)	(71,081)	(29,282)	(24,326)	(56,437)	(22,481)
Intangible assets, net	\$ 55,828	\$ 71,919	\$ 8,718	\$ 107,974	\$ 86,563	\$ 15,519
Weighted average useful life	6 years	10 years	6 years	15 years	10 years	6 years

Amortization expense for intangible assets was \$74 million, \$40 million and \$58 million for the years ended December 31, 2025, 2024, and 2023. The increase as compared to the prior year was driven by the remaining useful life for an intangible asset being modified as of June 30, 2025, as a result of a notice of a contract termination with a commercial Payor. The updated future intangible amortization is reflected in the table below.

As of December 31, 2025, based on the current carrying value of intangible assets subject to amortization and expected remaining useful life, estimated amortization expense were as follows:

Year	
2026	\$ 68,122
2027	13,872
2028	11,953
2029	11,953
2030	11,953
Thereafter	18,612
Total future amortization	\$ 136,465

Note 6—Leases

The components of lease expense were as follows:

	Classification	Years Ended December 31,		
		2025	2024	2023
Operating lease cost	SG&A expenses	\$ 52,333	\$ 53,283	\$ 47,090
Short-term lease cost	SG&A expenses, Cost of net revenue	6,475	10,203	7,106
Variable lease cost	SG&A expenses, Cost of net revenue	24,746	25,024	24,368
Total lease cost		\$ 83,554	\$ 88,510	\$ 78,564

Variable lease cost consists primarily of taxes, insurance, and common area or other maintenance costs for our leased facilities and patient service equipment which are paid as incurred.

[Table of Contents](#)

Supplemental balance sheet information was as follows:

	Classification	As of December 31, 2025	As of December 31, 2024
Assets:			
Operating lease assets	Operating lease assets	\$ 109,099	\$ 126,928
Liabilities:			
Current operating leases	Other current liabilities	\$ 43,272	\$ 41,217
Noncurrent operating leases	Operating lease liabilities, excluding current portion	70,317	89,466
Total operating lease liabilities		<u>\$ 113,589</u>	<u>\$ 130,683</u>

Other information related to leases was as follows:

	Years Ended December 31,		
	2025	2024	2023
<u>Supplemental cash flow information</u>			
Cash paid for amounts included in the measurement of lease liabilities:			
Operating cash flows from operating leases	\$ 52,705	\$ 52,606	\$ 49,352
Right-of-use assets obtained in exchange for new operating lease liabilities	\$ 33,211	\$ 40,176	\$ 69,666
<u>Weighted average remaining lease term (years)</u>			
Operating leases	3.3	3.7	4.0
<u>Weighted average discount rate</u>			
Operating leases	8.0 %	6.2 %	5.8 %

Maturities of lease liabilities as of December 31, 2025 were as follows:

2026	\$ 49,425
2027	36,682
2028	24,709
2029	13,396
2030	6,423
Thereafter	2,207
Total lease payments	<u>132,842</u>
Less: Interest	(19,253)
Present value of lease liabilities	<u>\$ 113,589</u>

Note 7—Exit and Realignment Charges, Net

We incur exit and realignment and other charges associated with optimizing our operations which include IT strategic initiatives and other strategic actions. These charges include professional fees, severance and other costs to streamline functions and enhance processes. These costs are not normal, cash operating expenses necessary for the Company to operate its business on an ongoing basis.

Exit and realignment charges, net were \$18 million, \$47 million and \$7.3 million for the years ended December 31, 2025, 2024 and 2023. These charges were primarily related to strategic operational improvements to increase net revenue and lower costs as well as a provision to accounts receivable related to our Fusion5 business which is in the process of being wound down. Exit and realignment charges, net for the year ended December 31, 2025 also

[Table of Contents](#)

included a \$4.8 million gain on sales of patient service equipment in response to the contract termination with a commercial Payor.

As a result of the sale of our P&HS business, we expect to incur up to \$65 million in future exit & realignment costs associated with reimbursement to the Purchaser for certain future costs incurred by the Purchaser, as described in Note 3. We will be obligated to reimburse Purchaser for any such costs incurred after December 31, 2025, except that such reimbursements will not need to be paid: (1) in advance of April 1, 2026; (2) for amounts in excess of \$15 million prior to October 1, 2026, or (3) for amounts in excess of \$55 million prior to January 1, 2027.

The following table summarizes the activity related to exit and realignment cost accruals through December 31, 2025:

	Total
Accrued exit and realignment costs, December 31, 2022	\$ 244
Provision for exit and realignment activities:	
Professional fees	2,066
IT strategic initiatives and other	5,270
Cash payments	(4,471)
Accrued exit and realignment costs, December 31, 2023	3,109
Provision for exit and realignment activities:	
Professional fees	36,173
IT strategic initiatives and other	10,633
Cash payments	(43,183)
Accrued exit and realignment costs, December 31, 2024	6,732
Provision for exit and realignment activities:	
Severance	5,365
Professional fees	8,351
IT strategic initiatives and other	1,491
Cash payments	(17,295)
Accrued exit and realignment costs, December 31, 2025	\$ 4,644

In addition to the exit and realignment accruals in the preceding table and the \$4.8 million gain on sales of patient service equipment, we also incurred \$8.0 million of costs that were expensed as incurred for the year ended December 31, 2025, which primarily related to wind-down costs of Fusion5.

Note 8—Debt

Debt, net of unamortized deferred financing costs, as of December 31, 2025 and 2024 consisted of the following:

	December 31, 2025		December 31, 2024	
	Carrying Amount	Estimated Fair Value	Carrying Amount	Estimated Fair Value
Term Loan A	\$ 324,647	\$ 321,356	\$ 322,957	\$ 327,066
Revolving Credit Facility	203,500	203,500	—	—
4.500% Senior Notes, due March 2029	475,077	327,261	473,976	427,117
Term Loan B	502,489	492,159	499,871	518,665
6.625% Senior Notes, due April 2030	544,163	348,901	542,311	518,671
Other	—	—	2,144	2,144
Total debt	2,049,876	1,693,177	1,841,259	1,793,663
Less current maturities, including anticipated repayments	(250,000)	(250,000)	(42,866)	(42,866)
Long-term debt	\$ 1,799,876	\$ 1,443,177	\$ 1,798,393	\$ 1,750,797

On March 29, 2022, we entered into a Security Agreement Supplement pursuant to which the Security and Pledge Agreement (the Security Agreement), dated March 10, 2021 was supplemented to grant collateral on behalf of the holders of the 2024 Notes, and the parties secured under the credit agreements including first priority liens and security interests in (a) all present and future shares of capital stock owned by the Grantors (as defined in the Security Agreement) in the Grantors' present and future subsidiaries, subject to certain customary exceptions, and (b) all present and future personal property and assets of the Grantors, subject to certain exceptions.

On March 29, 2022, we entered into a term loan credit agreement with an administrative agent and collateral agent and a syndicate of financial institutions, as lenders (the Credit Agreement) that provides for two credit facilities: (i) a \$500 million Term Loan A facility (the Term Loan A), and (ii) a \$600 million Term Loan B facility (the Term Loan B). The interest rate on the Term Loan A is based on the sum of either Term SOFR or the Base Rate and an Applicable Rate which varies depending on the current Debt Ratings or Total Leverage Ratio, determined as to whichever shall result in more favorable pricing to the Borrowers (each as defined in the Credit Agreement). The interest rate on the Term Loan B is based on either the Term SOFR or the Base Rate plus an Applicable Rate. The Term Loan A will mature in March 2027 and the Term Loan B will mature in March 2029. The Term Loan A and Term Loan B have \$326 million and \$511 million of principal outstanding excluding unamortized deferred financing costs as of December 31, 2025.

On March 10, 2021, we issued \$500 million of 4.500% senior unsecured notes due in March 2029 (the 2029 Unsecured Notes), with interest payable semi-annually. The 2029 Unsecured Notes were sold at 100% of the principal amount with an effective yield of 4.500%. The 2029 Unsecured Notes have \$479 million in principal outstanding excluding unamortized deferred financing costs as of December 31, 2025.

On March 29, 2022, we issued \$600 million of 6.625% senior unsecured notes due in April 2030 (the 2030 Unsecured Notes), with interest payable semi-annually. The 2030 Unsecured Notes were sold at 100% of the principal amount with an effective yield of 6.625%. The 2030 Unsecured Notes have \$552 million in principal outstanding excluding unamortized deferred financing costs as of December 31, 2025.

The 2029 Unsecured Notes and the 2030 Unsecured Notes are subordinated to any of our secured indebtedness, including indebtedness under our credit agreements.

On March 29, 2022, we entered into an amendment to our revolving credit agreement, dated as of March 10, 2021 with an administrative agent and collateral agent and a syndicate of financial institutions, as lenders (Revolving Credit Agreement). The amendment: (i) increased the aggregate revolving credit commitments under the Revolving Credit Agreement by \$150 million, to an aggregate amount of \$450 million and (ii) replaced the Eurocurrency Rate with the Adjusted Term SOFR Rate (each as defined in the Revolving Credit Agreement). The Revolving Credit Agreement matures in March 2027.

[Table of Contents](#)

At December 31, 2025 we had \$204 million in outstanding borrowings on our Revolving Credit Agreement. At December 31, 2024 our Revolving Credit Agreement was undrawn. At December 31, 2025 and December 31, 2024, we had letters of credit, which reduce Revolver availability, totaling \$30 million and \$31 million, leaving \$217 million and \$419 million available for borrowing.

The Revolving Credit Agreement, the Credit Agreement, the 2029 Unsecured Notes and the 2030 Unsecured Notes contain cross-default provisions which could result in the acceleration of payments due in the event of default of any of the related agreements. The terms of the applicable credit agreements also require us to maintain ratios for leverage and interest coverage, including on a pro forma basis in the event of an acquisition or divestiture. We were in compliance with our debt covenants at December 31, 2025.

As of December 31, 2025, future principal payments due under our debt agreements or anticipated to be repaid within twelve months, were as follows:

Year	
2026	\$ 250,000
2027	279,750
2028	—
2029	989,654
2030	552,189

Current maturities at December 31, 2025 include \$250 million in debt anticipated to be voluntarily repaid within the next twelve months in connection with net cash proceeds received from the P&HS business sale.

Note 9—Share-Based Compensation

We maintain a share-based compensation plan (the Plan) that is administered by the Our People & Culture Committee of the Board of Directors. The Plan allows us to award or grant to officers, directors and teammates incentive, non-qualified and deferred compensation stock options, stock appreciation rights (SARs), performance stock units and performance shares (collectively Performance Stock Awards (PSAs)), restricted stock units and restricted stock (collectively Restricted Stock Awards (RSAs)) and unrestricted stock. We use authorized and unissued common shares for grants of RSAs, SARs, PSAs or for stock option exercises. At December 31, 2025, approximately 4.6 million common shares were available for issuance under the Plan. Unvested shares of approximately 1.8 million were cancelled in connection with closing the sale of the P&HS business.

RSAs under the Plan generally vest over one, three or five years. PSAs under the Plan are issuable as restricted stock or common shares upon meeting performance goals and generally have a total performance and vesting period of three years. Under the 2018 Stock Incentive Plan, if outstanding equity awards are not assumed or substituted in connection with a change in control, unvested awards will vest in full upon the change in control. Under the 2023 Omnibus Incentive Plan, unless the individual award agreements provide otherwise, if the successor company assumes the awards, vesting of the award will be accelerated upon a subsequent termination of employment without cause or, if the teammates resigns for good reason (to the extent applicable), in each case, within 24 months following the change in control, with any performance-based awards deemed earned based on the greater of the target and actual performance levels.

We recognize the fair value of stock-based compensation awards, which is based upon the market price of the underlying common stock at the grant date, on a straight-line basis over the estimated requisite service period. RSAs are earned based on service conditions and PSAs are earned based on service conditions, performance conditions, market conditions, or any combination of these. The fair value of PSAs as of the date of grant is estimated assuming that performance goals will be achieved at target levels. If such goals are not probable of being met, or are probable of being met at different levels, recognized compensation cost is adjusted to reflect the change in estimated fair value.

Total share-based compensation expense for December 31, 2025, 2024 and 2023 was \$13 million, \$17 million and \$14 million with recognized tax benefits of \$3.3 million, \$4.3 million and \$3.7 million. During the year ended

[Table of Contents](#)

December 31, 2025, we incurred a \$4.0 million benefit for changes in performance achievement assumptions associated with our 2023, 2024, and 2025 PSAs within selling, general and administrative expenses in our consolidated statement of operations. Unrecognized compensation cost related to nonvested RSAs, net of estimated forfeitures, was \$20 million at December 31, 2025. This amount is expected to be recognized over a weighted-average period of 1.9 years, based on the maximum remaining vesting period required under the awards. Unrecognized compensation cost related to nonvested PSAs as of December 31, 2025 was \$3.7 million and will be recognized primarily in 2026 and 2027 if the related performance targets are met at the current level expected.

The following table summarizes the activity and value of nonvested RSAs and PSAs for the years ended December 31, 2025, 2024 and 2023:

	Years Ended December 31,					
	2025		2024		2023	
	Number of Shares	Weighted Average Grant-date Fair Value Per Share	Number of Shares	Weighted Average Grant-date Fair Value Per Share	Number of Shares	Weighted Average Grant-date Fair Value Per Share
Nonvested awards at beginning of period	1,970	\$ 21.45	1,985	\$ 21.70	1,722	\$ 22.52
Granted	2,494	9.18	1,024	23.37	1,945	18.34
Vested	(660)	21.67	(685)	25.16	(1,076)	14.04
Forfeited	(443)	19.50	(354)	21.25	(606)	26.82
Nonvested awards at end of period	<u>3,361</u>	<u>\$ 12.56</u>	<u>1,970</u>	<u>\$ 21.45</u>	<u>1,985</u>	<u>\$ 21.70</u>

The total fair value of RSAs and PSAs vested during the years ended December 31, 2025, 2024 and 2023 was \$12 million, \$16 million and \$11 million.

Note 10—Retirement Plan

U.S. Retirement Plan. We have a frozen noncontributory, unfunded retirement plan for certain retirees in the U.S. (U.S. Retirement Plan).

The following table sets forth the U.S. Retirement Plan’s financial status and the amounts recognized in our consolidated balance sheets:

December 31,	2025	2024
Change in benefit obligation		
Benefit obligation, beginning of year	\$ 31,209	\$ 34,059
Interest cost	1,578	1,524
Actuarial gain	815	(1,295)
Benefits paid	(3,043)	(3,079)
Benefit obligation, end of year	<u>\$ 30,559</u>	<u>\$ 31,209</u>
Change in plan assets		
Fair value of plan assets, beginning of year	\$ —	\$ —
Employer contribution	3,043	3,079
Benefits paid	(3,043)	(3,079)
Fair value of plan assets, end of year	<u>\$ —</u>	<u>\$ —</u>
Funded status, end of year	<u>\$ (30,559)</u>	<u>\$ (31,209)</u>
Amounts recognized in the consolidated balance sheets		
Other current liabilities	\$ (2,899)	\$ (2,936)
Other liabilities	(27,661)	(28,273)
Accumulated other comprehensive loss	5,535	4,838
Net amount recognized	<u>\$ (25,025)</u>	<u>\$ (26,371)</u>
Accumulated benefit obligation	<u>\$ 30,559</u>	<u>\$ 31,209</u>
Weighted average assumptions used to determine benefit obligation		
Discount rate	5.02 %	5.31 %
Rate of increase in compensation levels	N/A	N/A

Plan benefit obligations of the U.S. Retirement Plan were measured as of December 31, 2025 and 2024. Plan benefit obligations are determined using assumptions developed at the measurement date. The weighted average discount rate, which is used to calculate the present value of plan liabilities, is an estimate of the interest rate at which the plan liabilities could be effectively settled at the measurement date. When estimating the discount rate, we review yields available on high-quality, fixed-income debt instruments and use a yield curve model from which the discount rate is derived by applying the projected benefit payments under the plan to points on a published yield curve.

The components of net periodic benefit cost for the U.S. Retirement Plan were as follows:

	2025	2024	2023
Interest cost	\$ 1,578	\$ 1,524	\$ 1,827
Recognized net actuarial loss	118	198	431
Net periodic benefit cost	<u>\$ 1,696</u>	<u>\$ 1,722</u>	<u>\$ 2,258</u>
Weighted average assumptions used to determine net periodic benefit cost			
Discount rate	5.31 %	4.68 %	4.87 %
Rate of increase in future compensation levels	N/A	N/A	N/A

Amounts recognized for the U.S. Retirement Plan as a component of accumulated other comprehensive loss as of the end of the year that have not been recognized as a component of the net periodic benefit cost are presented in the

[Table of Contents](#)

following table. We expect to recognize approximately \$0.2 million of the net actuarial loss reported in the following table as of December 31, 2025, as a component of net periodic benefit cost during 2026.

<u>Years Ended December 31,</u>	<u>2025</u>	<u>2024</u>
Net actuarial loss	\$ (5,535)	\$ (4,838)
Deferred tax benefit	3,660	3,479
Amounts included in accumulated other comprehensive loss, net of tax	<u>\$ (1,875)</u>	<u>\$ (1,359)</u>

As of December 31, 2025, the expected benefit payments required, based on the same assumptions used to measure our year-end benefit obligation, for each of the next five years and the five-year period thereafter for the U.S. Retirement Plan were as follows:

<u>Year</u>		
2026	\$	2,864
2027		2,697
2028		2,531
2029		2,386
2030		2,220
2031-2035		8,263

Note 11—Derivatives

We are directly and indirectly affected by changes in interest rates, which may adversely impact our financial performance and are referred to as “market risks.” When deemed appropriate, we use derivatives as a risk management tool to mitigate the potential impact of certain market risks. We do not enter into derivative financial instruments for trading purposes.

We pay interest on our Credit Agreement which fluctuates based on changes in our benchmark interest rates. In order to mitigate the risk of increases in benchmark rates on our term loans, we entered into an interest rate swap agreement whereby we agree to exchange with the counterparty, at specified intervals, the difference between fixed and variable amounts calculated by reference to the notional amount. The interest rate swaps were designated as cash flow hedges. Cash flows related to the interest rate swap agreement are included in interest expense, net.

We determine the fair value of our interest rate swaps based on observable market-based inputs or unobservable inputs that are corroborated by market data. We do not view the fair value of our derivatives in isolation, but rather in relation to the fair values or cash flows of the underlying exposure. All derivatives are carried at fair value in our consolidated balance sheets. We consider the risk of counterparty default to be minimal. We report cash flows from our hedging instruments in the same cash flow statement category as the hedged items.

The following table summarizes the terms and fair value of our outstanding derivative financial instruments as of December 31, 2025:

	<u>Notional Amount</u>	<u>Maturity Date</u>	<u>Derivative Assets</u>		<u>Derivative Liabilities</u>	
			<u>Classification</u>	<u>Fair Value</u>	<u>Classification</u>	<u>Fair Value</u>
Interest rate swaps	\$ 250,000	March 2027	Other assets, net	\$ 1,338	Other liabilities	\$ —

The following table summarizes the terms and fair value of our outstanding derivative financial instruments as of December 31, 2024:

	<u>Notional Amount</u>	<u>Maturity Date</u>	<u>Derivative Assets</u>		<u>Derivative Liabilities</u>	
			<u>Classification</u>	<u>Fair Value</u>	<u>Classification</u>	<u>Fair Value</u>
Interest rate swaps	\$ 300,000	March 2027	Other assets, net	\$ 6,113	Other liabilities	\$ —

[Table of Contents](#)

The notional amount of the interest rate swap represents the amount in effect at the end of the period. Based on contractual terms, the notional amount will decrease in increments of \$50 million on the last business day of March of each year until the maturity date.

The following table summarizes the effect of cash flow hedge accounting on our consolidated statements of operations for the year ended December 31, 2025:

	Amount of Loss Recognized in Other Comprehensive (Loss) Income	Location of Gain Reclassified from Accumulated Other Comprehensive Loss into Income	Total Amount of Expense Line Items Presented in the Consolidated Statement of Operations in Which the Effects are Recorded	Amount of Gain Reclassified from Accumulated Other Comprehensive Loss into Income
Interest rate swaps	\$ (1,047)	Interest expense, net	\$ 107,183	\$ 3,728

The amount of ineffectiveness associated with these contracts was immaterial for the periods presented.

The following table summarizes the effect of cash flow hedge accounting on our consolidated statements of operations for the year ended December 31, 2024:

	Amount of Gain Recognized in Other Comprehensive (Loss) Income	Location of Gain Reclassified from Accumulated Other Comprehensive Loss into Income	Total Amount of Expense Line Items Presented in the Consolidated Statement of Operations in Which the Effects are Recorded	Amount of Gain Reclassified from Accumulated Other Comprehensive Loss into Income
Interest rate swaps	\$ 5,492	Interest expense, net	\$ 107,566	\$ 7,826

The amount of ineffectiveness associated with these contracts was immaterial for the periods presented.

The following table summarizes the effect of cash flow hedge accounting on our consolidated statements of operations for the year ended December 31, 2023:

	Amount of Gain Recognized in Other Comprehensive (Loss) Income	Location of Gain Reclassified from Accumulated Other Comprehensive Loss into Income	Total Amount of Expense Line Items Presented in the Consolidated Statement of Operations in Which the Effects are Recorded	Amount of Gain Reclassified from Accumulated Other Comprehensive Loss into Income
Interest rate swaps	\$ 2,707	Interest expense, net	\$ 116,769	\$ 9,720

The amount of ineffectiveness associated with these contracts was immaterial for the periods presented.

Note 12—Income Taxes

The components of (loss) income from continuing operations before income taxes consist of the following:

Years Ended December 31,	2025	2024	2023
(Loss) income from continuing operations before income taxes			
U.S.	\$ (104,080)	\$ (331,882)	\$ 14,547
Foreign	\$ 2,127	\$ 1,997	\$ 718
Total	\$ (101,953)	\$ (329,885)	\$ 15,265

[Table of Contents](#)

The income tax provision consists of the following:

Years Ended December 31,	2025		2024		2023	
Income tax provision from continuing operations						
Current tax provision						
Federal	\$	15,770	\$	22,935	\$	7,504
State		1,205		5,454		4,679
Foreign		1,641		503		181
Total current tax provision		18,616		28,892		12,364
Deferred tax (benefit) provision:						
Federal		(14,577)		(8,755)		(3,622)
State		(3,310)		713		(2,382)
Foreign		—		—		—
Total deferred tax benefit		(17,887)		(8,042)		(6,004)
Total income tax provision (benefit):						
Federal		1,193		14,180		3,882
State		(2,105)		6,167		2,297
Foreign		1,641		503		181
Total income tax provision	\$	729	\$	20,850	\$	6,360

A reconciliation of the federal statutory rate to our effective income tax rate is shown below:

Years Ended December 31,	2025		2024		2023	
US federal statutory income tax rate	\$	(21,410) 21.0 %	\$	(69,276) 21.0 %	\$	3,206 21.0 %
Domestic state and local income taxes, net of federal effect		(2,214) 2.2 %		5,124 (1.6)%		558 3.7 %
Tax credits		(144) 0.2 %		(315) 0.1 %		(398) (2.6)%
Nondeductible / nontaxable items						
Goodwill impairment		— — %		62,788 (19.0)%		— — %
Compensation		892 (0.9)%		867 (0.3)%		344 2.3 %
Other		1,191 (1.2)%		457 (0.1)%		139 0.9 %
Excess tax expense on share-based payments		1,727 (1.7)%		1,117 (0.3)%		1,209 7.9 %
Changes in unrecognized tax benefits		20,929 (20.5)%		19,745 (6.0)%		1,362 8.9 %
Other adjustments		(242) 0.2 %		343 (0.1)%		(60) (0.4)%
Total income tax provision	\$	729 (0.7)%	\$	20,850 (6.3)%	\$	6,360 41.7 %

The domestic state jurisdictions that comprise the majority of the domestic state and local income taxes, net of federal benefit are California, New York, Illinois and Oregon for all years presented.

[Table of Contents](#)

The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities are presented below:

December 31,	2025	2024
Deferred tax assets:		
Employee benefit plans	\$ 18,712	\$ 21,445
Accrued liabilities not currently deductible	3,983	10,127
Lease liabilities	32,949	34,195
Allowance for losses on accounts receivable	7,678	7,403
Net operating loss carryforwards	89,029	15,409
Capital loss carryover	47,733	508
Interest limitation	35,732	14,564
Insurance	2,250	1,978
Merchandise Inventories	3,301	2,574
Other	8,800	6,649
Total deferred tax assets	<u>250,167</u>	<u>114,852</u>
Less: valuation allowances	<u>(47,747)</u>	<u>(2,247)</u>
Net deferred tax assets	<u>202,420</u>	<u>112,605</u>
Deferred tax liabilities:		
Goodwill	6,413	5,009
Property, equipment and computer software	52,855	36,543
Right-of-use assets	32,282	33,001
Intangible assets	32,875	51,600
Other	347	2,473
Total deferred tax liabilities	<u>124,772</u>	<u>128,626</u>
Net deferred tax asset (liability)	<u>\$ 77,648</u>	<u>\$ (16,021)</u>

The valuation allowances relate to deferred tax assets for U.S. federal and state capital loss carryforwards and net operating loss carryforwards and credit carryforwards in various state jurisdictions. The U.S. gross capital loss carryforward of \$184 million has an expiration date of five years. A gross valuation allowance of \$164 million has been established against the capital loss as future capital gain income of \$20 million is projected before the expiration. As of December 31, 2025, gross federal net operating losses of approximately \$362 million are available to offset future federal taxable income, of which \$206 million represents reattributed net operating loss carryforwards resulting from negotiated terms included within the sale agreement of our P&HS business. The entire \$362 million of net operating losses have an unlimited carryforward period and will not expire. In addition, as of December 31, 2025 \$147 million of gross deferred interest deductions that have an unlimited carryforward period are available, of which \$33 million has been reattributed resulting from the negotiated terms included within the sale agreement of our P&HS business. As of December 31, 2025, there are \$13 million of state tax effected net operating losses available with various expiration dates ranging from five years to an unlimited carryforward period. As of December 31, 2025, there are \$4.0 million of credit carryforwards available, with various expiration dates ranging from five to twenty years. Based on management's judgment using available evidence about historical and expected future taxable earnings, management believes it is more likely than not that we will realize the benefit of the existing deferred tax assets, net of valuation allowances, as of December 31, 2025.

[Table of Contents](#)

Cash payments for income taxes (net of refunds), including interest, for 2025, 2024 and 2023 were as follows disaggregated for jurisdictions that comprise 5% or more of total taxes paid in the year presented:

Years Ended December 31,	2025	2024	2023
U.S. Federal	\$ 229	\$ 513	\$ (12,918)
U.S. State and local			
Illinois	*	*	374
Massachusetts	*	405	*
Mississippi	*	(518)	*
Oregon	892	895	1,014
Pennsylvania	740	449	*
Virginia	*	*	(693)
Other	4,796	2,297	1,467
	<u>6,428</u>	<u>3,528</u>	<u>2,162</u>
Foreign			
Australia	883	(819)	1,561
Belgium	865	746	(778)
Canada	*	*	538
Germany	*	312	491
India	741	865	334
Ireland	(804)	(3,257)	1,311
Japan	*	409	(1,420)
Mexico	1,483	1,417	900
Thailand	2,279	1,277	1,249
Other	367	562	287
	<u>5,814</u>	<u>1,512</u>	<u>4,473</u>
Total	\$ <u>12,471</u>	\$ <u>5,553</u>	\$ <u>(6,283)</u>

* The amount of income taxes paid during the year does not meet the 5% disaggregation threshold.

A summary of the changes in the liability for unrecognized tax benefits from the beginning to the end of the reporting period is as follows:

	2025	2024
Unrecognized tax benefits at January 1,	\$ 36,379	\$ 22,741
Increases for positions taken during current period	20,800	430
Increases for positions taken during prior periods	(4,916)	16,676
Settlements	(2,868)	-
Lapse of statute of limitations	(150)	(3,468)
Unrecognized tax benefits at December 31,	\$ <u>49,245</u>	\$ <u>36,379</u>

Unrecognized tax benefits of \$49 million and \$36 million at December 31, 2025 and 2024 would impact our effective tax rate if recognized.

We recognize accrued interest and penalties related to unrecognized tax benefits. Accrued interest at December 31, 2025 and 2024 was \$12 million and \$13 million. The amounts recognized in interest expense for the years ended December 31, 2025, 2024 and 2023 were (\$1.0) million, \$7.6 million and \$1.7 million. There were no penalties accrued at December 31, 2025, 2024 and 2023 or recognized in 2025, 2024 and 2023.

[Table of Contents](#)

On August 26, 2020, we received a Notice of Proposed Adjustment (NOPA) from the Internal Revenue Service (IRS) regarding our 2015 and 2016 consolidated income tax returns. On June 30, 2021, we received a NOPA from the IRS regarding our 2017 and 2018 consolidated income tax returns. Within the NOPAs, the IRS has asserted that our taxable income for the aforementioned years should be higher based on their assessment of the appropriate amount of taxable income that we should report in the U.S. in connection with our sourcing of products by our foreign subsidiaries for sale in the U.S. by our domestic subsidiaries. The transfer pricing methodology was consistently applied for all years subject to the NOPAs and 2019 into 2022, but is no longer employed.

In late June 2024, the IRS and the relevant foreign taxing authority mutually agreed to proposed adjustments to our 2015 through 2018 consolidated tax returns. As a result, we remeasured the uncertain tax position for the 2015 through 2018 tax years, as well as the affected 2019 through 2022 tax years, to the amount expected to be paid upon a final agreement with the IRS. In June 2025, we received the final assessment from the IRS for the 2015 through 2018 tax years including interest. The uncertain tax position for these years and related accrued interest has been remeasured to reflect the final amount to be paid. This matter does not impact our 2023, 2024 or future tax years. As of December 31, 2025, we owed \$35 million associated with the NOPA matter, which includes \$11 million of interest accrued on the matter through December 31, 2025. The balance sheet classification and amount owed may be subject to change depending on the timing of a final agreement with the IRS.

On July 4, 2025, the U.S. Congress enacted budget reconciliation bill H.R. 1 referred to as the One Big Beautiful Bill (OBBB). The OBBB contains several changes to corporate taxation including modification to limitations on deductions for interest expense and accelerated fixed asset depreciation. We expect the legislation to decrease future U.S. cash taxes with no material impact to the effective tax rate.

We file income tax returns in the U.S. federal and various state jurisdictions. Our U.S. federal income tax returns for the years 2019 through 2024 are subject to examination. Our income tax returns for U.S. state and local jurisdictions are generally open for the years 2019 through 2024; however, certain returns may be subject to examination for differing periods.

Note 13—Net (Loss) Income per Common Share

The following summarizes the calculation of net (loss) income per common share attributable to common shareholders for the years ended December 31, 2025, 2024 and 2023:

(in thousands, except per share data)

Years Ended December 31,	2025	2024	2023
(Loss) income from continuing operations, net of tax	\$ (102,682)	\$ (350,735)	\$ 8,905
Loss from discontinued operations, net of tax	(997,960)	(11,951)	(50,206)
Net loss	\$ (1,100,642)	\$ (362,686)	\$ (41,301)
Weighted average shares outstanding - basic	76,897	76,741	75,785
Dilutive shares	—	—	1,582
Weighted average shares outstanding - diluted	76,897	76,741	77,367
Basic loss per common share:			
(Loss) income from continuing operations, net of tax	\$ (1.34)	\$ (4.57)	\$ 0.12
Loss from discontinued operations, net of tax	(12.97)	(0.16)	(0.66)
Net loss	\$ (14.31)	\$ (4.73)	\$ (0.54)
Diluted loss per common share:			
(Loss) income from continuing operations, net of tax	\$ (1.34)	\$ (4.57)	\$ 0.12
Loss from discontinued operations, net of tax	(12.97)	(0.16)	(0.65)
Net loss	\$ (14.31)	\$ (4.73)	\$ (0.53)

[Table of Contents](#)

Share-based awards for the years ended December 31, 2025 and 2024, of approximately 2.2 million and 1.5 million shares were excluded from the calculation of net loss per diluted common share as the effect would be anti-dilutive. In accordance with ASC 260, dilutive shares are included in computing the diluted loss per common share from discontinued operations, net of tax and net loss per diluted common share for the year ended December 31, 2023 even though they were anti-dilutive, as the control number (income from continuing operations, net of tax) was in an income position.

Note 14—Accumulated Other Comprehensive (Loss) Income

The following tables show the changes in accumulated other comprehensive (loss) income by component for the years ended December 31, 2025, 2024 and 2023:

	Retirement Plans	Currency Translation Adjustments	Derivatives	Total
Accumulated other comprehensive (loss) income, December 31, 2024	\$ (5,770)	\$ (48,099)	\$ 4,525	\$ (49,344)
Other comprehensive income (loss) before reclassifications	1,305	26,211	(1,047)	26,469
Income tax	(339)	—	272	(67)
Other comprehensive income (loss) before reclassifications, net of tax	966	26,211	(775)	26,402
Amounts reclassified from accumulated other comprehensive income (loss)	118	—	(3,728)	(3,610)
Income tax	(31)	—	969	938
Amounts reclassified from accumulated other comprehensive income (loss), net of tax	87	—	(2,759)	(2,672)
Other comprehensive income (loss)	1,053	26,211	(3,534)	23,730
P&HS Sale reclassification adjustment	2,841	21,888	—	24,729
Accumulated other comprehensive (loss) income, December 31, 2025	\$ (1,876)	\$ —	\$ 991	\$ (885)

	Retirement Plans	Currency Translation Adjustments	Derivatives	Total
Accumulated other comprehensive (loss) income, December 31, 2023	\$ (5,115)	\$ (32,954)	\$ 6,251	\$ (31,818)
Other comprehensive income before reclassifications	(1,082)	(15,145)	5,492	(10,735)
Income tax	280	—	(1,428)	(1,148)
Other comprehensive income before reclassifications, net of tax	(802)	(15,145)	4,064	(11,883)
Amounts reclassified from accumulated other comprehensive income (loss)	198	—	(7,826)	(7,628)
Income tax	(51)	—	2,036	1,985
Amounts reclassified from accumulated other comprehensive income (loss), net of tax	147	—	(5,790)	(5,643)
Other comprehensive loss	(655)	(15,145)	(1,726)	(17,526)
Accumulated other comprehensive (loss) income, December 31, 2024	\$ (5,770)	\$ (48,099)	\$ 4,525	\$ (49,344)

[Table of Contents](#)

	Retirement Plans	Currency Translation Adjustments	Derivatives	Total
Accumulated other comprehensive (loss) income, December 31, 2022	\$ (7,201)	\$ (40,095)	\$ 11,441	\$ (35,855)
Other comprehensive income (loss) before reclassifications	2,405	7,141	2,707	12,253
Income tax	(639)	—	(704)	(1,343)
Other comprehensive income (loss) before reclassifications, net of tax	1,766	7,141	2,003	10,910
Amounts reclassified from accumulated other comprehensive loss	431	—	(9,720)	(9,289)
Income tax	(111)	—	2,527	2,416
Amounts reclassified from accumulated other comprehensive loss, net of tax	320	—	(7,193)	(6,873)
Other comprehensive income (loss)	2,086	7,141	(5,190)	4,037
Accumulated other comprehensive loss, December 31, 2023	\$ (5,115)	\$ (32,954)	\$ 6,251	\$ (31,818)

We include amounts reclassified out of accumulated other comprehensive (loss) income related to defined benefit pension plans as a component of net periodic benefit cost recorded in Other expense, net.

Note 15— Commitments, Contingent Liabilities, and Legal Proceedings

We are party to various legal claims that are ordinary and incidental to our business, including ones related to commercial disputes, employment, workers' compensation, product liability, regulatory and other matters. We maintain insurance coverage for cybersecurity, employment, product liability, workers' compensation and other personal injury litigation matters, subject to policy limits, applicable deductibles and insurer solvency. From time to time, we establish estimated liabilities based upon periodic assessment of the potential outcomes of pending matters.

Based on current knowledge and the advice of counsel, we believe that the liability recorded on the consolidated balance sheet as of December 31, 2025 for currently pending matters considered probable of loss, is sufficient. In addition, we believe that other currently pending matters are not reasonably possible to result in a material loss, as payment of the amounts claimed is remote, the claims are immaterial, individually and in the aggregate, or the claims are expected to be adequately covered by insurance, subject to policy limits, applicable deductibles, exclusions, and insurer solvency.

Note 16—Segment Information

As described in Note 1, the P&HS business sale was completed on December 31, 2025, and we no longer report the P&HS business within continuing operations. The P&HS business was initially classified as discontinued operations and assets held for sale as of June 30, 2025. Our President and Chief Executive Officer is the chief operating decision maker (CODM). The CODM reviews financial information about the continuing operations business at an enterprise-wide consolidated level when allocating resources and assessing business performance. Accordingly, we have determined that our business activities comprise a single operating and reporting segment. Net income (loss) from continuing operations is the profit or loss measure used by the CODM that is most consistent with GAAP and therefore is the required measure of profitability.

Note 17—Shareholders' Equity

On February 26, 2025, our Board of Directors authorized a share repurchase program of up to \$100 million. The program expires February 2027. Under the program, we may repurchase shares of common stock on a discretionary basis from time to time through open market repurchases, privately negotiated transactions and 10b5-1 trading plans.

During the year ended December 31, 2025, we repurchased in open-market transactions and retired approximately 2.0 million shares of our common stock for an aggregate of \$10 million, or a weighted average price per share of \$5.19.

Report of Independent Registered Public Accounting Firm

To the Shareholders and Board of Directors
Accendra Health, Inc.:

Opinion on the Consolidated Financial Statements

We have audited the accompanying consolidated balance sheets of Accendra Health, Inc. and subsidiaries (the Company) as of December 31, 2025 and 2024, the related consolidated statements of operations, comprehensive (loss) income, changes in shareholders' equity, and cash flows for each of the years in the three-year period ended December 31, 2025, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2025, in conformity with U.S. generally accepted accounting principles.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2025, based on criteria established in *Internal Control – Integrated Framework (2013)* issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated February 20, 2026 expressed an unqualified opinion on the effectiveness of the Company's internal control over financial reporting.

Basis for Opinion

These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matter

The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinions on the critical audit matter or on the accounts or disclosures to which they relate.

Estimates of variable consideration on equipment and supplies sales and estimated adjustments on equipment rental revenues

As discussed in Note 1 to the consolidated financial statements, revenues are recognized under fee-for-service arrangements for equipment rented to patients and sales of equipment, supplies and other items sold to patients. The Company's net revenue was \$2,762 million for the year ended December 31, 2025. Revenues are recorded at amounts estimated to be received under reimbursement arrangements with third-party payors, including private insurers, prepaid

[Table of Contents](#)

health plans, Medicare, Medicaid and patients. The Company determines the transaction price based on contractually agreed-upon amounts or rates, adjusted for estimates of variable consideration on equipment and supplies sales and estimated adjustments to record revenue at an amount probable of being collected for equipment rental revenues. The Company uses contractual agreements, historical experience, and other operating trends to determine the estimates of variable consideration on equipment and supplies sales and estimated adjustments on equipment rental revenues.

We identified the evaluation of the estimates of variable consideration on equipment and supplies sales and estimated adjustments on equipment rental revenues as a critical audit matter. A higher degree of auditor judgment was required to evaluate the relevance and reliability of the historical experience and other operating trends.

The following are the primary procedures we performed to address this critical audit matter. We evaluated the design and tested the operating effectiveness of internal controls over the Company's estimate of variable consideration on equipment and supplies sales and estimated adjustments to record revenue at an amount probable of being collected for equipment rental revenues. We assessed management's ability to estimate by comparing previous estimates to actual results and current estimates. We also compared current operating trends to the current year estimates.

/s/ KPMG LLP

We have served as the Company's auditor since 1987.

Richmond, Virginia
February 20, 2026

Index to Exhibits

- 2.1 [Purchase Agreement, dated as of October 31, 2017, by and among Halyard Health, Inc., the other sellers party thereto and Owens & Minor, Inc. \(incorporated herein by reference to our Current Report on Form 8-K/A, Exhibit 2.1, dated November 1, 2017\) **](#)
- 2.2 [Amended and Restated Purchase Agreement, dated as of April 30, 2018, by and among Halyard Health, Inc., the other sellers party thereto and Owens & Minor, Inc. \(incorporated herein by reference to our Current Report on Form 8-K, Exhibit 2.1, dated May 1, 2018\)](#)
- 2.3 [Agreement and Plan of Merger, dated as of January 7, 2022, by and among the Company, Apria and Merger Sub \(incorporated herein by reference to the Company's Current Report on Form 8-K, Exhibit 2.1, dated January 10, 2022\)](#)
- 2.4 [Agreement and Plan of Merger, dated as of July 22, 2024, by and among the Company, Rotech, Merger Sub and Representative \(incorporated herein by reference to the Company's Current Report on Form 8-K, Exhibit 2.1, dated July 23, 2024\)](#)
- 2.5 [Equity Purchase Agreement, dated as of October 7, 2025, by and among the Company, Purchaser and Purchaser Parent \(incorporated by reference to Exhibit 2.1 to the Company's Form 8-K filed with the SEC on October 7, 2025\).**](#)
- 3.1 [Amended and Restated Articles of Incorporation of Owens & Minor, Inc. \(incorporated herein by reference to our Current Report on Form 8-K, Exhibit 3.1, dated July 29, 2008\)](#)
- 3.2 [Article of Amendment of Owens & Minor, Inc. \(incorporated herein by reference to our Current Report on Form 8-K, Exhibit 3.1, dated December 24, 2025\)](#)
- 3.3 [Amended and Restated Bylaws of Accendra Health, Inc. effective December 31, 2025 \(incorporated herein by reference to our Current Report on Form 8-K, Exhibit 3.2, dated December 24, 2025\)](#)
- 4.1 [Indenture, dated March 10, 2021, among Owens & Minor, Inc., the guarantors named therein and Regions Bank, as Trustee \(incorporated herein by reference to the Company's Current Report on Form 8-K, Exhibit 4.1, dated March 11, 2021\)](#)
- 4.2 [Form of Global Note for the 4.500% Senior Notes due 2029 \(incorporated herein by reference to the Company's Current Report on Form 8-K, Exhibit 4.2, dated March 11, 2021\)](#)
- 4.3 [Indenture dated March 29, 2022 by and among the Company, the guarantors named therein and Regions Bank, as trustee \(incorporated herein by reference to the Company's Current Report on Form 8-K, Exhibit 4.1, dated March 29, 2022\)](#)
- 4.4 [Form of Global Note for the 6.625% Senior Notes due 2030 \(incorporated herein by reference to the Company's Current Report on Form 8-K, Exhibit 4.2, dated March 29, 2022\)](#)
- 4.5 [First Supplemental Indenture dated as of March 29, 2022, by and among the Company, the guarantors named therein and Regions Bank, as trustee, to the Indenture dated as of March 10, 2021 \(incorporated herein by reference to the Company's Current Report on Form 8-K, Exhibit 4.4, dated March 29, 2022\)](#)
- 4.6 [First Supplemental Indenture dated as of March 29, 2022, by and among the Company, the guarantors named therein and Regions Bank, as trustee, to the Indenture dated of March 29, 2022 \(incorporated herein by reference to the Company's Current Report on Form 8-K, Exhibit 4.5, dated March 29, 2022\)](#)
- 4.7 [Description of Securities - filed herewith](#)

Table of Contents

- 10.1 [Form of Owens & Minor, Inc. Restricted Stock Agreement under the 2018 Stock Incentive Plan effective February 28, 2019 \(incorporated herein by reference to our Current report on 8-K, Exhibit 10.1, dated March 1, 2019\)*](#)
- 10.2 [Form of Owens & Minor, Inc. Executive Change in Control Severance Agreement between Owens & Minor, Inc. and Edward A. Pesicka effective March 4, 2019 \(incorporated herein by reference to our Current Report on Form 8-K, Exhibit 10.1, dated February 25, 2019\)*](#)
- 10.3 [Form of Owens & Minor, Inc. Executive Change in Control Severance Agreement effective October 25, 2018 \(incorporated herein by reference to our Annual Report on Form 10-K, Exhibit 10.7, for the year ended December 31, 2018\)*](#)
- 10.4 [Owens & Minor, Inc. Supplemental Executive Retirement Plan, as amended and restated effective January 1, 2005 \(“SERP”\) \(incorporated herein by reference to our Quarterly Report on Form 10-Q, Exhibit 10.1, for the quarter ended September 30, 2008\)*](#)
- 10.5 [Resolutions of the Board of Directors of the Company amending the SERP \(incorporated herein by reference to our Annual Report on Form 10-K, Exhibit 10.12, for the year ended December 31, 2011\)*](#)
- 10.6 [Amendment effective March 1, 2016 of the Company’s SERP \(incorporated herein by reference to our Quarterly Report on Form 10-Q, Exhibit 10.6, for the quarter ended March 31, 2016\)*](#)
- 10.7 [Amendment effective March 1, 2016 of Exhibit II of the Company’s SERP \(incorporated herein by reference to our Quarterly Report on Form 10-Q, Exhibit 10.7, for the quarter ended March 31, 2016\)*](#)
- 10.8 [Owens & Minor, Inc. Amended and Restated Management Equity Ownership Program and Stock Ownership Rewards Program \(incorporated herein by reference to our Annual Report on Form 10-K, Exhibit 10.15, for the year ended December 31, 2009\)*](#)
- 10.9 [Amendment to MEOP effective January 1, 2014 \(incorporated herein by reference to our Annual Report on Form 10-K, Exhibit 10.10, for the year ended December 31, 2013\)*](#)
- 10.10 [Owens & Minor, Inc. Executive Deferred Compensation and Retirement Plan effective January 1, 2013 \(incorporated herein by reference to our Quarterly Report on Form 10-Q, Exhibit 10.1, for the quarter ended March 31, 2013\)*](#)
- 10.11 [Form of Owens & Minor Restricted Stock Unit Agreement under the Company’s 2018 Stock Incentive Plan \(incorporated herein by reference to our Current Report on Form 8-K, Exhibit 10.3, dated May 9, 2018\)*](#)
- 10.12 [Owens & Minor, Inc. Officer Severance Policy dated February 27, 2025 \(incorporated herein by reference to our Form 10-K, Exhibit 10.13, dated February 28, 2025\)*](#)
- 10.13 [Owens & Minor, Inc. 2018 Stock Incentive Plan \(incorporated herein by reference to our Registration Statement on Form S-8, Registration number 333-224787\)*](#)
- 10.14 [Restated Guaranty Agreement, dated as of the February 12, 2019, by and among Owens & Minor, Inc., the other Guarantors party thereto and Bank of America, N.A., as administrative agent for the Pro Rata Facilities and the Term B Facility \(incorporated herein by reference to our Current Report on Form 8-K, Exhibit 10.2, dated February 19, 2019\)**](#)

Table of Contents

- 10.15 [Security and Pledge Agreement, dated as of April 30, 2018, by and among Owens & Minor, Inc., O&M Halyard, Inc., Owens & Minor Distribution, Inc., Owens & Minor Medical, Inc., Barista Acquisition I, LLC and Barista Acquisition II, LLC, Bank of America, N.A., U.S. Bank National Association, and the other secured parties thereto. \(incorporated herein by reference to our Current Report on Form 8-K, Exhibit 10.2, dated May 4, 2018\)**](#)
- 10.16 [Amendment to the Owens & Minor, Inc. 2018 Stock Incentive Plan \(Incorporated herein by reference to our Current Report on Form 8-K, Exhibit 10.1, dated May 10, 2019\)*](#)
- 10.17 [Owens & Minor, Inc. Directors' Deferred Compensation Plan, as Amended and Restated Effective May 10, 2019 \(Incorporated herein by reference to our Current Report on Form 8-K, Exhibit 10.2, dated May 10, 2019\)*](#)
- 10.18 [Amendment No. 2 to the Owens & Minor, Inc. 2018 Stock Incentive Plan \(incorporated by reference to Appendix A to the Company's Definitive Proxy Statement on Schedule 14A filed March 19, 2020. \(File No. 001-09810\)\)*](#)
- 10.19 [Form of Restricted Stock Agreement \(incorporated herein by reference to the Company's Current Report on Form 8-K, Exhibit 10.1, dated February 26, 2021\)*](#)
- 10.20 [Form of Restricted Stock Unit Award Agreement \(incorporated herein by reference to the Company's Current Report on Form 8-K, Exhibit 10.2, dated February 26, 2021\)*](#)
- 10.21 [Credit Agreement, dated as of March 10, 2021, by and among Owens & Minor, Inc. and certain subsidiaries of Owens & Minor, Inc. as borrowers, Bank of America, N.A., as an administrative agent and collateral agent, and a syndicate of financial institutions, as lenders \(incorporated herein by reference to the Company's Current Report on Form 8-K, Exhibit 10.1, dated March 11, 2021\)**](#)
- 10.22 [Owens & Minor, Inc. 2021 Teammate Stock Purchase Plan \(incorporated by reference to Appendix C to the Company's definitive Proxy Statement filed March 19, 2020 \(File No. 001-09810\)\)*](#)
- 10.23 [Agreement of Resignation, Appointment, and Acceptance, dated as September 10, 2021, by and among Owens & Minor, Inc., U.S. Bank National Association, as Prior Trustee, and Regions Bank, as Successor Trustee \(incorporated herein by reference to our Form 10-Q, Exhibit 10.1, dated November 3, 2021\)](#)
- 10.24 [Form of Owens & Minor, Inc. Restricted Stock Agreement under the Company's 2018 Stock Incentive Plan \(incorporated herein by reference to our Form 10-Q, Exhibit 10.2, dated November 3, 2021\)*](#)
- 10.25 [Form of Owens & Minor, Inc. Restricted Stock Unit Award Agreement under the Company's 2018 Stock Incentive Plan \(incorporated herein by reference to our Form 10-Q, Exhibit 10.3, dated November 3, 2021\)*](#)
- 10.26 [Amendment No. 1 to Credit Agreement, among Owens & Minor Distribution, Inc., Owens & Minor Medical, Inc., Barista Acquisition I, LLC, Barista Acquisition II, LLC, O&M Halyard, Inc., Byram Healthcare Centers, Inc., Owens & Minor, Inc., and Bank Of America \(incorporated herein by reference to our Form 10-K, Exhibit 10.56, dated February 23, 2022\)**](#)
- 10.27 [Form of Restricted Stock Agreement \(incorporated herein by reference to the Company's Current Report on Form 8-K, Exhibit 10.1, dated March 1, 2022\)*](#)
- 10.28 [Form of Restricted Stock Unit Award Agreement \(incorporated herein by reference to the Company's Current Report on Form 8-K, Exhibit 10.2, dated March 1, 2022\)*](#)
- 10.29 [Form of 2022 Performance Stock Unit Award Agreement \(incorporated herein by reference to the Company's Current Report on Form 8-K, Exhibit 10.3, dated March 1, 2022\)**](#)

[Table of Contents](#)

- 10.30 [Credit Agreement dated as of March 29, 2022, by and among the Company, certain subsidiaries of the Company party thereto, as borrowers, JPMorgan Chase Bank, N.A., as an administrative agent and collateral agent, and a syndicate of financial institutions, as lenders \(incorporated herein by reference to the Company's Current Report on Form 8-K, Exhibit 10.1, dated March 29, 2022\)**](#)
- 10.31 [Joinder to Credit Agreement, Amendment No. 2 to Credit Agreement, Amendment No. 1 to Security Agreement and Amendment No. 1 to Guaranty, dated as of March 29, 2022, by and among the Company and certain subsidiaries of the Company, as borrowers, the guarantors and lenders thereto and Bank of America, N.A., as administrative agent and collateral agent, L/C issuer and swing line lender \(incorporated herein by reference to our Quarterly Report on Form 10-Q, Exhibit 10.6, for the quarter ended March 31, 2022\)**](#)
- 10.32 [Amendment No. 3 to the Owens & Minor, Inc. 2018 Stock Incentive Plan \(incorporated herein by reference to our Quarterly Report on Form 10-Q, Exhibit 10.7, for the quarter ended March 31, 2022\)*](#)
- 10.33 [Form of Employee Restricted Stock Unit Grant Notice and Award Agreement \(incorporated herein by reference to the Company's Current Report on Form 8-K, Exhibit 10.1, dated May 10, 2023\)*](#)
- 10.34 [Form of Non-Employee Director Restricted Stock Unit Grant Notice and Award Agreement \(incorporated herein by reference to the Company's Current Report on Form 8-K, Exhibit 10.2, dated May 10, 2023\)*](#)
- 10.35 [Owens & Minor, Inc. 2023 Omnibus Incentive Plan \(incorporated herein by reference to Annex A to Owens & Minor, Inc.'s definitive Proxy Statement filed on March 29, 2023\)*](#)
- 10.36 [Form of Performance Stock Unit Grant Notice and Performance Stock Unit Agreement \(incorporated herein by reference to the Company's Current Report on Form 8-K, Exhibit 10.1, dated March 1, 2024\)*](#)
- 10.37 [Amendment No. 1 to the Owens & Minor, Inc. 2023 Omnibus Incentive Plan \(incorporated by reference to Annex A to Owens & Minor, Inc.'s definitive Proxy Statement filed on March 27, 2024\)*](#)
- 10.38 [Executive Separation Agreement and General Release, dated June 21, 2024, by and between Alexander J. Bruni and Owens & Minor, Inc. \(incorporated herein by reference to our Quarterly Report on Form 10-Q, Exhibit 10.1, for the quarter ended June 30, 2024\)*, **](#)
- 10.39 [Amended & Restated Receivables Purchase Agreement, dated as of December 31, 2025, by and among Accendra Funding LLC \(formerly known as O&M Funding LLC\), as seller, the persons from time to time party thereto, as purchasers, PNC Bank, National Association, as administrative agent, and PNC Capital Markets LLC, as structuring agent \(incorporated herein by reference to the Company's Current Report on Form 8-K, Exhibit 10.1, dated December 31, 2025\)**](#)
- 10.40 [Second Amended and Restated Purchase and Sale Agreement, dated as of December 31, 2025, by and among various entities, as originators, Accendra Medical, Inc. \(formerly known as Owens & Minor Medical, Inc.\), as servicer, and Accendra Funding LLC \(formerly known as O&M Funding LLC\), as buyer \(incorporated herein by reference to the Company's Current Report on Form 8-K, Exhibit 10.2, dated December 31, 2025\)**](#)
- 10.41 [Second Amended and Restated Performance Guaranty of Accendra Health, Inc. \(formerly known as Owens & Minor, Inc.\), dated as of December 31, 2025, in favor of PNC Bank, National Association \(incorporated herein by reference to the Company's Current Report on Form 8-K, Exhibit 10.3, dated December 31, 2025\)](#)
- 10.42 [Form of Amended and Restated Executive Change of Control Severance Agreement \(incorporated herein by reference to the Company's Current Report on Form 10-K, Exhibit 10.61, dated December 31, 2024\)*](#)

[Table of Contents](#)

10.43	Termination Agreement, dates as of June 3, 2025, by and among Owens & Minor, Inc., Rotech Healthcare Holdings Inc., and Hitchcock Merger Sub Inc. (incorporated by reference to Exhibit 10.1 to the registrant's Current Report on Form 8-K filed on June 5, 2025).
10.44	Amendment to the Accendra Health, Inc. Executive Deferred Compensation and Retirement Plan, dated as of December 16, 2025 (filed herewith)*
10.45	Amended Accendra Health, Inc. Executive Deferred Compensation and Retirement Plan, dated as of December 31, 2025 (filed herewith)*
19.1	Insider Trading Policy
21.1	Subsidiaries of Registrant
23.1	Consent of KPMG LLP, independent registered public accounting firm
31.1	Certification of Chief Executive Officer pursuant to Rule 13(a)-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	Certification of Chief Financial Officer pursuant to Rule 13(a)-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1	Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2	Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
97	Owens & Minor, Inc. Policy on Recoupment of Executive Incentive Compensation (incorporated herein by reference to our Form 10-K, Exhibit 97, dated February 20, 2024)
101.INS	Inline XBRL Instance Document
101.SCH	Inline XBRL Taxonomy Extension Schema Document
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	Inline XBRL Taxonomy Definition Linkbase Document
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

* Management contract or compensatory plan or arrangement.

** Certain exhibits and schedules to these agreements have been omitted pursuant to Item 601(b)(2) of Regulation S-K. We hereby undertake to furnish copies of such omitted materials supplementally upon request by the SEC.

Item 16. Form 10-K Summary

None.

**DESCRIPTION OF THE COMPANY'S SECURITIES REGISTERED
PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934**

The following is a brief description of the common stock, \$2.00 par value per share (the "Common Stock"), of Accendra Health, Inc. (the "Company," "we," "us," and "our"), which is the only security of the Company registered pursuant to Section 12 of the Securities Exchange Act of 1934 (the "Exchange Act"). The following description is qualified in its entirety by reference to our amended and restated articles of incorporation ("Articles of Incorporation") and our amended and restated bylaws ("Bylaws"). Because this is a summary description, it does not contain all of the information that may be important to you. For a more detailed description of our common stock, you should refer to the provisions of our Articles of Incorporation and our Bylaws, each of which is filed as an exhibit to the Form 10-K to which this description is an exhibit, as well as the applicable provisions of the Virginia Stock Corporation Act (the "VSCA").

Authorized Capital Stock

Our authorized capital stock consists of 200,000,000 shares of common stock, par value \$2.00 per share, and 10,000,000 shares of cumulative preferred stock, par value \$100.00 per share.

Common Stock

Dividends

Subject to the rights of any series of preferred stock that we may issue, the holders of common stock may receive dividends when, as and if declared by our board of directors, out of our assets legally available therefor.

Fully Paid

All outstanding shares of common stock are fully paid and non-assessable.

Voting Rights

Holders of shares of our common stock are entitled to one vote for each share held of record on all matters on which shareholders are entitled to vote generally. The holders of our common stock do not have cumulative voting rights in the election of directors. The affirmative vote of more than two-thirds of the outstanding shares of common stock is required for certain amendments to our Articles of Incorporation and the approval of mergers, statutory share exchanges, certain sales or other dispositions of assets outside the usual and regular course of business, conversions, domestications and dissolutions. All other matters to be voted on by shareholders must be approved by a majority of the votes cast on the matter.

Liquidation Rights

Upon our dissolution, liquidation or winding up and after payment in full of all amounts required to be paid to creditors and to the holders of shares of our preferred stock having liquidation preferences, if any, the holders of shares of our common stock will be entitled to receive pro rata our remaining assets available for distribution.

Other Rights

We will notify shareholders of any shareholders' meetings according to applicable law. Holders of shares of our common stock do not have preemptive, subscription, redemption or conversion rights. Shares of our common stock will not be subject to further calls or assessment by us. There will be no redemption or sinking fund provisions applicable to shares of our common stock. The rights, powers, preferences and privileges of holders of shares of our common stock will be subject to those of the holders of any shares of our preferred stock that we may authorize and issue in the future.

Transfer Agent

The transfer agent and registrar for shares of our common stock is Computershare, Inc.

Listing

Our common stock is listed on the New York Stock Exchange (the “NYSE”) under the symbol “ACH.”

Preferred Stock

Our Articles of Incorporation authorize our board of directors to establish one or more series of shares of preferred stock (including shares of convertible preferred stock). Unless required by law or by the NYSE, the authorized shares of preferred stock will be available for issuance without further action by our shareholders. Our board of directors is able to determine, with respect to any series of shares of preferred stock, the powers (including voting powers), preferences and relative, participating, optional or other special rights, and the qualifications, limitations or restrictions thereof, including:

- the rate of dividend, the time of payment and the dates from which any dividends shall be cumulative and the extent of participation rights, if any;
- any right to vote with holders of shares of any other series or class and any right to vote as a class either generally or as a condition to specified corporate action, subject to certain limitations;
- the price at which and the terms and conditions upon which shares may be redeemed;
- the amount payable upon shares in the event of involuntary or voluntary liquidation;
- sinking fund provisions of the redemption or purchase of shares, if any; and
- the terms and conditions upon which shares may be converted, if the shares of any series are issued with the privilege of conversion.

Virginia Stock Corporation Act and our Articles of Incorporation and Bylaws

General

We are a Virginia corporation subject to the VSCA. Provisions of the VSCA, in addition to provisions in our Articles of Incorporation and our Bylaws, address corporate governance issues, including the rights of shareholders. Certain of these provisions may make it more difficult or discourage a takeover of our business or removal of our incumbent directors or officers. This anti-takeover effect may, in some circumstances, reduce the control premium that might otherwise be reflected in the value of our common stock.

Certain key provisions of the VSCA, our Articles of Incorporation and our Bylaws are summarized below. This summary is necessarily general and is not intended to be a complete description of all features and consequences of those provisions, and is qualified in its entirety by reference to our Articles of Incorporation, our Bylaws and the VSCA.

Certain Provisions of Our Articles of Incorporation and Bylaws

Election and Removal of Directors; Vacancies. Each of our directors is elected by the vote of a majority of the votes cast at any meeting of shareholders for the election of directors at which a quorum is present, provided that if the number of director nominees at such meeting exceeds the number of directors to be elected, the directors are elected by a plurality of the votes cast. Under our Bylaws, a majority of the votes cast means that the number of shares voted “for” a director must exceed the number of shares voted “against” that director.

Our directors are elected for one-year terms and can be removed, with or without cause, if the number of votes cast for removal at a shareholder meeting called for that purpose at which a quorum is present constitutes a majority of the votes entitled to be cast at an election of directors. Our Bylaws provide that the number of directors will from time to time be fixed by resolution adopted by the affirmative vote of a majority of our directors then in office.

Vacancies in the board may be filled by the board. Subject to the rights of any preferred stock, any vacancy on our board of directors resulting from any death, resignation, retirement, disqualification, removal from office or newly created directorship resulting from an increase in the authorized number of directors or otherwise may be filled by majority vote of the remaining directors then in office, even if less than a quorum.

Special Meetings of Shareholders. Special meetings of shareholders may be called at any time and from time to time only by the chair of our board of directors, our chief executive officer or by a majority of the board of directors.

Advance Notice Requirements for Shareholder Director Nominations and Shareholder Business. Our Bylaws require that advance notice of shareholder director nominations and shareholder business for annual meetings of shareholders be made in writing and given

to our corporate secretary, together with certain specified information, not earlier than the close of business on the 150th day nor later than the close of business on the 120th day before the anniversary of the immediately preceding annual meeting of shareholders, subject to other timing requirements as specified in our Bylaws, including in the case of a change in the date of the annual meeting of shareholders.

Director nominations and shareholder business that are given late or that do not include all required information may be rejected. This could prevent shareholders from bringing certain matters before an annual or special meeting, including making nominations for directors.

Proxy Access. Our Bylaws permit a shareholder, or a group of up to 20 shareholders, owning 3% or more of our outstanding common stock continuously for at least three years, to nominate and include in our annual meeting proxy materials director candidates to occupy up to two or 20% of the number of directors in office (whichever is greater), provided that such shareholder or group of shareholders satisfies the requirements set forth in our Bylaws.

Authorized but Unissued Capital Stock. Our Articles of Incorporation currently authorize more capital stock than we have issued. The listing requirements of the NYSE, which will apply so long as our common stock remains listed on the NYSE, require shareholder approval of certain issuances equal to or exceeding 20% of then-outstanding voting power or then-outstanding number of shares of common stock. These additional shares may be used for a variety of corporate purposes, including future public offerings, to raise additional capital or to facilitate acquisitions.

One of the effects of the existence of unissued and unreserved common stock or preferred stock may be to enable our board of directors to issue shares to persons friendly to current management, which issuance could render more difficult or discourage an attempt to obtain control of our company by means of a merger, tender offer, proxy contest or otherwise, and thereby protect the continuity of our management and possibly deprive shareholders of opportunities to sell their shares of common stock at prices higher than prevailing market prices.

Certain Provisions of Virginia Law

Directors' Duties. Under Section 13.1-690 of the VSCA, directors of Virginia corporations must discharge their duties in accordance with their good faith business judgment of the best interests of the corporation. In discharging their duties, directors may rely on the advice or acts of others, including officers, employees, attorneys, accountants and board committees if they have a good faith belief in their competence. Directors' actions are not subject to a reasonableness or prudent person standard. Virginia's federal and state courts have focused on the process involved with directors' decision-making and are generally supportive of directors if they have based their decision on an informed process. These elements of Virginia law could make it more difficult to take over a Virginia corporation than corporations in other states.

Control Share Acquisitions Statute. Virginia law contains provisions relating to "control share acquisitions," which are transactions causing the voting power of any person acquiring beneficial ownership of shares of a Virginia public corporation to meet or exceed certain threshold percentages (20%, 33 1/3% or 50%) of the total votes entitled to be cast for the election of directors. Under Virginia law, shares acquired in a control share acquisition have no voting rights unless granted by a majority vote of all outstanding shares entitled to vote in the election of directors other than those held by the acquiring person or held by any officer or employee director of the corporation, unless at the time of any control share acquisition, the articles of incorporation or bylaws of the corporation provide that this statute does not apply to acquisitions of its shares. An acquiring person that owns 5% or more of the corporation's voting stock may require that a special meeting of the shareholders be held, within 50 days of the acquiring person's request, to consider the grant of voting rights to the shares acquired or to be acquired in the control share acquisition. If voting rights are not granted and the corporation's articles of incorporation or bylaws permit, the acquiring person's shares may be redeemed by the corporation, at the corporation's option, at a price per share equal to the acquiring person's cost. Unless otherwise provided in the corporation's articles of incorporation or bylaws, Virginia law grants appraisal rights to any shareholder who objects to a control share acquisition that is approved by a vote of disinterested shareholders and that gives the acquiring person control of a majority of the corporation's voting shares. As permitted by Virginia law, we have opted out of the Virginia anti-takeover law regulating control share acquisitions.

Affiliated Transactions Statute. Virginia law also contains provisions governing "affiliated transactions." An affiliated transaction is generally defined as a merger, a share exchange, a material disposition of corporate assets not in the ordinary course of business, any dissolution of the corporation proposed by or on behalf of a holder of more than 10% of any class of the corporation's outstanding voting shares (a "10% holder") or any reclassification, including reverse stock splits, recapitalization or merger of the corporation with its subsidiaries, that increases the percentage of voting shares owned beneficially by a 10% holder by more than 5%. In general, these provisions prohibit a Virginia corporation from engaging in affiliated transactions with any 10% holder for a period of three years following the date that such person became a 10% holder unless (1) a majority of disinterested directors of the corporation and the holders of two-thirds of the voting shares, other than the shares beneficially owned by the 10% holder, approve the affiliated transaction or (2) before the date the person became a 10% holder, the board of directors approved the transaction that resulted in the shareholder becoming a 10% holder. A disinterested director is a director who was a director on the date on which a 10% holder became a 10% holder or was recommended for election or elected by a majority of the disinterested directors then on the board. After

three years, an affiliated transaction must be (i) approved by either the holders of two-thirds of the voting shares, other than the shares beneficially owned by the 10% holder, or a majority of disinterested directors or (ii) satisfy certain fair price requirements in the statute. Virginia law permits corporations to opt out of the affiliated transactions provisions. We have not opted out of the Virginia anti-takeover law regulating affiliated transactions.

Shareholder Action by Unanimous Consent. Virginia law provides that, unless provided otherwise in a Virginia corporation's articles of incorporation, any action that could be taken by shareholders at a meeting may be taken, instead, without a meeting and without notice if a consent in writing is signed by all the shareholders entitled to vote on the action. Our Articles of Incorporation do not include a provision that permits shareholders to take action without a meeting other than by unanimous written consent.

Limitations on Liability and Indemnification of Officers and Directors

Virginia law permits, and our Articles of Incorporation provide for, the indemnification of our directors and officers with respect to certain liabilities and expenses imposed upon them in connection with any civil, criminal or other proceeding by reason of having been a director or officer of the Company. This indemnification does not apply in the case of willful misconduct or a knowing violation of the criminal law. Insofar as indemnification for liabilities arising under the Securities Act of 1933 (the "Securities Act") may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions, we have been informed that, in the opinion of the U.S. Securities and Exchange Commission, indemnification for liabilities under the Securities Act is against public policy and is unenforceable.

BOARD OF DIRECTORS

OWENS & MINOR, INC.

December 16, 2025

OWENS & MINOR, INC.

EXECUTIVE DEFERRED COMPENSATION AND RETIREMENT PLAN

WHEREAS, Owens & Minor, Inc. (the "Corporation") maintains the Owens & Minor, Inc. Executive Deferred Compensation and Retirement Plan (the "Plan");

WHEREAS, pursuant to rights reserved under Section 10.1 of the Plan, the Corporation, by action of its Board of Directors (the "Board"), may amend the Plan;

WHEREAS, the Corporation desires to amend the Plan effective as of January 1, 2026, to freeze participation in the Plan and the following contributions thereunder: (i) Participant contributions made pursuant to Article 4 of the Plan and Section 4.01 of the Plan's Adoption Agreement; (ii) Employer Matching Contributions made pursuant to Section 5.1 of the Plan and Section 5.01(a) of the Plan's Adoption Agreement; and (iii) other discretionary Employer contributions made pursuant to Section 5.2 of the Plan and Section 5.01(b) of the Plan's Adoption Agreement.

NOW THEREFORE, BE IT RESOLVED, that the Plan is hereby amended effective January 1, 2026, as follows:

1. Section 3.1 of the Plan shall be amended to add the following sentence to the end thereof:

No employee of the Employer who is not already a Participant in the Plan shall become a Participant on and after January 1, 2026.

2. Section 4.1 of the Plan shall be amended to add the following sentence to the end thereof:

No Participant contributions may be made to the Plan with respect to compensation paid on and after January 1, 2026.

3. Section 5.1 of the Plan shall be amended to add the following sentence to the end thereof:

No Employer Matching Contributions shall be made to the Plan on and after January 1, 2026.

4. Section 5.2 of the Plan shall be amended to add the following sentence to the end thereof:

No other discretionary Employer contributions shall be made to the Plan on and after January 1, 2026.

FINALLY RESOLVED, the Board hereby directs that the Corporation's President & Chief Executive Officer; Executive Vice President, Chief Financial Officer; Executive Vice President, General Counsel & Corporate Secretary; and Executive Vice President, Chief Human Resources Officer are, and each of them hereby is, authorized to take such steps necessary to implement the foregoing resolutions.

[Secretary's Certificate to Follow]

SECRETARY'S CERTIFICATE

I, Rosemarie W. France, the Assistant Corporate Secretary of Owens & Minor, Inc., hereby certify that the foregoing resolutions were approved and adopted by the Board of Directors of the Corporation on December 16, 2025, and remains in effect.

IN WITNESS WHEREOF, I have hereunto set my hand and the corporate seal of the Corporation as of the date set forth below.

OWENS & MINOR, INC.



Name: Rosemarie W. France
Title: Assistant Corporate Secretary

Date: December 16, 2025

150465994.2

**AMENDMENT TO THE
OWENS & MINOR, INC.
EXECUTIVE DEFERRED COMPENSATION
AND RETIREMENT PLAN**

WHEREAS, Owens & Minor, Inc., a Virginia corporation (the “Corporation”), maintains the Owens & Minor, Inc. Executive Deferred Compensation and Retirement Plan (the “Plan”); and

WHEREAS, pursuant to rights reserved under Section 10.1 of the Plan, the Corporation, by action of its Board of Directors, may amend the Plan; and

WHEREAS, the Corporation is party to that certain Equity Purchase Agreement, dated as of October 7, 2025, by and among the Corporation, Dominion Healthcare Acquisition Corporation, a Delaware corporation (“Purchaser”), and Dominion Healthcare Holdings, L.P., a Delaware limited partnership (as amended, modified or supplemented from time to time, the “Purchase Agreement”); and

WHEREAS, the Corporation desires to amend the Plan, effective as of January 1, 2026, to remove the entities that are part of the Transferred Entities (as defined in the Purchase Agreement) from the list of entities that have been authorized by the Plan Sponsor (as defined in the Plan) to participate in and have adopted the Plan; and

WHEREAS, the Corporation desires to amend the Plan, effective as of January 1, 2026, to update the name of the Corporation to Accendra Health, Inc.

NOW THEREFORE BE IT RESOLVED THAT, the Plan is amended effective as of January 1, 2026, as follows:

1. **Section 1.04 (“Employer”)** of the Plan’s Adoption Agreement is restated as follows:

1.04 EMPLOYER

The following entities have been authorized by the Plan Sponsor to participate in and have adopted the Plan (insert "Not Applicable" if none have been authorized):


<u>Entity</u>	<u>Publicly Traded on Est. Securities Market</u>	
	Yes	No
<u>Accendra Health, Inc.</u>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
<u>Byram Healthcare Centers, Inc.</u>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
<u>Apria Healthcare LLC</u>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
_____	<input type="checkbox"/>	<input type="checkbox"/>

2. **Section 10.2 ("Plan Termination Following Change in Control or Corporate Dissolution")** of the Plan is amended to add the following new paragraph to the end thereof:

Pursuant to the Plan Sponsor's election in Section 11.01 of the Adoption Agreement, the Plan Sponsor has taken irrevocable action to terminate and liquidate the portion of the Plan that relates to "Business Employees" of the "Transferred Entities," as described in the Equity Purchase Agreement, dated October 7, 2025, who are participants in the Plan.

IN WITNESS WHEREOF, this amendment is hereby adopted as of the date set forth below:

OWENS & MINOR, INC

By:  DD17FED94E9B49F...

Printed Name: Heath H. Galloway

Title: Executive Vice President, General Counsel
& Corporate Secretary

Date: December 31, 2025

*[Signature Page to Amendment to Executive Deferred
Compensation and Retirement Plan]*



ACCENDRA HEALTH, INC.
Section 16 and Insider Trading Compliance Policy

Amended and Restated
Effective February 27, 2023



TABLE OF CONTENTS

	Page
I. INTRODUCTION	1
II. SECTION 16 COMPLIANCE	2
A. Reporting Obligations	2
(i) Form 3 Initial Report.....	2
(ii) Form 4 Report	3
(iii) Form 5 Report	3
(iv) Form 144.....	3
B. Filing Requirements	4
C. Reporting Following Cessation of Insider Status.....	4
D. Consequences of Delinquent Filings	4
E. Section 16(b) “Short-Swing” Profit Liability and Disgorgement.....	5
III. INSIDER TRADING COMPLIANCE	5
A. Prohibition on Insider Trading.....	5
B. 10b5-1 Plans.....	8
C. Prohibition on Certain Transactions.....	10
IV. COMPLIANCE PROCESSES AND PROCEDURES.....	11
A. Restrictions on Transactions in Company Securities By Insiders and Restricted Persons	11
B. Mandatory Pre-Clearance Procedure for Insiders and Restricted Persons.....	11
C. Restrictions on Transactions by Departing Insiders and Restricted Persons	12
D. Filing Coordinator	13
E. Ultimate Responsibility for Compliance	13
Appendix A - Certification	15
Appendix B - Transaction Reporting Checklist.....	16
Appendix C - Power of Attorney.....	18

I. INTRODUCTION

The Section 16 and Insider Trading Compliance Policy (the "Compliance Policy") summarizes the obligations and restrictions imposed upon the directors and officers of Accendra Health, Inc. (the "Company") by Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").¹ In addition, this Compliance Policy summarizes other insider trading provisions of the Exchange Act that apply to all Company teammates as well as the trading window and pre-clearance restrictions imposed on all directors and officers and other Restricted Persons (as defined in Section IV(A) herein).

The description of the obligations and restrictions imposed by Section 16, the prohibition on insider trading and the outline of the Compliance Policy set forth below is a summary. Directors, officers and other Restricted Persons are encouraged to consult with the Company's General Counsel as may be necessary to comply with Section 16 and any provision of the Exchange Act concerning insider trading. Each of the Company's directors and officers and Restricted Persons must confirm that he or she has received, read and agrees to comply with the Compliance Policy by executing the certification attached hereto as Appendix A.

Section 16 of the Exchange Act and the rules promulgated by the Securities and Exchange Commission (the "SEC") impose the following obligations on the Company's directors and officers, as well as persons beneficially owning more than 10% of the Company's equity securities registered under the Exchange Act (individually, an "Insider," and collectively, "Insiders"):

- to notify the SEC of ownership of Company equity securities upon attaining the status of a Section 16 Insider (SEC Form 3);
- to report changes in beneficial ownership of Company equity securities by Insiders (SEC Forms 4 and 5); and
- to pay to the Company any "short-swing" profit made on purchases and sales of Company equity securities within a six-month period.

One of the purposes of the Compliance Policy is to assist the Company's directors and officers in avoiding violations of the reporting, "short-swing" and other insider trading rules of the Exchange Act.

¹ The term "director" means "any director of a corporation or any person performing similar functions with respect to any organizations, whether incorporated or unincorporated." The term "officers" means the following persons: the president; the principal financial officer; the principal accounting officer (or, if there is no such accounting officer, the controller); any vice president in charge of a principal business unit, division or function; any other officer who performs a significant policy-making function; and any other person who performs similar policy making functions of the issuer. The person's duties, rather than title, determine whether a person constitutes a Section 16 "officer." Persons identified as "executive officers" in the Company's proxy statement, Form 10-K or in any other filing with the SEC are presumed to be subject to Section 16 and must file reports.

All Company teammates are also subject to the restrictions on insider trading included in the Company's Code of Honor.

II. SECTION 16 COMPLIANCE

A. Reporting Obligations

All equity securities of the Company² beneficially owned by Insiders are subject to the reporting obligations set forth in Section 16(a) of the Exchange Act. A person is deemed to beneficially own equity securities if such person, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares a direct or indirect pecuniary interest in the Company's equity securities. "Pecuniary interest" means the opportunity, directly or indirectly, to profit or share in any profit from a transaction in the Company's securities. Thus, the concepts of "beneficial ownership" and "pecuniary interest" not only include securities held directly of record or in the name of an Insider, but also securities held indirectly through other persons or entities, such as securities held by the members of an Insider's immediate family sharing an Insider's household or certain trust and partnership holdings attributable to an Insider. Insiders remain free, however, to disclaim beneficial ownership of securities under certain circumstances if a reasonable basis for disclaimer exists.³

The Section 16(a) reporting obligations also apply to acquisitions and dispositions of derivative securities, such as options, warrants, convertible securities, stock appreciation rights, phantom stock and similar instruments whose value is derived from the Company's equity securities.

The SEC has adopted three reporting forms under Section 16(a) that require Insiders to disclose their transactions in and holdings of the Company's equity securities:

(i) Form 3 Initial Report

Form 3 is the initial ownership report filed by new Insiders. The SEC must receive Form 3 within 10 days following the date on which the person becomes subject to the Section 16(a) reporting obligations, disclosing all equity securities of the Company beneficially

² Currently, the Company's common stock (including derivative securities convertible into or exchangeable for the Company's common stock, such as options) constitutes its only class of equity securities outstanding.

³ While all equity securities directly or indirectly held must be reported, the issue of beneficial ownership need not be conceded. A disclaimer of beneficial ownership may be made whenever there is question as to whether beneficial ownership is deemed to exist. When the reporting director or officer disclaims beneficial ownership of securities held indirectly through another, it is appropriate to make such disclaimer in Form 3 and also in any Form 4 or 5 required to be filed. An appropriate form of disclaimer is as follows: "The undersigned disclaims beneficial ownership of the securities indicated, and the reporting herein of such securities shall not be construed as an admission that the undersigned is the beneficial owner of any such securities for the purpose of Section 16 of the Securities Exchange Act of 1934."

owned on the date of becoming an Insider. Even if no securities are owned on such date, new Insiders must file a Form 3.

(ii) Form 4 Report

Form 4 must be filed within two business days following the day on which there has been a transaction which results in any change in beneficial ownership of Company equity securities that is not exempt from reporting or subject to deferred reporting on Form 5 as described below.⁴

(iii) Form 5 Report

Form 5 is a year-end report to be used by any person who was an Insider during the Company's most recent fiscal year. Form 5 must be filed within 45 days after the end of the Company's fiscal year to report any transactions that should have been reported during the fiscal year on Forms 3 or 4, but either because of deferred reporting or an Insider's failure to file a required report, were not. Form 5 is not required from Insiders who had no reportable transactions during the preceding year or if all reportable transactions and holdings were previously reported.⁵

(iv) Form 144

In addition to the foregoing reporting obligations on Forms 3, 4 and 5, if the amount of Company securities which a director or officer sells on the open market during any three-month period exceeds 5,000 shares or has an aggregate sale price in excess of \$50,000, then a notice of proposed sale on Form 144 must be filed electronically with the SEC via EDGAR.⁶ The filing of Form 144 must occur concurrently with the placement of an order to sell with a broker or the execution of a sale with a market maker. Form 144 must be submitted by the person (or by the broker on the person's behalf) for whose account the securities are to be sold. To ensure compliance with Rule 144, any Insider contemplating the sale of Company securities should first contact the Company's General Counsel and instruct his or her broker to do the same.

⁴ Almost every transaction that results in an increase or decrease in direct or indirect beneficial ownership is a reportable event, except acquisitions under dividend or interest reinvestment plans and transactions under tax-qualified plans, such as 401(k) plans. Other reportable transactions include: the receipt or donation of bona fide gifts of securities, exercises and conversions of derivative securities; grants, awards or other distributions from the Company and all dispositions to the Company. See [Appendix B](#) for the proper treatment of certain transactions under the Company's stock plans and programs.

⁵ Generally, the Form 5 will include disclosure of transactions exempted by the Section 16 rules, such as small acquisitions.

⁶ Form 144 must be filed by "affiliates" of the Company. The term "affiliate" refers to persons controlling, controlled by or under common control with the Company and presumably includes directors, executive officers, 10% shareholders, any relative or spouse of such person, or any relative of such spouse who shares the same home.

B. Filing Requirements

It is important to note that the filing of Forms 3, 4, 5 and 144 remain the legal obligation of the reporting person, not the Company. Nevertheless, the Company will assist directors and officers with the preparation and filing of Forms 3, 4, 5 and 144.

All Section 16(a) reports must be filed with the SEC electronically through EDGAR and become immediately available to the public. The electronic filing with the SEC also satisfies the requirement to file any Forms 3, 4 or 5 with the New York Stock Exchange. No provisions for the extension of filing deadlines generally exist, but if the due date of a filing falls on a Saturday, Sunday or holiday, then the due date is automatically deferred until the next business day. There are no filing fees associated with Forms 3, 4, 5 and 144. Finally, the Company must also post the Forms 4 and 5 for its Insiders on its website by the end of the next business day following the filing of such forms with the SEC.

Appendix B sets forth the applicable treatment under Section 16(a) of certain transactions under the Company's stock plans and programs.

C. Reporting Following Cessation of Insider Status

A reporting officer or director who ceases to be subject to Section 16 (by virtue of retirement or termination of employment, for instance) must continue to file Form 4 reports after his or her change of status only if he or she executes a non-exempt purchase or sale within six months of a non-exempt sale or purchase that occurred during his or her tenure. In other words, former directors or officers may have to report transactions on Form 4 for six months after the last change in beneficial ownership that occurred while he or she was still an Insider. Former directors and officers may also be required to file Form 5. Transactions in the Company's equity securities by the Company's directors and officers before they became directors or officers must be reported under certain limited circumstances.

D. Consequences of Delinquent Filings

Penalties for failure to comply with the reporting scheme under Section 16(a) can be embarrassing and substantial. The Company is required to disclose in its proxy statement for the annual meeting the name of any director or officer who, during the last fiscal year and without regard to fault, failed to file or who filed late any Form 3, 4 or 5. The Company must also report such delinquencies in the Company's Form 10-K. In addition, civil penalties of \$5,000 to \$100,000 per violation may be assessed against persons for failing to comply with the reporting rules. The SEC may also impose other civil penalties, such as cease and desist orders or injunctions, on persons who are chronically delinquent in the filings of any Form 3, 4 or 5. For truly egregious violators, the SEC may also impose criminal penalties or imprisonment.

E. Section 16(b) “Short-Swing” Profit Liability and Disgorgement

Section 16(b) of the Exchange Act discourages speculative trading by requiring Insiders to pay over to the Company any “short-swing” profits. Under Section 16(b), profits realized by an Insider on a “short-swing” transaction (any non-exempt purchase and sale, or sale and purchase, of the Company’s equity securities within a period of six months) must be disgorged to the Company upon demand by the Company or a shareholder acting on behalf of the Company.⁷ For the purposes of determining profits, the highest price received in any sale will be matched against the lowest price paid in any purchase. Section 16(b) applies to all transactions by Insiders. Transactions occurring after a person ceases to be an Insider remain subject to Section 16(b) and the Company may match certain transactions made during the six months following termination of Insider status with transactions made while an Insider to find “short-swing” profits owed to the Company. Transactions made by persons before becoming an Insider are generally exempt from “short-swing” liability. Liability under Section 16(b) for “short-swing” transactions is imposed in a mechanical fashion without regard to intent. Therefore, an Insider’s good faith, lack of intent or the absence of material non-public information is irrelevant. An active group of professional plaintiff’s attorneys monitors Section 16(a) reports for “short-swing” transactions and often receives attorney’s fees from the recovery.

III. INSIDER TRADING COMPLIANCE

A. Prohibition on Insider Trading

All Company teammates are subject to the prohibition on insider trading. “Insider trading” is a broad term that covers a number of factual situations, but generally refers to the purchase or sale of a company’s securities (including debt securities) by persons who are aware of material information about that company that is not generally known or available to the public. Federal and state securities laws, as well as the Company’s policies and Code of Honor, prohibit insider trading. These laws also prohibit persons who are aware of such material nonpublic information from disclosing it to others, including spouses and family members, who may trade (a practice known as “tipping”). Tipping can also violate the securities laws and result in the same civil and criminal penalties that apply to insider trading, even though you did not trade and did not gain any benefit from another’s trading. Both the person who provides the information, recommendation or opinion and the person who trades based on it may be liable.

It is important to note that insider trading prohibitions are not limited to trading in the Company’s securities but also include trading in the securities of other companies, such as

⁷ The matching rules for determining whether a “purchase and sale” or “sale and purchase” have occurred within a six-month period are broadly construed to accomplish the purposes of Section 16(b). The general rule is that a change in beneficial ownership that is “volitional” on the part of the beneficial owner will constitute a “purchase” or “sale,” unless exempt. While every change in beneficial ownership required to be reported may not constitute a “purchase” or “sale,” directors and officers should consult the Company’s General Counsel before effecting a transaction if any other change in beneficial ownership has occurred within the preceding six months, including transactions resulting from participation in employee benefit plans, gifts and dividend reinvestment plans.

customers, suppliers and other companies with which the Company may be doing business or negotiating a transaction involving material non-public information.

What constitutes “material information” is often difficult to determine. Generally, information is material if there is a substantial likelihood that a reasonable investor would consider it important in deciding whether to buy, hold or sell a security. Any information that could reasonably be expected to affect the price of the security is material. Both positive and negative information can be material. Financial information such as non-public financial results or earnings projections is frequently material, even if it covers only part of a fiscal period or less than all of the Company’s operations, since either of these might convey enough information about the Company’s consolidated results to be considered material information.

There is no bright-line standard for assessing materiality; rather, materiality is based on an assessment of all of the facts and circumstances, and is often evaluated by enforcement authorities with the benefit of hindsight. While it is not possible to define all categories of material information, some examples of information that ordinarily would be regarded as material are:

- Projections of future earnings or losses, or other earnings guidance;
- Changes to previously announced earnings guidance, or the decision to suspend earnings guidance;
- A pending or proposed merger, acquisition or tender offer;
- A pending or proposed acquisition or disposition of a significant asset;
- A pending or proposed joint venture;
- A Company restructuring;
- Significant related party transactions;
- A change in dividend policy, the declaration of a stock split, or an offering of additional securities;
- Bank borrowings or other financing transactions out of the ordinary course;
- The establishment of a repurchase program for Company Securities;
- A change in the Company’s pricing or cost structure;
- Major marketing changes;

- A change in management;
- A change in auditors or notification that the auditor's reports may no longer be relied upon;
- Development of a significant new product, process, or service;
- Pending or threatened significant litigation, or the resolution of such litigation;
- Impending bankruptcy or the existence of severe liquidity problems;
- The gain or loss of a significant customer or supplier;
- Significant cybersecurity incidents; and
- The imposition of a ban on trading in Company Securities or the securities of another company.

If Company teammates are unsure whether information is material, they should either consult the General Counsel before making any decision to disclose such information (other than to persons who need to know it) or to trade in or recommend securities to which that information relates or assume that the information is material.

Material information is "non-public" if it has not been widely disseminated to the public through filings with the SEC, press releases, newswire or otherwise disclosed to the marketplace. The circulation of rumors, even if accurate, and even if reported in the media, does not constitute public disclosure. Further, information may still be non-public even though it is widely known within the Company. For purposes of this Compliance Policy, information will generally be considered public (i.e. no longer non-public) beginning on the third full trading day following the Company's widespread public release of the information. For example, if the Company issues an earnings release after the close of business on a Monday, the information in the release would be considered public upon the opening of the market on Thursday.

Material non-public information about the Company or its business partners is the property of Company, and unauthorized disclosure or use of that information is prohibited. That information should be maintained in strict confidence and should be discussed, even within the Company, only with persons who have a "need to know." You should exercise the utmost care and circumspection in dealing with information that may be material non-public information. Conversations in public places, such as hallways, elevators, restaurants and airplanes, involving information of a sensitive or confidential nature should be avoided. Written information should be appropriately safeguarded and should not be left where it may be seen by persons not entitled to the information. The unauthorized disclosure of information could result in serious

consequences to the Company, whether or not the disclosure is made for the purpose of facilitating improper trading in securities.

Any written or verbal statement that would be prohibited under the law or under this Compliance Policy is equally prohibited if made on electronic bulletin boards, chat rooms, blogs, websites or any other form of social media, including the disclosure of material non-public information about the Company or material non-public information with respect to other companies that you come into possession of as a teammate of the Company.

The trading restrictions of this Compliance Policy apply to Company teammates' family members who reside with them (including a spouse, a child, a child away at college, stepchildren, grandchildren, parents, stepparents, grandparents, siblings and in-laws), anyone else who lives in their household, and any family members who do not live in their household but whose transactions in Company securities are directed by the Company teammates or are subject to their influence or control, such as parents or children who consult with them before they trade in Company securities (collectively referred to as "Family Members"). Company teammates are responsible for the transactions of these other persons and therefore should make them aware of the need to confer with them before they trade in Company securities, and they should treat all such transactions for the purposes of this Compliance Policy and applicable securities laws as if the transactions were for their own account. The trading restrictions of this Compliance Policy do not, however, apply to personal securities transactions of Family Members where the purchase or sale decision is made by a third party not controlled by, influenced by or related to the Company teammates or their Family Members.

The trading restrictions of this Compliance Policy also apply to any entities that Company teammates influence or control, including any corporations, partnerships or trusts (collectively referred to as "Controlled Entities"), and transactions by these Controlled Entities should be treated for the purposes of this Policy and applicable securities laws as if they were for their own account.

Insider trading is a serious offense and a violation of the anti-fraud provisions of the Exchange Act, vigorously enforced by the SEC, and may result in disgorgement of profits, criminal fines of up to \$5 million and imprisonment of up to 20 years. In addition, liability may extend beyond the insider to the Company under the doctrine of controlling-person liability.

Additionally, a teammate's failure to comply with this Compliance Policy may subject him or her to sanctions and/or discipline imposed by the Company including termination of employment.

B. 10b5-1 Plans

A Rule 10b5-1 plan is a written plan for trading securities designed in accordance with Rule 10b5-1(c) under the Exchange Act that provides an affirmative defense to insider trading allegations for persons trading pursuant to the plan. Properly structured and implemented 10b5-1 plans can effectively permit Insiders to engage in trading transactions pre-

established in the plan without regard to “window periods” and whether the Insider may be aware of material non-public information about the Company at the time of the actual trading transactions.

It is the Company’s policy that directors and officers subject to Section 16 shall only trade in Company securities pursuant to a 10b5-1 plan adopted in accordance with the Compliance Policy unless otherwise pre-approved by the General Counsel of the Company (or the General Counsel’s designee). This requirement shall not apply to transactions that are customarily not made under 10b5-1 plans, such as any transaction with the Company, gifts, contributions to a trust or transfers to a Family Member or affiliated entity.

Any and all 10b5-1 plans adopted by a director or officer must be reviewed and pre-approved by the General Counsel of the Company. The Company requires that a 10b5-1 plan must meet the following requirements⁸:

- (1) the 10b5-1 plan must be in writing and signed by the person adopting the plan;
- (2) the 10b5-1 plan must be entered into within a “safe harbor” window period and the plan may only be modified or terminated when there is no quarterly, special or other blackout in effect with respect to the person modifying the plan;
- (3) the 10b5-1 plan must be adopted at a time when the person adopting the trading plan is not aware of any material nonpublic information;
- (4) the 10b5-1 plan must include a “cooling-off period” between adoption or modification of the plan and execution of the first trade. Directors and officers are subject to a cooling-off period of the later of: (a) ninety (90) days following the adoption or any modification of such 10b5-1 plan or (b) two business days following the disclosure in Form 10-Q or Form 10-K of the Company’s financial results for the fiscal quarter in which such plan was adopted or modified (but not to exceed 120 days following plan adoption or modification);
- (5) the 10b5-1 plan must be adopted, modified, or terminated in good faith and not as part of a plan or scheme to evade or circumvent the prohibitions of Rule 10b-5. The person who adopts the trading plan must act in good faith with respect to the trading plan throughout the 10b5-1 plan’s duration;

⁸ Any teammate who enters into a 10b5-1 plan shall be subject to all of the provisions of this Section III B except that the reference to “ninety (90)” days in Section III B(4)(a) shall be modified to read “thirty (30) days” and Sections III B(4)(b) and III B(8) shall not be applicable.

- (6) the 10b5-1 plan must provide that such plan cannot be suspended, modified or terminated without the pre-approval of the General Counsel of the Company (and again subject to the applicable “waiting period”);
- (7) the 10b5-1 plan must only be modified or terminated when the person modifying the trading plan is not aware of material nonpublic information;
- (8) directors and officers must certify in writing, at the time of the adoption of a new or modified 10b5-1 plan, that they are (a) not aware of any material nonpublic information about the Company or its securities and (b) adopting the 10b5-1 plan in good faith and not as part of a plan or scheme to evade the prohibitions of Rule 10b5-1; and
- (9) the 10b5-1 plan must either specify the amount, pricing and timing of transactions in advance or delegate discretion on these matters to an independent third party.

The Company reserves the right to disapprove any submitted plan, and to suspend or instruct a director, officer and/or teammate to terminate any 10b5-1 plan that it has previously approved.

C. Prohibition on Certain Transactions

Because certain trading transactions signal a lack of confidence in the Company’s prospects, are inappropriate for officers and directors to engage in and may lead to inadvertent insider trading violations, the Company prohibits the following transactions in the Company’s securities:

Short-Term Trading: Any director, officer or other employee of the Company who purchases Company securities in the open market may not, unless approved in advance by the Company, sell any Company securities of the same class during the six months following the purchase (or vice versa).

Short Sales. Sales of securities not then owned, including sales with delayed delivery (a “sale against the box”).

Publicly Traded Options. Transactions such as puts, calls and other derivative securities, which evidence a bet about the short-term movement of the Company’s securities.

Hedging Transactions. Hedging or monetization transactions such as zero-cost collars and forward sales contracts.

Margin Accounts and Pledges. Holding Company securities in a margin account or pledging Company securities as collateral for a loan.

IV. COMPLIANCE PROCESSES AND PROCEDURES

A. Restrictions on Transactions in Company Securities By Insiders and Restricted Persons

Transactions effected in Company securities by directors or officers of the Company are restricted to a “safe harbor” window. The “safe harbor” window begins on the third full trading day after the public release of the Company’s earnings information and ends on the last trading day of the second month of the fiscal quarter in which such release occurs; provided that for the first quarter of any fiscal year, the trading window may extend into the third month of the fiscal quarter to ensure that the window is approximately 10 business days in duration. As an example, if the first quarter results of the Company are announced in the evening of May 2, trading would be permissible from the morning of May 5 until the close of trading on May 31.

In addition to officers and directors, the Company has identified certain other teammates (“Restricted Persons”) who, by virtue of their positions and the material non-public information to which they have access, must restrict their trading to the designated “safe harbor” windows. Teammates who are Restricted Persons are so notified by the Company.

Occasionally, the Company may determine not to open the “safe harbor” window, adjust its opening and closing dates or impose a special “off-cycle” blackout period based on specific pending events, transactions or circumstances that may constitute material non-public information. The General Counsel, in consultation with the Chief Executive Officer, the Chief Financial Officer and Treasurer, will determine whether an off-cycle blackout period should be imposed. The existence of an off-cycle blackout period will not be generally announced. If a director, officer or teammate is covered by the off-cycle blackout period, he/she will be notified by the General Counsel. Any person made aware of an off-cycle blackout period should not disclose the existence of the black-out period to anyone else.

Additionally, please note that any Insider or Restricted Person who possesses material non-public information is not protected by the “safe harbor” provision during a window period and remains prohibited from trading while in possession of material non-public information.

B. Mandatory Pre-Clearance Procedure for Insiders and Restricted Persons

In addition to restricting trading during window periods, the Company also maintains a mandatory pre-clearance procedure under which Insiders and Restricted Persons must obtain pre-clearance from the Company’s General Counsel *prior to* engaging in any transaction involving the Company’s securities.

The Company's Insiders and Restricted Persons, together with their family members, may not engage in any transaction involving the Company's securities (including a stock plan transaction such as an option exercise, gifts, loans, pledges, contributions to a trust, or any other transfer) without first obtaining pre-clearance of the transaction from the General Counsel. The pre-clearance requirement is in effect even during a "safe harbor" window described above. A request for pre-clearance should be submitted to the General Counsel at least two business days in advance of the proposed transaction and may be made verbally or in writing. A copy of the written request or a memo memorializing the verbal request shall be maintained in the teammate's file. The General Counsel will then determine whether the transaction may proceed and, if so, assist in complying with applicable Section 16 reporting requirements and insider trading provisions under the Exchange Act. Unless revoked, a grant of permission will normally remain valid until the earlier of (i) five business days following the day on which it was granted and (ii) the end of the "safe harbor" window period.

Although the above trading restrictions and pre-clearance procedures generally apply to all transactions in the Company's securities, there are certain exceptions relating to Company stock plans as follows:

- (i) Teammate Stock Purchase Plan. The trading restrictions do not apply to purchases of Company stock in the Teammate Stock Purchase Plan resulting from periodic payroll contributions to the plan under an election made at the time of enrollment. The trading restrictions would apply to a new election to participate in the plan, changes in participation levels and to sales of Company stock purchased under the plan.
- (ii) Dividend Reinvestment Plan. The trading restrictions do not apply to purchases of Company stock under the Company's dividend reinvestment plan resulting from the reinvestment of dividends paid on Company securities. The trading restrictions would apply to a new election to participate in the plan, voluntary purchases of Company stock resulting from additional elective contributions and changes in level of participation in the plan, as well as any sale of Company stock purchased pursuant to the plan.
- (iii) 10b5-1 Plans. As described in Section III(B) above, the trading restrictions do not apply to transactions under a validly adopted 10b5-1 plan.
- (iv) Automatic Sale for Tax Withholding. The trading restrictions do not apply to the automatic sale of Company stock on behalf of a Restricted Person to cover tax withholding obligations as a result of the vesting of restricted stock or restricted stock units.

C. Restrictions on Transactions by Departing Insiders and Restricted Persons

Insiders and Restricted Persons who are leaving the Company have a continuing obligation not to trade in Company securities while they possess material non-public information

about the Company. Accordingly, it is the Company's policy that any departing Insider or Restricted Person who has material non-public information at the time he or she leaves the Company (such as information about the Company's financial results or projections) may not trade in Company securities until that information has become public or is no longer material. The pre-clearance procedures specified under the heading "Mandatory Pre-Clearance Procedure for Insiders and Restricted Persons" above, however, will cease to apply to transactions in Company securities upon the expiration of any blackout period or other Company-imposed trading restrictions applicable at the time of the termination of service.

D. Filing Coordinator

Rosemarie France, Assistant Corporate Secretary, is the Company's designated Compliance Policy filing coordinator (the "Filing Coordinator"). The Filing Coordinator will monitor and keep records of all transactions in the Company's securities by Insiders, including a list of brokers used by Insiders. The Filing Coordinator will also assist the directors and officers in the preparation of Form 3 filings upon an individual's assumption of director or officer status and in preparing Form 4 filings whenever an acquisition or disposition of Company securities requires a filing. In addition, the Filing Coordinator will assist in the preparation of any requisite Form 5 filings at fiscal year-end.

To further assist the Company's directors and officers in complying with the Section 16 reporting obligations, the Filing Coordinator will also forward annual ownership reports to all directors and officers. The Filing Coordinator will be available to answer questions and to provide information at any time. Directors and officers should review the reports carefully upon receipt and verify the accuracy of the reports by signing and returning them to the Filing Coordinator.

For the Company to assist directors and officers in meeting their filing obligations, each director or officer must authorize, designate and appoint the General Counsel and the Filing Coordinator as his or her attorney-in-fact to prepare, execute and file, on the director or officer's behalf, all Forms 3, 4 and 5 by executing the Power of Attorney attached hereto as Appendix C.

E. Ultimate Responsibility for Compliance

While the Company will assist directors and officers in complying with Section 16 and other Exchange Act provisions concerning insider trading, the directors and officers themselves remain legally obligated to ensure that filings are timely and correct and to comply with the Company's mandatory pre-clearance procedures. The Company disclaims any legal responsibility or liability arising from unlawful "short-swing" transactions by Insiders as well as any liability arising from unlawful transactions by Insiders based upon material non-public information. The Company cannot and expressly does not assume any legal responsibility in this regard.

[this page intentionally left blank]

APPENDIX A

CERTIFICATION

I hereby certify that I have received, read and agree to comply with the Accendra Health, Inc. Section 16 and Insider Trading Compliance Policy, including the appendices thereto.

Executed this ____ day of _____, 20__.

Signature

Print Name

Title

APPENDIX B

TRANSACTION REPORTING CHECKLIST

The following is a summary of the appropriate forms for use under Section 16 for certain transactions under the Company's stock plans and programs:

TRANSACTION	FORM REQUIRED
<u>General Transactions</u>	
Open Market Purchase of Stock	4
Open Market Sale of Stock	4
Gift (by or to insider)	4
Inheritance	5
<u>Stock Option Transactions</u>	
Grant of Stock Option	4
Exercise of Stock Option	4
Sale of Stock to Pay Exercise Price	4
Surrender of Stock in Payment of Exercise Price or Taxes	4
<u>Restricted Stock Transactions</u>	
Grant of Restricted Stock	4
Vesting of Restricted Stock	--
Sale of Stock to Satisfy Tax Obligation	4
Forfeiture of Restricted Stock	4
Surrender of Stock in Payment of Taxes	4

Teammate Stock Purchase Plan

Acquisition of Stock	4 or 5
Withdrawal of Stock	5
Sale of Stock	4
Cessation of Contributions	--
Reinvestment of Dividends	5

Dividend Reinvestment & Stock Purchase Plan

Stock Purchased upon Reinvestment of Dividends	5
Optional Cash Purchases	4
Withdrawal of Stock	--
Sale of Stock	4

Directors Compensation Plan

Receipt of Stock in Lieu of Directors Fees	4
Deferral of Directors Fees to Stock Fund	4
Stock Award	4
Grant of Stock Option	4

APPENDIX C

POWER OF ATTORNEY

This Statement confirms that the undersigned, _____, has authorized, designated and appointed each of Heath H. Galloway and Rosemarie W. France his or her lawful attorney-in-fact and agent, with full power of attorney and agency to execute and file on the undersigned's behalf all Forms 3, 4 and 5 (including any amendments thereto) that the undersigned may be required to file with the U.S. Securities and Exchange Commission as a result of the undersigned's ownership of or transactions in securities of Accendra Health, Inc. The authority of each of Heath H. Galloway and Rosemarie W. France under this power of attorney shall continue until the undersigned is no longer required to file Forms 3, 4 and 5 with regard to the undersigned's ownership of or transactions in Accendra Health, Inc., unless earlier revoked in writing. The undersigned expressly acknowledges that neither Heath H. Galloway nor Rosemarie W. France is assuming any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

Date

[Name]

Subsidiaries of Registrant

<u>Subsidiary</u>	<u>State of Incorporation/ Organization</u>	<u>Country</u>
Accendra Health, Inc.	Virginia	USA
Accendra Holdings, LLC	Virginia	USA
Apria Healthcare Group LLC	Delaware	USA
Apria Healthcare LLC	Delaware	USA
Apria Holdco LLC	Delaware	USA
Apria, Inc.	Delaware	USA
Barista Acquisition I, LLC	Virginia	USA
Barista Acquisition II, LLC	Virginia	USA
Byram Healthcare Centers, Inc.	New Jersey	USA
Byram Holdings I, Inc.	New Jersey	USA
Clinical Care Services, L.L.C.	Utah	USA
CPAP Sleep Store LLC	Delaware	USA
Diabetes Specialty Center, L.L.C.	Utah	USA
DMEhub LLC	Delaware	USA
Fusion 5 Inc.	Delaware	USA
Healthy Living Home Medical LLC	Delaware	USA
Lite Run Investment Holdings, LLC	Virginia	USA
Lofta, Inc.	California	USA
O&M Byram Holdings, GP	Delaware	USA
O&M Funding LLC	Delaware	USA
O&M IT Holdings I, Inc.	Virginia	USA
O&M IT Holdings II, Inc.	Virginia	USA
O&M-Bermuda Insurance Co. Ltd.	N/A	Bermuda
Owens & Minor India Private Limited	N/A	India
Owens & Minor Ventures, LLC	Virginia	USA
Owens & Minor, Inc. Executive Deferred Compensation Trust	Virginia	USA
PD Support Services Holding Co I, Inc.	Virginia	USA
PD Support Services Holding Co II, Inc.	Virginia	USA
Piedra Support Services Mexico, S. de R.L. de C.V.	N/A	Mexico

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the registration statements (Nos. 033-32497, 333-203826, 333-217783, 333-224787, 333-231386, 333-238059, 333-251376, 333-264671, 333-271859 and 333-279297) on Form S-8 and registration statement (No. 333-238068) on Form S-3 of our reports dated February 20, 2026, with respect to the consolidated financial statements of Accendra Health, Inc. and the effectiveness of internal control over financial reporting.

/s/ KPMG LLP

Richmond, Virginia
February 20, 2026

**CERTIFICATION PURSUANT TO
RULE 13a-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Edward A. Pesicka, certify that:

1. I have reviewed this Annual Report on Form 10-K for the year ended December 31, 2025, of Accendra Health, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: February 20, 2026

/s/ Edward A. Pesicka

Edward A. Pesicka

President, Chief Executive Officer & Director

**CERTIFICATION PURSUANT TO
RULE 13a-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Jonathan A. Leon, certify that:

1. I have reviewed this Annual Report on Form 10-K for the year ended December 31, 2025, of Accendra Health, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: February 20, 2026

/s/ Jonathan A. Leon

Jonathan A. Leon

Executive Vice President & Chief Financial Officer

**CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Annual Report of Accendra Health, Inc. (the "Company") on Form 10-K for the year ended December 31, 2025, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Edward A. Pesicka, President, Chief Executive Officer & Director of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

- (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Edward A. Pesicka

Edward A. Pesicka

President, Chief Executive Officer & Director

Accendra Health, Inc.

February 20, 2026

**CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Annual Report of Accendra Health, Inc. (the "Company") on Form 10-K for the year ended December 31, 2025, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Jonathan A. Leon, Executive Vice President & Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

- (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Jonathan A. Leon

Jonathan A. Leon

Executive Vice President & Chief Financial Officer

Accendra Health, Inc.

February 20, 2026
